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Summary
It is well known that Interleukin (IL)-6 is important in the regulation of both the 
chemokine directed recruitment and apoptotic removal of neutrophils and lymphocytes 
(Hurst et al 2001, McLoughlin et al 2003, 2005). However little is currently known 
about the role of IL-6 in governing the phenotype, activation and inflammatory 
trafficking of monocytic cells. In this thesis, an in vivo model of peritoneal inflammation 
was utilised in combination with in vitro studies using murine resident peritoneal 
leukocytes, to determine a role for IL-6 in the regulation of monocytic cell activity and 
trafficking during inflammation. In this respect, it was shown that resident peritoneal 
macrophages and dendritic cells (DC) were non-responsive to IL-6 signalling, which in 
DC was associated with an activation-induced loss of IL-6 receptor. This provides a 
potential mechanism by which DC are able to remove themselves from the 
immunosuppressive constraint imposed by IL-6, which is known to maintain immature 
DC (Park et al 2004), allowing them to mature into activated DC. Upon activation, 
resident DC did not display a change in chemokine receptor expression, suggesting that 
they may remain within the peritoneal cavity and undergo antigen presentation and 
lymphocyte activation locally. In vivo studies revealed that IL-6 did not regulate the 
inflammatory trafficking of resident macrophages, DC or recruited circulatory monocytes 
during acute peritonitis. However upon repeated inflammatory activation, IL-6 directed 
the increased recruitment of infiltrating monocytes to the peritoneal cavity, implicating 
them as a contributing factor to the peritoneal tissue damage and fibrosis associated with 
chronic disease progression. Later studies focused on IL-10, since there is a known 
interplay that exists between IL-6 and IL-10 (Niemand et al 2003, Fiorentino et al 1991, 
Chemoff et al 1995). In vivo studies defined an anti-inflammatory role for IL-10, 
whereby it was responsible for limiting inflammatory leukocyte recruitment via its 
control of chemokine expression, and the suppression of IL-17A secreting T cell 
development and recruitment. Therefore the pro-inflammatory and anti-inflammatory 
roles of IL-6 and IL-10 respectively must be finely balanced to allow competent cell 
mediated immunity against infection whilst preventing excessive tissue damage 
associated with disease progression.
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CHAPTER 1 
General Introduction
1.1 Thesis overview and objectives
Interleukin (IL)-6 is a vital regulator of the inflammatory response and is important for 
cellular proliferation, differentiation, lymphocyte activation, the acute phase response 
(Kishimoto et al 1995, Dienz et al 2009, Stockinger and Veldhoen 2007). Importantly, 
IL-6 is also essential for the transition from innate to acquired immunity (Jones 2005). In 
acute inflammation, this process is defined by a precise regulation of leukocyte 
recruitment and clearance, during which IL-6 is vital for the transition from a neutrophil 
to a mononuclear cell infiltrate (Hurst et al 2001, Jones 2005). Inappropriate regulation 
of this process can lead to a chronic inflammatory state, characterised by the retention of 
an activated mononuclear cell population within the affected tissue (Jones 2005). 
Research has shown that this is characteristic of a number of chronic inflammatory and 
autoimmune conditions including rheumatoid arthritis and Crohn’s disease and a 
particular problem during persistent or recurrent bacterial peritoneal infections (known as 
peritonitis), which give rise to inflammation induced tissue damage. Bacterial peritonitis 
is a common complication in end stage renal failure patients receiving peritoneal dialysis 
treatment (Davies et al 1996). This treatment utilises the peritoneal membrane as a 
dialysing barrier to remove waste products from the blood (Venkat et al 2006). 
Infections are often triggered during treatment by the introduction of commensal bacteria 
such as Staphylococcus spp. via a catheter. Repeated infections lead to damage and 
thickening of the peritoneal membrane, compromising its ability to act as a dialysing 
barrier, and rendering the treatment ineffective (Davies et al 1996, Williams et al 2002, 
Di Paolo et al 1986, Devuyst et al 2002). In a murine model of repeated peritonitis, IL-6 
deficient animals are protected from these fibrotic changes indicating that while IL-6 is 
important for the successful resolution of acute inflammation, its long-term activity may 
be detrimental to the underlining tissue (Fielding et al 2009, submitted, Hurst et al 2001, 
Jones 2005).
Much is known about the role of IL-6 in regulating the recruitment and apoptotic 
clearance of neutrophils and lymphocytes (Hurst et al 2001, McLoughlin et al 2003, 
2005), however relatively little is known about the roles of IL-6 and related cytokines in 
determining monocyte activation and trafficking both during the resting state and
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inflammation. The aims of this thesis were to characterise monocyte subsets found in the 
peritoneal cavity, with particular focus on macrophages and dendritic cells, and 
investigate how their phenotype, activity and trafficking were determined by IL-6 and 
related cytokines, both homeostatically, and during acute and recurrent peritoneal 
inflammation. In this respect, the aim was to determine how IL-6 progresses from being 
an important regulator for the resolution of acute inflammation, to becoming a 
detrimental cytokine driving the onset of recurrent inflammation induced tissue fibrosis.
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1.2 The Immune System and Inflammation
The immune system has evolved into a highly orchestrated defence mechanism that 
protects the host from infection and disease by identifying and eliminating pathogens and 
tumor cells. Regulation of this response requires a complex array of specialized cells and 
biological mediators. The first and most simple are physical anatomical barriers. The 
main anatomical barrier is the epithelial layer of the skin, which is designed to prevent 
penetration by infectious agents. However, as organisms cannot be completely sealed 
against their environments, other systems act to protect the lining of the lungs, intestines, 
and the urinogenital tract. In the lungs, coughing and sneezing mechanically eject 
pathogens and other irritants from the respiratory tract. Cilia present in the airways and 
digestive tract direct a peristalsis motion to remove pathogens that become trapped in the 
secreted mucous layer, and the flushing action of tears and urine mechanically expel 
pathogens. Chemical barriers also protect against infection with the secretion of 
antimicrobial peptides by the skin and respiratory tract, and enzymes in saliva, tears, and 
breast milk, which all act to target bacterial infections. In the stomach, gastric acid and 
proteases serve as powerful chemical defenses against ingested pathogens. Finally, 
within the urinogenitary and gastrointestinal tracts, commensal flora serve as biological 
barriers by competing with pathogenic bacteria for food and space and, in some cases, by 
changing the local physiological environment, such as pH or available iron. This reduces 
the probability that pathogens will be able to reach sufficient numbers to cause illness 
(Murphy et al 2008).
Should pathogens penetrate any one of these multiple barriers, an inflammatory response 
is triggered. Inflammation can be defined as a complex cellular defence mechanism 
designed to combat infection or fibrotic damage by balancing a co-ordinate innate and 
adaptive immunological response. During inflammation, leukocytes migrate from the 
vasculature into damaged tissues to destroy the agents that potentially can cause tissue 
injury. When successfully controlled, inflammation results in minimal damage and 
complete clearance of cellular infiltrate, returning to homeostasis (Murphy et al 2008). 
Inflammation can be sub-defined as being acute or chronic. A single inflammatory 
episode that is successfully resolved is referred to as an acute inflammatory response.
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This is a limited beneficial response. During the acute inflammatory response, the initial 
leukocyte infiltrate is mostly neutrophilic, which is replaced by a more sustained 
population of mononuclear cells. This mononuclear infiltrate includes both monocytic 
cells and lymphocytes (Jones 2005, Topley et al 1996). Chronic inflammation can arise 
as a result of repeated infection, but is also characteristic of many autoimmune 
conditions, arising when the immune system attacks the body’s own tissue. It is defined 
as a persistent phenomenon that can lead to substantial host tissue injury or damage as a 
result of the immunological efforts to counteract the recurrent or persistent infections, 
which can be associated with leukocyte infiltrate retention and reduced resolution of the 
inflammatory response. Chronic inflammation is often defined by a much larger 
neutrophil infiltrate, which is much more closely followed by an elevated mononuclear 
cell infiltrate which is consequently retained for much longer periods of time (Gabay et al
2006).
The inflammatory response plays three essential roles in the combat of infection. First it 
allows the recruitment of additional effector molecules and cells to the site of infection to 
augment the killing of invading microorganisms. The second is to prevent dissemination 
of the infection to other tissues and the third is to promote tissue injury repair. Usually 
this response is coordinated both by a stromal compartment, which can release 
inflammatory mediators to attract effector cells, usually blood leukocytes, which 
comprise the haematopoietic compartment.
1.3 Innate and acquired immunity - two arms of the immune response
Generally, the immune response can be characterised by two stages termed the early 
innate and late acquired immune response. The innate and acquired arms of the immune 
response are in no way separate entities, but are linked, and interact to co-ordinate the 
clearance of bacteria, prevention of tissue damage, apoptotic removal of leukocytes and 
resolution of the infection, as well as promoting tissue injury repair.
Innate immunity provides a rapid yet generally non-specific response. This early innate 
immune response stems the rapid expansion of microbial infections and provides many
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components for the induction of the more specific adaptive immune response. Here, the 
immune system “adapts” its response to one with an improved recognition of the specific 
pathogen, and this recognition is retained after the pathogen has been eliminated, which 
is known as immunological memory. This allows the immune system to mount a quicker 
and stronger response to the pathogen when it is re-encountered. The innate and acquired 
immune responses are linked, with recent studies endorsing a role for the innate immune 
system in driving acquired immunity, so that they work together to orchestrate an 
efficient and competent combat against infection. Both arms of the immune response are 
discussed in Sections 1.4 and 1.6 .
1.4 Innate Immunity
The innate immune response is the most highly conserved mechanism of host defence, 
and basic innate immune type responses are observed in plants, fish, reptiles and insects. 
Innate immunity is therefore the initial host response to invading microbes, and prevents 
their further dissemination. The innate immune system is comprised of cellular 
components and secretory molecules, which play a role in antigen non-specific defence 
mechanisms. These innate immune regulators are fixed and do not change. The 
secretory components include cytokines and chemokines, which are discussed in Section 
1.14 onwards. The cellular components of the innate immune system include phagocytic 
cells such as neutrophils, eosinophils, monocytes and macrophages, and cells that release 
inflammatory mediators such as eosinophils, neutrophils, macrophages, mast cells, 
basophils, and natural killer (NK) cells (Murphy et al 2008). Specific cells of the innate 
immune response are discussed further in Sections 1.5 and 1.10.
1.5 Polymorphonuclear cells: Neutrophils
Neutrophils are a common leukocyte in the blood and form an essential part of the innate 
immune system. They are characterized by their multi-lobed nuclei, which 
phenotypically distinguish polymorphonuclear cells. Originating from the bone marrow, 
maturing neutrophils are released into the blood where they circulate to monitor the 
micro-environment and peripheral tissues. Neutrophils have a short half-life and are 
replaced every three days. In this respect, once a neutrophil leaves the circulation and
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enters the tissue, for example during an inflammatory response, they are programmed to 
die by apoptosis (Akgul et al 2001).
Neutrophils are recruited to the site of inflammation via trans-migration across the 
endothelial blood vessel wall into the underlining damaged or infected tissue. The initial 
contact between circulating neutrophils and the endothelium is established via selectins 
and their ligands, which results in neutrophils rolling along the activated endothelium. It 
is thought that this contact signals the neutrophils to mobilise their secretory vesicles, 
which then transport C D llb to the cell surface. This enhances firm adhesion of the 
neutrophil to the endothelium, arresting rolling, and allowing the neutrophil to migrate 
across the endothelial wall, a process referred to as diapedesis (Borregard and Cowland
1997).
Neutrophils possess highly effective microbicidal mechanisms for killing of pathogens. 
Neutrophils can phagocytose microbes, resulting in the formation of a phagosome 
enclosing the microbe, into which reactive oxygen species and hydrolytic enzymes are 
released to kill the micro-organism (Dale et al 2008, Borregard and Cowland 1997, 
Faurschou and Borregaard 2003). This killing is further enhanced by the secretion of 
additional anti-microbial enzymes, and peptides such as P-defensins. Neutrophils possess 
many granules, which start to form during neutrophil maturation, and contain anti­
microbial proteins like those described above. The contents of these granules are 
secreted into the surrounding environment via a process known as degranulation, to 
combat infection (Akgul et al 2001).
It has recently been observed that activation of neutrophils causes the release of web-like 
structures of DNA known as neutrophil extracellular traps (NETs), which comprise a web 
of fibres composed of chromatin and serine proteases that trap and kill microbes 
extracellularly. This activation induced release of NETs by neutrophils has been shown 
to be induced by TLR4 activated platelets, which have been seen to bind to the surface of 
the neutrophils, and result in NET formation (Clark et al 2007). It has been suggested 
that NETs provide a high local concentration of antimicrobial components and bind,
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disarm, and kill microbes independent of phagocytic uptake. In addition to their possible 
antimicrobial properties, NETs may serve as a physical barrier that prevents further 
spread of pathogens (Brinkmann et al 2004).
In addition to their role in innate immunity, neutrophils also release a number of 
inflammatory cytokines, including Tumour Necrosis Factor (TNF)-a and Interleukin 
(IL)-1|3, and chemokines such as IL-8, Macrophage Inhibitory Factor (MlP)-la,
MIP-1|3 and Interferon-y-inducible Protein (IP)-10. The chemokines IL-8, MIP-la, 
MIP-ip and IP-10 are responsible for the further recruitment of neutrophils, as well as 
the subsequent accumulation of monocytes, immature dendritic cells (DC) and T 
lymphocyte subsets (Scapini et al 2000). A review of cytokines and chemokines is found 
in Sections 1.14 and 1.15.
1.6 Acquired immunity
Acquired or adaptive immunity refers to the antigen antibody generating specific 
response by lymphocytes, providing the defence mechanism that develops a few days 
following infection. Cellular mechanisms involved in acquired immunity adapt to the 
pathogen or antigen and consequently take time to develop. This more specialized 
immune response triggers immunoglobulin production and drives “immunological 
memory” (Murphy et al 2008).
1.7 Cell mediated immunity
Induction of the adaptive immune response begins with the phagocytosis of a pathogen 
by an antigen presenting cell (APC) (e.g. Langerhans cells, dendritic cells, macrophages 
or B cells), and subsequent presentation of antigen on the cell surface. On doing this, the 
APC then migrates to the peripheral lymphoid tissues where it matures into an effective 
antigen-presenting cell. Here it presents antigen to naive T lymphocytes, which, once 
stimulated, proliferate and differentiate into their fully functional form of T helper (Th) 
cells of which there are currently four main known subtypes, Thl, Th2, Thl7 and T 
regulatory cells (Zhu and Paul 2008). While the T helper pool is currently sub-classified 
into distinct groups, it is thought that these subsets may display a degree of plasticity
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suggesting that the environment may impact the expansion of these subsets (O’Shea et al 
2009, Weaver et al 2009).
Antigens are presented on the surface of APC by Major Histocompatibility Complex 
(MHC) molecules. There are two different kinds of MHC molecules known as MHC 
class I and MHC class II, which obtain peptides at different cellular locations. MHC I 
molecules bind peptides from the cytosol such as viral and self-antigens, which are then 
recognized by CD8+ T lymphocytes. MHC II molecules bind peptides generated in 
intracellular vesicles such as phagosomes, and these are recognized by CD4+ T 
lymphocytes. MHC I is expressed on all nucleated cells whereas MHC II is only 
expressed on professional antigen presenting cells such as dendritic cells, macrophages 
and B cells (Chaplin 2003). This thesis deals exclusively with MHC II mediated antigen 
presentation to CD4+ T cells.
1.8 CD4+ T helper subsets within the immune system
1.8.1 T helper cells
T helper (Th) cells are a set of differentiated lymphocytes that play an important role in 
establishing and maximizing the capabilities of the immune system. These cells have no 
cytotoxic or phagocytic activity; they cannot kill infected host cells or pathogens, and 
without other immune cells they would usually be considered useless against an 
infection. T helper cells are involved in activating and directing other immune cells, and 
are particularly important in the immune system. They are essential in determining B cell 
antibody class switching, in the activation and growth of cytotoxic T cells, and in 
maximizing bactericidal activity of phagocytes such as macrophages (Murphy et al 
2008).
1.8.2 T helper 1 (Thl) cells
Thl cells mediate immune responses to intracellular pathogens and in humans are 
particularly important for the resistance to mycobacterial infections. Their differentiation 
and commitment from naive T helper cells is driven by IL-12 (Hsieh et al 1993).
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The main cytokines produced by these cells are interferon-y (IFN-y), lymphotoxin a  and 
Interleukin (IL)-2. IFN-y is important for the activation of macrophages to increase their 
microbicidal activity, IL-2 is important for T cell proliferation (Moretta et al 1982), CD4+ 
T cell memory, and IL-2 stimulation of CD8 cells during their priming phase, which is 
important for CD8 memory formation (Zhu and Paul, 2008). Thl cells also contribute to 
autoimmune pathology, and are therefore an important target for the treatment of various 
autoimmune diseases.
1.8.3 T helper 2 (Th2) cells
Th2 cells mediate immune responses to extracellular pathogens such as helminths, and 
are also important in the induction and persistence of asthma and allergic diseases. Th2 
cells produce cytokines such as IL-4, IL-5, IL-9, IL-10, IL-13 and IL-25. IL-4 mediates 
IgE class switching in B cells, IL-5 is crucial for recruitment of eosinophils, and IL-9 
induces mucin production in epithelial cells during allergic reactions. IL-10 suppresses 
Thl cells and dendritic cell function and IL-13 is responsible for helminth expulsion (Zhu 
and Paul, 2008). Both Thl and Th2 cells can activate B cells to produce antibodies in 
what is known as humoral immunity (see Section 1.9)
1.8.4 T helper 17 (Thl7) cells
IL-17-secreting T cells (Thl 7) are a recently discovered subset of T helper cells whose 
differentiation is driven by IL-6 , Transforming Growth Factor (TGF) (3 and IL-1(3 
(Bettelli et al 2006, 2007, Aliahmadi et al 2009), and their effector functions are known 
to be maintained by IL-23 (Veldhoen et al 2006). Thl 7 cells mediate immune responses 
against extracellular bacteria and fungi. These cells produce IL-17A and IL-17F, IL-21 
and IL-22. IL-17A can induce many inflammatory mediators, cytokines and chemokines 
and so plays an important role in inducing the inflammatory response. IL-17A and 
IL-17F also recruit and activate neutrophils during the immune response to bacteria and 
fungi (Witowski et al 2000). IL-21 made by T hl7 cells is a stimulatory factor for Thl7 
differentiation and serves as a positive feedback mediator as IFNy does for Thl cells and 
IL-4 does for Th2 cells (Zhu and Paul, 2008, Stockinger and Veldhoen 2007). IL-22 has 
been shown to act co-operatively with IL-17 to enhance the expression of anti-microbial
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peptides important for host defence (Liang et al 2006). Importantly Thl 7 cells have been 
implicated in a number of autoimmune diseases with a direct link to tissue injury 
(Langrish et al 2005).
1.8.5 T regulatory cells (T-regs).
T regulatory cells are a specialised subpopulation of T cells, which play a critical role in 
maintaining self tolerance as well as regulating immune responses and maintaining 
immune system homeostasis. Natural regulatory T cells express the cell-surface marker 
CD25 and the transcriptional repressor FOXP3 (forkhead box P3). These cells mature 
and migrate from the thymus and constitute 5-10% of peripheral T cells in normal mice. 
Other populations of antigen-specific regulatory T cells can be induced from naive 
CD4+CD25‘ or CD8+CD25' T cells in the periphery under the influence of semi-mature 
dendritic cells, IL-10, TGF|3 and possibly IFN-y. The inducible populations of regulatory 
T cells include distinct subtypes of CD4+ T cell: T regulatory 1 (TrI) cells, which secrete 
high levels of IL-10, no IL-4 and no or low levels of IFN-y; and T helper 3 (Th3) cells, 
which secrete high levels of TGF-P (Mills 2004). The expansion and activity of T-regs is 
suppressed by IL-6 , which is secreted from antigen presenting cells (Pasare and 
Medzhitov 2003). T-regulatory cells exert their suppressive functions through several 
mechanisms, some of which require cell-cell contact, and some are through their 
production of certain immunosuppressive cytokines such as TGF-p, IL-10 (Section 
1.17.1) and IL-35 (Zhu and Paul, 2008).
1.9 Humoral immunity
The humoral immune response protects extracellular regions by the production of 
antibodies by B cells. Naive B cells are activated by antigen and usually require the 
presence of helper T cells, which activate B cells that recognise the same antigen. B cells 
capture their cognate antigen through their B cell receptor, which is comprised of 
monomeric membrane immunoglobulin (Ig) in the form of IgD or IgM. Upon antigen 
binding B cells then internalise the antigen for intracellular processing and presentation 
on the cell surface, coinciding with an up-regulation of co-stimulatory molecules CD80 
and CD86 . T cells recognising the same specific antigen will bind, and signal
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reciprocally to the B cell by the interaction of T cell CD40 ligand with B cell CD40. 
Upon activation the B cell differentiates and matures into an antibody secreting plasma 
cell. Signalling via the CD40 ligand and cytokines produced by the activating T cell are 
able to control the isotype of Ig produced by B cells (known as isotype switching). This 
is characterised by the conversion of IgM to either IgA, IgD, IgG or IgE. Isotype 
switching is strongly associated with the development of B cell memory, defined by the 
rapid induction of high levels of high affinity antibody following secondary antigen 
challenge (Chaplin 2003).
The antibodies secreted by these cells perform a number of functions. The first is called 
“neutralisation”, which acts by antibodies binding to the pathogen to prevent them from 
binding to cell surface markers, which they do to invade cells. The second way 
antibodies act is by binding to bacteria outside the cell to prevent them from multiplying 
by facilitating their uptake by phagocytosis. This coating of the pathogen to enhance 
phagocytosis is known as opsonisation. The third mechanism of action by antibodies is 
the triggering of the complement cascade upon binding a pathogen, the terminal 
components of which can lyse the microorganism by the formation of pores in their 
membrane (Chaplin 2003).
B cells can also be activated independently of T cell help, by polymeric antigens with a 
repeating structure, which have the ability to cross link and cluster Ig molecules on the B 
cell surface. An example of such antigens is bacterial lipopolysaccharides (Chaplin 
2003).
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1.10 Mononuclear phagocytes: monocytes
Monocytes are a member of the mononuclear phagocyte system, which is important for 
non-specific defence against pathogens, tumour recognition and immunoregulation 
(Grage-Griebenow et al 2001). Monocytes are derived from dividing monoblasts (CD34+ 
myeloid progenitors) within the bone marrow, and are released into the bloodstream as 
non-dividing cells (Geissman et al 2003). Newly produced monocytes circulate in the 
blood stream for 1-3 days and then enter tissues where they perform an integral role in 
local tissue defence (see Figure 1.1) (Taylor and Gordon 2003). Monocytes have the 
capacity to differentiate into either macrophages or dendritic cells (DC), following 
appropriate cytokine activation, suggesting that these cells probably constitute a 
considerable systemic reservoir of myeloid precursors. This theory is supported by the 
fact that 50% of circulating monocytes leave the circulation under steady state conditions 
each day (Geissman et al 2003).
1.10.1 Murine monocytic cells
Murine blood monocytes have bean shaped nuclei and are defined by the expression of 
F4/80, CD1 lb and CD1 lc. Adoptive transfer experiments in mice have shown that there 
are two distinct populations of blood monocytic cells which are equally represented in the 
blood: a short lived “inflammatory” subset that migrate to inflamed tissue where they can 
trigger immune responses, and a “resident” subset with a longer life that home to non­
inflamed tissues (Geissman et al 2003). These subsets are further defined by the 
expression of particular markers, with the inflammatory subset characterised as 
CX3CRlloCCR2+G rl+, whilst the resident subset are CX3CRlhlCCR2‘G rl\ Grl refers to 
an antibody that recognises two epitopes, Ly6C and Ly6G, which are 
glycosylphosphotidylinositol (GPI) linked proteins, and are generally recognised as 
differentiation markers for certain cell types including monocytes. The monocytic 
subsets described have been defined as Grl positive or negative based on their expression 
of Ly6C, and have been referred to as either G rl+/‘ or Ly6C+/' in subsequent literature 
(Geissman et al 2003, Gordon and Taylor 2005, Sunderkotter et al 2004). From herein, 
they will be referred to as Grl+/' subtypes. Further characteristic features of these subsets 
are presented in Table 1.1.
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Figure 1.1: Development of monocytes from bone marrow precursor cells, and 
subsequent differentiation into macrophages and dendritic cells. HSC: Haematopoietic 
stem cell, GM-CFU: Granulocyte/monocyte colony forming unit, G-CFU: Granulocyte 
colony forming unit, M-CFU: monocyte colony forming unit.
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Both subsets have been shown to have the potential to differentiate into dendritic cells in 
vivo, with the inflammatory subset being able to do so in inflamed tissue where they can 
initiate naive T cell proliferation (Geissman et al 2003). It is also believed, however not 
supported, that both subsets have the capacity to generate tissue resident or inflammatory 
macrophages. The ‘inflammatory’ subset derived its name following experiments by 
Geissman et al in 2003 who showed that when this subset was adoptively transferred into 
mice with experimentally induced peritonitis, it infiltrated the peritoneal cavity, and often 
acquired CD1 lc expression, while MHC II expression by these cells was shown in vitro, 
demonstrating their differentiation into antigen presenting DC (Geissman et al 2003). 
When the inflammatory subset was adoptively transferred into naive mice however, they 
remained undetectable in nearly all tissues except the spleen, unlike the ‘resident’ subset, 
which were widely disseminated in the blood, spleen, lung, liver and brain of recipient 
mice for several days, demonstrating an ability by the resident subset to replenish tissue 
resident myeloid populations. The distribution of the adoptively transferred resident 
subset did not greatly alter in mice with induced peritonitis, reinforcing its identification 
of a resident monocytic subset (Geissman et al 2003). Geissman and colleagues also 
showed that some of the donor resident monocytic cells recovered from the spleen had 
developed a DC-like phenotype following adoptive transfer into naive mice (Geissman et 
al 2003), consequently resident monocytic cells can enter tissues and acquire a DC like 
phenotype under steady state conditions. As a result it has been proposed that the 
‘resident’ subpopulation traffic into tissues in the resting state in a CX3CRI dependent 
manner, where they differentiate into either resident macrophages or DC under the 
control of the local cytokine network (Geissman et al 2003).
The resident monocyte population has also recently been assigned another function 
whereby they have been observed to ‘patrol’ healthy tissues through long range crawling 
on the resting endothelium lining the blood vessels, allowing for a rapid monocyte 
response following damage or infection. This patrolling behaviour is dependent on the 
integrin LFA-1 and the chemokine receptor CX3CRI and is required for rapid tissue 
invasion by the “resident” monocytes at the site of infection or tissue damage (Auffrey et 
al 2007). Once in the tissue, an immune response is initiated, and they differentiate into
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macrophages (Auffrey et al 2007). Activation of an inflammatory response therefore 
gives rise to waves of monocyte recruitment, with patrolling resident monocytes arriving 
prior to the recruitment of Grl+ ‘inflammatory’ monocytes which then go on to 
differentiate into inflammatory macrophages or DC (Auffrey et al 2007).
Work by Sunderkotter et al has uncovered a third population of monocytic cells in the 
circulation. This group identified a rare population of Grl intermediate monocytes, 
which they have defined as CCR2+ G rllnt. The work done by this group suggests that the 
CCR2' G rl' “resident” monocyte population may derive from the CCR2+ Grl+ 
“inflammatory” population, via this intermediary CCR2+ G rlint subset (Figure 1.2) 
(Sunderkotter et al 2004). This was concluded from observations that the first of the 
monocyte subsets to appear in the circulation is the CCR2+ inflammatory subset and in 
the absence of inflammatory stimuli, these monocytes differentiate into the resident 
subset, via the intermediate subset they describe (Sunderkotter et al 2004). This 
intermediate subset can also respond to pro-inflammatory cues and migrate to inflamed 
tissues and differentiate into macrophages or DC. This population is associated with 
selective expression of CCR7 and CCR8 and retention of CCR2, making them uniquely 
disposed to emigrate to the draining lymphatic system, where they have the potential to 
acquire DC properties (Qu et al 2004).
1.10.2 Human monocytic cells
Humans also have two subsets of blood monocytes, which are believed to be equivalent 
to the mouse subsets described in Section 1.10.1. These populations are defined by the 
differential expression of CD 14 (a co-receptor associated with TLR4 activation by 
lipopolysaccharide) and CD 16 (an Fc-gamma receptor FcyRIII). The so-called 
“classical” CD14+CD16' monocytes represent approximately 95% of the monocytic cells 
in a healthy individual, with a “non-classical” CD14loCD16+ population comprising the 
remainder. A further characteristic description of these cells is presented in Table 1.1.
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Figure 1.2: Differentiation of resident and inflammatory macrophages and dendritic 
cells from GrD monocytes. Resident DC and macrophages differentiate from 
G rl' monocytes that develop from G rl+ monocytes via a G rlmt intermediate.
G rl+/mt monocytes give rise to inflammatory macrophages and DC upon 
inflammatory stimuli. Adapted from Gordon and Taylor, 2005.
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These subsets differ in a number of aspects including adhesion molecule and chemokine 
receptor expression. CD14+CD16‘ monocytes express CCR2, CD62L and low CX3CRI 
and are thought to be the human equivalent of the murine CX3CRlloCCR2+Grl+ subset, 
whereas the CD14IowCD16+ monocytes lack CCR2 and have higher levels of MHCII and 
CX3CRI, and are equivalent to the murine CX3CRlhlCCR2 'G rl' subset (Tacke and 
Randolph 2006, Geissman et al 2003). The CD14+CD16' population and the murine 
CX3CRlloCCR2+G rl+ counterpart both have a high forward and side scatter profile when 
analysed by flow cytometry, whereas the CD14,0WCD16+ population and its murine 
CX3CRlhlCCR2 'GrT equivalent are smaller and less granular (Geissman et al 2003). 
There is evidence to suggest that the CD14lowCD16+ population are precursors of DC 
given their predisposition to become DC in vitro compared to the CD14+CD16' 
population (Randolph et al 2002). This does not however rule out the CD 16’ population 
acting as DC precursors in vivo. A further intermediary CD14+CD16+ population of 
human monocytes was also recently identified, which is characterised by the expression 
of CCR5 (Tacke and Randolph 2006).
Interest in CD16+ monocytes originally arose due to their elevation in the blood during 
inflammatory conditions, hence these cells are often referred to as inflammatory 
monocytes (Ziegler-Heitbrock 2007). This was compounded by the fact that this 
population produce lower levels of IL-10 in response to Toll-like Receptor (TLR)-4 
stimulation, and higher levels of TNF-a in response to TLR-2 and -4 stimulation 
(Frankenberger et al 1996, Beige et al 2002). However this remains controversial since 
data presented by Zeigler-Heitbrock et al showed that the CD14,0WCD16+ subset produce 
less TNFa, IL-1 and IL-6 than the CD 16' subset of human monocytes (Zeigler-Heitbrock 
et al 1992). Consequently, many refrain from defining the CD16+ monocytic subset as an 
inflammatory population until further characterisation of these cells in vivo has been 
undertaken, especially since the CD16+ population do not express CCR2 (Weber et al 
2000) and have an enhanced capacity for transendothelial migration (Randolph et al
2002). This level of caution reflects the contrasting function displayed by their murine 
equivalent, “resident” CX3CRlhlCCR2 'G rl' population, which show limited migration 
into sites of inflammation in vivo as compared to the CX3CRlloCCR2+Grl+ subset (Tacke
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and Randolph 2006). Based on this, many refer to the CD14+CD16' population as the 
inflammatory subset due to their murine equivalent being the “inflammatory” 
CX3CRlloCCR2+G r r  population.
Antigen Human CD14I>‘ 
CD16'
‘inflammatory’
monocytes
Human CD14+ 
CD16+ 
‘resident’ 
monocytes
Mouse CCR2+ 
Grl+
CX3CR110
‘inflammatory’
monocytes
Mouse CCR2 
Grl
CX3CRlhi
‘resident’
monocytes
CCR1 + - ND ND
CCR2 + - + -
CCR4 + - ND ND
CCR5 - + ND ND
CCR7 + - ND ND
CD llb ++ ++ ++ ++
CD llc ++ +++ - +
F4/80 ND ND + +
CD14 +++ + ND ND
CD80 ND ND ND ND
CD86 + ++ ND ND
Ly6C ND ND + -
7/4 ND ND + -
MHC II + ++ - -
CD62L ++ - + -
Table 1.1: Comparison o f human and mouse subsets by their phenotypic
characterisation. Data have been assigned arbitrary symbols: -  refers to no expression 
of the antigen, + refers to low expression, ++ refers to medium expression, +++ refers to 
high expression and N.D refers to expression not determined. Adapted from Gordon and 
Taylor 2005.
1.11 Mononuclear phagocytes: Macrophages and dendritic cells
Traditionally, the cellular network comprising peripheral mononuclear phagocytes has 
been subdivided into macrophages and dendritic cells. Both of these populations are 
known to consist of multiple subsets that are defined upon their distinct anatomical 
location and their phenotypes. Macrophages include tissue specific representatives in the 
intestinal lamina propria, alveolar, and interstitial spaces of the lung, brain (microglia),
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bone (osteoclasts), liver (kupffer cells) and kidneys. Dendritic cells have been divided 
into lymphoid-resident DC, pre-DC, conventional DC and inflammatory DC (Shortman 
and Naik 2007).
1.11.1 Macrophage and dendritic cell origin and differentiation
Circulating monocytes give rise to a variety of tissue resident macrophages as well as 
specialised DC, in both the steady and inflammatory states, which contribute to host 
defence, tissue remodelling and repair (Gordon and Taylor 2005, Geissman et al 2003, 
Sunderkotter et al 2004). As previously described, murine monocytes, identified by their 
F4/80 and C D llb expression, can be subdivided into two subsets: inflammatory 
(CX3CRl'°CCR2+G rl+), and resident (CX3CRlhiCCR2'Grl ) subsets. The bone marrow 
derived monocytes (CCR2+CX3CR1 G rl+ “inflammatory” subset) are released into the 
circulation and are recruited to an inflammatory site in the case of injury or infection, 
where they are believed to differentiate into either macrophages or DC (Geissman et al 
2003). In the absence of infection, these cells are believed to alter their functional and 
phenotypic characteristics, passing through an intermediate phenotype 
(CCR2+CCR7+CCR8+G rlm,d), which is also able to migrate to an inflammatory site 
through CCL1, to the resident population of monocytes (CCR2 'G rrCX 3CRlhl). These 
are then able to enter tissues and are suggested to replenish tissue resident macrophage 
and DC populations (Sunderkotter et al 2004, Gordon and Taylor 2005). There is also 
evidence to suggest that many tissue resident populations of macrophages are replenished 
by local proliferation (Gordon and Taylor, 2005).
Dendritic cells are not only derived from myeloid cells, but also from lymphoid- 
committed progenitor cells (Figure 1.3). Bone marrow derived haematopoietic stem cells 
give rise to multipotent progenitors, which then form common myeloid and lymphoid 
progenitor cells. Myeloid progenitors go on to form granulocytes and monocytes, which, 
as previously stated, can give rise to macrophages and DC. Lymphoid precursor cells go 
on to form T and B lymphocytes and NK cells, but can also differentiate into DC (Wu 
and Liu 2007, Shotman and Naik 2006). DC subtypes are discussed further in Section 
1.13.
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Haematopoietic 
stem cell
Multipotent
progenitor
Common myeloid Common lymphoid
precursor precursor
Granulocyte/
macrophage
precursor
Macrophage/ 
DC precursor
\  /
FIt3L
GM-CSF
Monocyte
Inflammatory DC 
e.g Tip DC
Macrophage
Figure 1.3: DC subtypes arise from specific precursors. DC can be both myeloid and 
lymphoid derived, giving rise to pre-DC such as plasmacytoid DC, and conventional DC as 
well as monocyte derived DC and Tip DC (see Section 1.13.1).
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1.12 Macrophages
Metchnikoff (1893) was the first person to use the term macrophage to describe a large 
cell able to take up microorganisms. Macrophages are mononuclear phagocytes, which 
orchestrate the initiation and resolution of the inflammatory response, playing a central 
role in acute and chronic inflammation. They also play a broad homeostatic role in the 
clearance of senescent cells and in tissue remodelling and repair following injury and 
infection (Gordon 1995, Gordon 2003, Gordon and Taylor 2005).
Macrophages are an important part of the innate immune system as illustrated by their 
ability to recognise, engulf and destroy many potential pathogens including bacteria, 
pathogenic protozoa, fungi and helminths. They also recognise and are involved in the 
clearance of tumour cells, some viral infected cells and cells undergoing programmed cell 
death or apoptosis. Macrophages can also recruit haematopoietic cells to local sites of 
inflammation and regulate their activities through the secretion of chemokines and 
cytokines respectively (Gordon 1998). As well as their involvement in primary innate 
immunity, macrophages also play an important role in adaptive immunity and act as 
antigen presenting cells. Macrophages therefore provide a link between innate and 
acquired immunity and the physiological changes that contribute to humoral and cell 
mediated immunity (Gordon 1998). The specific roles of macrophages are discussed in 
Section 1.12.2.
1.12.1 Macrophage heterogeneity
Macrophages have long been known as a vastly heterogeneous population with many 
subsets arising as a result of the specialisation of tissue macrophages in particular micro­
environments (Gordon and Taylor 2005). Table 1.2 details the different macrophage 
populations that are currently known.
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Tissue Specific macrophage 
Name
Function
Bone Osteoclast Bone remodelling and providing a stem cell niche
Bone marrow 
macrophage
Erythropoiesis
Brain Microglial cell Neuronal survival and connectivity, repair after 
injury
Epidermis Langerhans cell Immune surveillance
Eye NA Vascular remodelling
Intestine Crypt macrophage Immune surveillance
Kidney NA Ductal development
Liver Kupffer cells Clearance of debris from blood and liver tissue 
regeneration after damage
Mammary
gland
NA Branching morphogenesis and ductal 
development
Ovary NA Steroid hormone production and ovulation
Pancreas NA Islet development
Testis NA Steroid hormone production
Uterus Uterine DC Angiogenesis and decidualisation
Uterine macrophage Cerival ripening
Peritoneum Peritoneal
macrophage
Immune surveillance
Table 1.2: Tissue macrophage heterogeneity andfunction. Adapted from Pollard 2009. 
1.12.2 Macrophage immune function
Macrophages recognise and engulf pathogens via a process called phagocytosis using 
opsonins (antibody, complement) or non-opsonic pattern recognition receptors (PPRs) 
e.g. Mannose receptors (Examples of membrane bound and intracellular PPRs and their 
functions are summarised in Table 1.3) (Taylor et al 2005). Pattern recognition receptors 
recognise a limited set of conserved molecular patterns on microbes referred to as 
pathogen-associated molecular patterns (PAMPs). Macrophages express a range of 
plasma membrane bound and intracellular receptors that mediate their interaction with 
natural and altered self-components as well as a range of micro-organisms. Recognition 
is followed by surface changes, uptake, signalling, and altered gene expression, which all 
contribute to homeostasis, host defence, innate effecter mechanisms, and the induction of 
acquired immunity (Taylor et al 2005).
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Receptor Family Example Function (example)
Scavenger (collagenous) SR-A (Scavenger receptor A) Phagocytosis of bacteria and 
apoptotic cells, endocytosis of 
modified Low Density 
Lipoprotein (LDL), adhesion.
Scavenger (non-collagenous) CD36 Phagocytosis of apoptotic 
cells, diacyl lipid recognition 
of bacteria.
GPI-anchored CD14 LPS-binding 
protein/interactions 
MD2/MyD88, TLR signalling, 
apoptotic cell recognition.
Integrin CR3 (Complement Receptor 
3) (CD 18/1 lb)
Complement receptor (C3bi) 
mediated phagocytosis, 
adhesion to endothelium
Ig Superfamily FcR (ITAM/ITIM- 
Immunoreceptor Tyrosine- 
based Activation/Inhibition 
Motif)
TREM-1 (Triggering receptors 
expressed by myeloid cells) 
(ITAM)
Antibody dependent binding, 
uptake, killing 
Regulation of inflammation
Seven transmembrane CCR2
C5aR (Complement factor) 
EMR2 (EGF module 
containing mucin-like 
hormone receptor, part of the 
EGF-TM7-seven 
transmembrane receptor 
family)
f-MLP (formyl Met Leu Phe)
Receptor for MCP-1 
Chemotaxis, degranulation, 
myeloid cell adhesion, 
chondroitin sulphate binding 
Formyl peptide receptors
NK-like C-type lectin-like Dectin-1 
(ITAM-like)
(3-glucan receptor, fungal 
particle ingestion, TNFa 
release/interaction TLR2
C-type lectin (single CTLD) DC-sign Mostly DC, pathogen 
recognition, ICAM adhesion
Multiple CTLD Mannose receptor (MR) Clearance, alternative 
activation, antigen transport?
Toll-like receptors (leucine 
rich repeats)
TLR2 (Toll-like Receptor) 
TLR4
Response to peptidoglycan 
Response to LPS
NOD like receptors NODI (Nucleotide-binding 
Oligomerisation Domain) 
NOD2
Intracellular receptors 
recognising peptidoglycan
Table 1.3: An overview o f macrophage pattern recognition and innate immune receptors 
implicated in immune recognition. Adapted from Taylor et al 2005.
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Surface receptors on macrophages regulate their differentiation, growth, survival, 
adhesion, migration, activation, phagocytosis and cytotoxicity (Taylor et al 2005).
Following phagocytosis, macrophages degrade the proteins and process the antigens for 
presentation to T cells via MHC class II molecules. In addition to their role in antigen 
presentation, macrophages also possess microbicidal and tumoricidal activities 
characterised by their capacity to produce reactive-oxygen and reactive nitrogen 
metabolites, which kill ingested pathogens by the release of these metabolites into the 
phagosome. Bacteria are engulfed into a phagosome, a vacuole formed around the 
ingested material, which then fuses with a lysosome, an organelle containing digestive 
enzymes. Subunits of the enzyme NADPH (nicotinamide adenine dinucleotide 
phosphate) oxidase assemble in the lysosome membrane forming an active enzyme. This 
enzyme then catalyzes the synthesis of superoxide anions, and this activity produces a 
large increase in oxygen consumption, referred to as the "respiratory burst". Superoxide 
anions themselves are extremely toxic to pathogens. Superoxide dismutase (SOD) then 
converts these anions into oxygen and the highly reactive oxygen species, hydrogen 
peroxide, which kills the engulfed bacteria (Nathan et al 1977, Nathan et al 1979, Sasada 
etal 1980).
Reactive nitrogen species are produced by the enzyme nitric oxide synthase, which 
catalyses a reaction between L-arginine, oxygen and NADPH to form nitric oxide, which 
possesses potent anti-microbial activities (Nathan et al 1991). These nitrogen metabolites 
are released into the phagosome in the same way as reactive oxygen species. Once the 
ingested bacteria have been neutralised, residual and non-digested material within the 
phagosome is then expelled by exocytosis. When phagocytosis cannot occur, 
macrophages are able to release antimicrobial agents into the surrounding space to fight 
the infection.
Macrophages not only ingest pathogens, they also assist in the clearance of apoptotic 
cells, both homeostatically and during inflammation. This includes the clearance of
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apoptotic neutrophils and other cells that accumulate at sites of inflammation (Fadok et al
1998). This process is often associated with the induction of macrophage derived anti­
inflammatory mediators, which dampen the inflammatory response before it becomes 
detrimental to the host (Fadok et al 1998). Without this mechanism in place, the failure 
to clear apoptotic cells and debris at sites of inflammation would lead to exacerbation of 
inflammation and a predisposition to the development of autoimmunity (Pickering et al 
2000).
Finally, macrophages are involved in wound healing and tissue repair. Interleukin (IL)-4 
and IL-13 are important for this process, and have been shown to stimulate arginase 
activity allowing macrophages to convert arginine to ornithine, which is a precursor of 
polyamines and collagen, thereby contributing to the production of extracellular matrix 
(Deodhar et al 1997). Macrophages also contribute to fibrin dissolution, the removal of 
dead tissue, and the ingrowth of new blood vessels (angiogenesis), as well as regulating 
fibroblast recruitment, growth and connective tissue remodelling (Gordon 2003).
While macrophages have many beneficial roles that contribute to the clearance of 
microbial pathogens and tumourogenic cells, tissue homeostasis, remodelling and repair 
following injury, they have also been shown to have detrimental effects such as causing 
much of the pathology of infectious, inflammatory and malignant diseases. Many 
chronic inflammatory conditions are characterised by an increased and retained 
mononuclear infiltrate (Jones 2005, Nowell et al 2003, Nowell et al 2009), including 
monocytes/macrophages, which have been shown to contribute to tissue damage as a 
result of their production of reactive oxygen species and nitric oxide (Duffield et al 2000, 
Duffield et al 2001, Kipari et al 2002, Duffield et al 2001).
1.12.3 Peritoneal “resident” and “inflammatory” macrophages
As described in Section 1.12.2, macrophages display a high degree of functional and 
phenotypic heterogeneity, with a wide range of phenotypes observed in vivo, each of 
which adapt to their local environment to perform specific functions.
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In the peritoneal cavity, a population of macrophages exists known as the “resident” 
macrophages. These adapt to their local environment to perform specific functions, 
which include tissue homeostasis through the clearance of senescent cells and 
remodelling and repair of tissues following inflammation (Taylor et al 2005). Peritoneal 
macrophages are the most studied primary macrophages in mice because they are easily 
isolated by peritoneal lavage. During a mild acute inflammatory response, resident 
peritoneal macrophages have been shown to combat infection by providing the first line 
of defence against the invading pathogen (Dunn et al 1985). They have also been shown 
to be essential for sensing peritoneal injury, and initiating the recruitment of 
polymorphonuclear cells through the production of neutrophil activating CXC 
chemokines (Cailhier et al 2005).
During a more severe acute inflammatory response however, or when a disturbance 
occurs in the tissue normality, be it infection, normal cell turnover, wounding, immune 
response or malignancy, infiltrating monocytes are also recruited to the cavity. These 
monocytes go on to differentiate into inflammatory macrophages or DC, contributing to 
host defence, tissue remodelling and repair (Gordon 2007, Gordon and Taylor 2005). 
This process is facilitated by resident macrophages, which constitute an important source 
of inflammation-related factors such as chemokines and Matrix Metalloproteinase 
(MMP)-9, and coordinate leukocyte extravasation and trafficking into the peritoneal 
cavity (Kolaczkowska et al 2007). The rapidly recruited macrophages are appropriately 
named recruited or activated macrophages. These recruited macrophages often exhibit 
many phenotypic differences from resident tissue macrophages, and this depends on the 
nature of the recruiting stimulus and the tissue location and environment (Gordon 1995). 
Recruited macrophages are generally ascribed a greater destructive potential than resident 
macrophages (Gordon 1995), and are important for the propagation and resolution of 
inflammation (Taylor et al 2003).
It is currently unclear what happens to recruited macrophages once the recruiting 
stimulus has been resolved. One possibility is that many of the recruited macrophages 
die in situ. Apoptotic cells are a stimulus for macrophage recruitment (Messmer 2000),
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and it could be considered these macrophages may be cleared by newly elicited resident 
macrophages. Inflammatory macrophages also enter the draining lymphatics where they 
could either enter apoptosis or acquire antigen-presenting functions (Bellingan et al 
1996). There is no current evidence of macrophages being recycled back into the 
circulation as reverted monocyte-like cells.
1.12.4 Macrophage activation
In vitro studies have shown the ability of elicited macrophages to acquire distinct 
phenotypes and physiological activities (Figure 1.4). There are currently four suggested 
modes of macrophage activation that have been defined in vitro: 1) Classical activation 
is induced by lipopolysaccharide (LPS) and interferon (IFN)-y, and is associated with 
high microbicidal activity, pro-inflammatory cytokine production and cellular immunity;
2) Innate activation, triggered by TLR ligands, is associated with microbicidal activity 
and pro-inflammatory cytokine production; 3) Alternative activation, triggered by IL-4 
or IL-13 stimulation, is associated with tissue repair and humoral immunity; 4) 
Deactivation, triggered by IL-10 or TGF-(3, or ligation of inhibitory receptors such as 
CD200 and CD 172a, is associated with anti-inflammatory cytokine production, and 
reduced MHCII expression (Mosser 2003, Gordon 2003, Gordon and Taylor 2005, 
Taylor et al 2005).
1) Classically activated macrophages are activated by IFN-y and TNF, and they have 
enhanced microbicidal or tumouricidal capacity and secrete high levels of pro- 
inflammatory cytokines and mediators. IFNy is produced by innate and adaptive immune 
cells, with NK cells being an important innate early source of this cytokine. The IFN-y 
produced by NK cells primes macrophages to secrete pro-inflammatory cytokines, and 
produce increased levels of superoxide anions and oxygen and nitrogen radicals, which 
increases their microbial killing ability (Dale et al 2008). The production of IFN-y by 
NK cells is generally short lived and they cannot sustain a population of activated 
macrophages. Consequently an adaptive immune response is usually required to 
maintain these classically activated macrophages and provide prolonged host defence 
against invading pathogens (Mosser and Edwards 2008).
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Peripheral
blood
Inflamed
Tissue
7
M0
‘Innate activation’ by Toll-like receptor 
ligands e.g. Lipopolysaccharide (LPS), 
Leukotrienes (LTA), Prostoglandins (PGN).
Increased: Pro-inflammatory cytokines
iNOS, ROS
‘Classical activation’ by IFN-y and TNF- a
Increased: Pro-inflammatory cytokines
iNOS, ROS 
MHCII, CD86 
Antigen presentation 
Microbicidal activity
r
‘Alternative activation’ by IL-4/IL-13
Increased: Endocytic activity 
Mannose Receptor, 
Dectin-1, Cell growth, 
Tissue repair, Arginase, 
Parasite killing
‘Deactivation’ by e.g. IL-10/TGF- p, 
CD200:CD200R, CD172a:CD47 and steroids
Increased: IL-10, TGFp, Prostoglandin (PG)E2 
Reduced: MHCII
Figure 1.4: Macrophages exhibit four modes of activation in vitro, upon inflammatory 
stimuli. Innate activation is driven by TLR stimulation, triggering a pro-inflammatory 
macrophage action. Classical activation is driven by IFN-y and TNF-a stimulation, 
and also triggers a pro-inflammatory macrophage response. Alternative activation is 
driven by IL-4/13 stimulation, triggering tissue repair and parasite killing.
Deactivation is driven by IL-10/TGF-P and CD200:CD200R stimulation, leading to an 
anti-inflammatory effect on the macrophage. Adapted from Gordon and Taylor 2005.
29
The second signal, TNF is usually released endogenously as a result of macrophage TLR 
ligation. Thus, classically activated macrophages are developed in response to IFN-y in 
combination with exposure to a microbe or microbial product such as LPS (Mosser
2003). These macrophages produce IL-12 and IL-23 upon IFN-y stimulation, which are 
involved in the Thl cell mediated immune resolution of infection (Gordon 2003). They 
are also easily identified by their production of nitric oxide. These activated 
macrophages migrate to sites of inflammation where they encounter pathogens and 
degrade them. They have enhanced capacity to kill and degrade intracellular 
microorganisms, accomplished by an increase in the production of toxic oxygen species 
and nitric oxide (Mosser 2003). Unfortunately, whilst the pro-inflammatory cytokines 
produced by classically activated macrophages are an important component of host 
defence, they can also cause extensive host damage. IL-1, IL-6 and IL-23 produced by 
these cells are important for the development and expansion of Thl 7 cells which produce 
IL-17, a cytokine that is associated with a high level of PMN recruitment to tissues, 
which can contribute to inflammatory autoimmune pathologies (Langrish et al 2005).
2) Innate activation of macrophages is triggered when microbial stimuli are recognised 
by pattern recognition receptors such as TLRs, CD14/LPS binding protein and a range of 
non-opsonic receptors. These stimuli induce the production of pro-inflammatory 
cytokines such as IFN-a/p, reactive oxygen species and nitric oxide, followed by a 
regulated anti-inflammatory response. Enhanced co-stimulatory surface molecules also 
favor antigen presentation, and scavenger receptor-A and mannose receptor promote 
phagocytosis and endocytosis of host and exogenous ligands (Gordon 2003).
3) Alternatively activated macrophages are generally produced in Th2 type responses, 
particularly in allergic, cellular and humoral responses to parasitic and extracellular 
pathogens. IL-4 and IL-13 up-regulate expression of mannose receptor and MHC class II 
in macrophages, which stimulates endocytosis and antigen presentation, and they induce 
the expression of selective chemokines and intracellular enzymes such as arginase, which 
are implicated in cell recruitment and granuloma formation (an organised collection of 
macrophages). Alternatively activated macrophages have impaired ability to produce
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nitrogen radicals, making them relatively poor at killing intracellular pathogens, and even 
though they have up-regulated MHCII expression, they do not exhibit efficient antigen 
presentation, and in many instances, they inhibit T cell proliferation (Mosser 2003). 
Alternatively activated macrophages have been shown to produce a number of 
components involved in the synthesis of the extracellular matrix, including fibronectin 
and matrix associated proteins, as well as promoting fibrogenesis from fibroblastoid cells, 
and so it is thought that their primary role is involved in fibrosis and tissue repair 
(Gordon 2003, Mantovani et al 2004, Mosser 2003).
4) Deactivation of macrophages can be either innate or acquired in origin. The uptake of 
apoptotic cells or lysosomal storage of host molecules will generate anti-inflammatory 
responses. Certain pathogens can also deactivate macrophages by various mechanisms 
(Gordon 2003).
While these four modes of activation have been described in vitro, it is thought that the 
activity of macrophages displays a vast degree of plasticity in vivo.
1.13 Dendritic cells
Dendritic cells (DC) were first discovered in 1972 when experiments were designed to 
characterise “accessory” cells that enhanced immunity in response to antigen. This led to 
the discovery of unusual stellate cells in the murine spleen, which had the ability to form 
and retract dendrites and as a result were named dendritic cells (Steinman 2007).
In the steady state, DC reside in both peripheral tissues and lymphoid organs and also 
circulate in the blood. Dendritic cells are antigen-sampling cells of the peripheral tissue 
and specialise in antigen capture, processing and presentation to T cells. The function of 
DC is therefore to prime the expansion of antigen specific T cell responses (Novak et al
2008). Dendritic cells are crucial for the development of innate and adaptive immunity 
against infection, and for the maintenance of immune tolerance to self antigens (immune 
homeostasis) (Wu and Liu 2007, Steinman et al 2003). Dendritic cells represent a 
sparsely distributed population of bone marrow derived cells and whilst they share many
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common features, multiple subsets of DC have been identified with distinct life spans and 
immunological functions. This heterogeneity arises from the subset-specific expression 
of distinct surface markers, inflammatory cytokines, and by their location. Tissue micro­
environments appear to have a major impact on the function of resident DC, and their 
localisation determines their phenotype so that they can become highly specialised for 
their specific function, their trafficking to defined chemokine profiles, and their 
dependence on inflammatory stimuli for their generation (Wu and Lui 2007 and Wu and 
Dakie 2004).
1.13.1 Dendritic cell types and subtypes
Dendritic cells are derived from both a Common Myeloid Progenitor (CMP) and a 
Common Lymphoid Progenitor (CMP), which arise from the bone marrow (Shortman 
and Naik 2007). Both myeloid and lymphoid progenitors give rise to defined DC subsets 
(Figure 1.3). Classification of DC subsets is controversial, and many groups describe 
them differently. Dendritic cell sub-classification is presented here in Sections 1.13.1.2-
1.13.1.5, based on descriptions by Shortman and Naik, 2007.
1.13.1.1 Pre-Dendritic Cells (pre-DC)
Pre-Dendritic cells are so named because they are precursors of DC, and represent the 
last precursor phenotype in DC differentiation. This subset are often found in the 
circulation and may sometimes be referred to as circulatory DC, often considered as a 
pool of bystander DC which may be rapidly recruited where required (Novak and Bieber
2007). Different pre-DC can produce distinct subsets of DC, with some developing in the 
steady state, whilst other require further microbial or inflammatory stimulation. An 
example of a pre-DC is the plasmacytoid DC (pDC), which are instrumental in the 
defence against viral infections through their production of type I IFN (Cao and Liu 
2007, Shortman and Naik 2007). They have unique MHC class I compartments which 
directs the presentation of viral antigens to cytotoxic CD8+ T cells. In addition, they are 
also able to take up allergens via high affinity receptors for IgE and have the capacity to 
cross present allergens to T cells (Ueno et al 2007, Novak and Beiber 2007).
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1.13.1.2 Conventional Dendritic Cells (cDC)
Conventional DC (cDC) are fully differentiated and can be subdivided into migratory 
cDC and lymphoid-tissue-resident cDC (Sections 1.13.1.3 and 1.13.1.4).
1.13.1.3 Migratory cDC
Migratory cDC serve as antigen sampling sentinels in the circulation and peripheral 
tissues. Upon antigen capture they migrate through the lymph to the lymph nodes, and 
this may occur rapidly upon encounter of inflammatory stimulus, or at a lower rate in the 
steady state. Here they present antigen to T cells. An example of the migratory cDC is 
the Langerhans cell, which can be found in the epidermis, and the epithelia of the 
intestine and the respiratory and reproductive tracts. It is likely that most DC in the 
peripheral non-lymphoid tissues fall into this group (Shortman and Naik 2007). 
Migratory cDC may also be found in the blood, however their physiological role is so far 
unclear, but may represent a pool of precursor cells that migrate into the tissues to 
replenish the resident DC population, and also act as a sensor for blood borne pathogens 
(Ueno et al 2007).
1.13.1.4 Lymphoid-tissue resident cDC
Unlike migratory cDC, lymphoid-tissue-resident DC do not travel to the lymphoid organs 
from the lymphatic system, but instead they collect and present antigen within the 
lymphoid organ (Spleen, thymus, lymphatic system) itself. The lymphoid tissue DC 
subset includes the majority of thymic and splenic DC, as well as approximately 50% of 
DC found in the lymph nodes (Lymph-Node resident DC). This subset can be further 
divided into CD8+ and CD8' lymphoid tissue resident cDC, which differ in immune 
functions, including cytokine production and antigen presentation (Shortman and Naik 
2007). Lymphoid tissue resident DC generally have an immature phenotype and are 
active in antigen uptake and processing, unlike the migratory DC, which have a mature 
phenotype upon reaching the draining lymph node, with their antigen uptake abilities 
suppressed (Wilson et al 2003) (Shortman and Naik 2007). The source of lymphoid- 
tissue-resident DC is controversial with some reports suggesting that DC colonise the 
lymphoid organs directly from the blood. These are then regarded as a static population
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of cells that form a network of secondary lymphoid organ-resident APC, able to 
phagocytose soluble antigen in the lymphoid organ itself or receive antigen carried to 
them by migratory DC (Carbone et al 2004). However this was challenged by other 
reports that showed evidence of DC proliferation in lymphoid organs, suggesting this 
population of DC may be replenished in situ (Kabashima et al 2005). In the steady state, 
lymphoid-tissue-resident DC capture self-antigens and induce tolerance (Ueno et al 
2007).
1.13.1.5 Inflammatory DC
Inflammatory DC are not present in the steady state, but appear as a consequence of 
inflammation or microbial stimuli. An example of inflammatory DC are the monocyte- 
derived DC. These inflammatory DC are derived from the CX3CRlloCCR2+Grl+ blood 
monocytes and are recruited to the peritoneal cavity and spleen upon inflammatory 
challenge (Geissman et al 2003). These monocyte-derived DC can be distinguished from 
steady state splenic cDC by their intermediate rather than high expression of CD1 lc and 
their high level of expression of C D llb (Naik et al 2006). Monocyte-derived DC are 
thought to be essential for the induction of effective defence mechanisms against 
infection (Lopez-Bravo and Ardavin 2008). Another example of an inflammatory DC is 
the tumour-necrosis factor and inducible nitric-oxide sythase-producing DC, termed Tip 
DC. These inflammatory Tip-DC were first discovered in mice infected with Listeria 
monocytogenes (Serbina et al 2003, Wu and Lui 2007 and Wu and Dakie 2004).
1.13.2 DC trafficking
Circulating DC and their precursors exit the blood in response to tissue specific homing 
signals that are displayed on the vascular wall. These signals may emanate from sites of 
inflammation, or from normal tissues that recruit precursor DC during initial seeding and 
subsequent turnover of tissue resident DC (Rot and Von Andrian 2004). Circulating DC 
can only follow recruitment signals by engagement with selectin molecules on the 
endothelium, which promote trans-endothelial migration into the underlining tissue. 
Homeostatic and inflammatory trafficking and tissue specific homing of DC occurs in 
vivo via a broad range of chemokine receptors expressed on their surface (Rot and Von
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Andrian 2004). Once DC are tethered to and rolling on the endothelium, they encounter 
a chemoattractant stimulus which is often, but not always, presented on the surface of the 
endothelium (Rot and Von Andrian 2004). The presentation of chemokines on the 
endothelium triggers the clustering of integrin molecules on the venular surface, such as 
LFA (lymphocyte function associated)-1, VLA-4 and Mac-1, which facilitates DC 
engagement with endothelial cell surface integrin ligands including ICAM-1, ICAM-2 
and VC AM (vascular cell adhesion molecule)-1 (Springer 1994). This process is often 
called firm arrest, and trans-endothelial migration into target tissue is subsequently driven 
by localised chemoattractant gradients.
Access by immature DC to non-lymphoid peripheral tissues is usually co-ordinated by 
chemokine receptor-ligand pathways such as CCR2-CCL2 (Geissman et al 2003), CCR5- 
CCL5 (Stumbles et al 2001) and CCR6-CCL20 (Merad et al 2004). CXCR4 is also 
expressed by monocytes, and may be responsible for low level constitutive recruitment in 
response to stromal cell-derived factor (SDF)-l (Sallusto et al 1998). Once DC become 
mature upon capture of antigen, they down-regulate their responsiveness to inflammatory 
chemokines, and traffic to the draining lymph nodes by up-regulating homeostatic 
chemokine receptors such as CCR7, which responds to ligands CCL19 and CCL21 
(Sozzani et al 1998). These chemokines are produced by peripheral lymphatic 
endothelial cells and lymph node stromal cells, and guide DC to downstream lymph 
nodes, where they can undergo antigen presentation to naive T cells (Martin-Fontecha et 
al 2003).
Recruitment of DC to peripheral organs is much more effective during inflammation 
suggesting that there is a pool of by-standing DC in the circulation which are ready to be 
rapidly recruited to the site of inflammation where antigen processing is required. 
Recruitment of monocyte-derived DC have been characterised by Geissman et al 2003, 
and Auffray et al 2007, who showed that the Grlhl CX3CRI10 CCR2+ “inflammatory” 
monocytes are preferentially recruited to inflamed tissues in a CCR2-CCL2 dependent 
manner, whereas the Grl' CX3CRI111 CCR2' “resident” monocytes interact with
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ffactalkine (CX3CLI) which is a transmembrane chemokine on resting endothelium 
(Geissman et al 2003, and Auffray et al 2007).
1.13.3 DC activation and function
In the periphery, DC reside in an immature state, specialised for antigen uptake via 
receptor mediated endocytosis (phagocytosis, pinocytosis) through pattern recognition 
receptors (PPRs) which are activated by a limited set of conserved molecular patterns on 
microbes referred to as pathogen-associated molecular patterns (PAMPs). Three distinct 
families of PPRs have been identified: 1) C-type lectin receptors (CLR); 2) Toll like 
receptors (TLR) and 3) Intracytoplamsic-nucleotide Oligomerisation Domain (NOD) like 
receptors (NLR). In the context of allergy however, multivalent cross-linking of the high 
affinity receptors for IgE may also act as a deactivation event. Toll-like receptors are 
also capable of recognising modified host structures, and DC have the capacity to 
phagocytose antigens (Novak and Beiber 2007 and Ueno et al 2007).
Dendritic cells are activated by numerous agents derived from microbes, apoptotic cells, 
and cell mediators derived from the innate or adaptive immune system. Conventional DC 
create cellular processes in the peripheral organs to create a large surface area for antigen 
sensing (Ueno et al 2007). Microbes can either directly activate DC through PPR, or 
indirectly by the capture of apoptotic or necrotic products of other cells dying in response 
to microbial exposure or damage. This indirect mode of DC activation occurs through 
the recognition of endogenous activating molecules by damage-associated molecular 
pattern molecules (DAMP) (Ueno et al 2007). These factors include heat shock proteins, 
high-mobility group box-1 containing polypeptides, p-defensins and uric acid. Microbes 
can also induce cells such as epithelial cells, fibroblasts, and cells of the innate immune 
system to produce cytokines that are capable of directing DC responses (Ueno et al 
2007). Different PPR are specific for, and recognise different PAMPs, which therefore 
deliver distinct molecular signals, thereby yielding the maturation of DC into distinct 
subsets, which influence specific immune responses to defined immunological challenge 
(Ueno et al 2007).
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Following antigen-uptake, processed antigens enter the endocytic compartments and 
antigenic peptides are linked to MHC molecules and presented on the cells surface. 
These events are associated with migration of DC to the T cell area of the draining lymph 
nodes. This chemokine directed process is accompanied with a series of maturation 
events and the down-regulation of antigen capturing capacity (Novak and Beiber 2007). 
These changes include:
■ Alterations in adhesive structures, cytoskeleton reorganisation and acquisition of 
high cellular motility.
■ Loss of endocytic/phagocytic receptors and decreased antigen uptake.
■ Secretion of chemokines in coordinated waves according to the stimulus.
■ Up-regulation of co-stimulatory molecules such as CD40, CD80 and CD86 .
■ Translocation of MHC class II molecules to the cell surface and increased 
half-life of MHC-peptide complexes.
■ Altered chemokine receptor expression.
■ Secretion of cytokines that direct the differentiation and polarisation of effector T 
cells. (Ueno et al 2007 and Wu and Dakie 2004).
Activated DC can orchestrate a variety of cells from the innate and adaptive immune 
systems. Dendritic cells secrete sets of chemokines in three waves, corresponding to the 
three stages of an immune response to a microbe: during the first wave, chemokines are 
produced within 2-4 hours of activation and include CXCL1, CXCL2, CXCL3 and 
CXCL8 which attract innate effector cells such as NK cells, and neutrophils with the aim 
of limiting the spread of infection. The second wave produced within 4-8 hours is 
CXCL9-11 and CCL3-5, which attract activated memory T cells, and monocytes that 
could replenish the pool of DC or tissue macrophages. Finally at 12 hours and later, 
when mature DC arrive in the draining secondary lymphoid organs, they secrete 
CXCL13, which attracts B cells and T cells specialised for humoral responses (Follicular 
T helper cells), CCL19 and CCL21, which attract naive T cells and CCL22 which attracts 
T-regs that will finally facilitate the termination of the immune response. Consequently
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DC act in a co-ordinated manner in order to orchestrate the immune response against 
infection (Piqueras et al 2006, Ueno et al 2007).
In the draining lymph nodes, DC present antigen to and promote the expansion of naive T 
cells into specific T helper populations (Thl, Th2, Thl7), as well as tolerogenic and 
regulatory T-cell subtypes (T-reg) (Novak and Beiber 2007). DC perform this role with 
the aid of three families of molecules: Cytokines, B7 family members and TNF family 
members. Cytokine release by activated DC serves to determine the differentiation fate 
of naive T helper cells for example IL-12 drives Thl cell differentiation (Heufler et al 
1996) whereas IL-6 and IL-23 drive Thl7 differentiation (Langrish et al 2005). The B7 
family includes the co-stimulatory molecules CD80 and CD86 , which bind to CD28 on 
naive T helper cells and deliver the signal for T cells to become functional effector cells. 
Finally, TNF (Caux et al 1992) and CD40 ligation (Caux et al 1994) were shown to 
activate DC with CD40/CD40L interaction promoting DC to up-regulate CD80 and 
CD86 and to secrete IL-12.
As well as activating T cells, DC have also been shown to interact with and activate cells 
of the innate immune system such as NK cells, NKT cells and y6 T cells (Lucas et al 
2007, Fujii et al 2002). The cytokines secreted by these activated innate immune cells in 
return act to activate immature DC to develop into mature cells with distinct phenotypes, 
which will then go on to induce distinct types of T-cell immunity. In addition, DC have 
been shown to activate B cells resulting in the development of a humoral immune 
response against antigens presented by DC (Ueno et al 2007).
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1.14 Cytokines
Cytokines are a group of pleiotropic regulatory polypeptides that are produced by 
haematopoietic and non-haematopoietic cell types to govern activities associated with 
homeostasis or inflammatory activation. These factors are rapidly induced following 
appropriate activation and elicit their activities via autocrine, paracrine and juxtacrine 
mechanisms (Heinrich et al 1998). Cytokines are critical to the development and 
functioning of both the innate and adaptive immune response and include members of the 
interleukin, interferon, growth factor and tumour necrosis factor like superfamilies. They 
are often secreted by immune cells that have encountered a pathogen, thereby activating 
and recruiting further immune cells to increase the system's response to the pathogen 
(Heinrich et al 1998). These soluble mediators are important for the communication 
between cells, and act through transmembrane cell surface receptors eliciting a cellular 
response by the activation of an intracellular signal transduction pathway (Yarden and 
Ullrich 1988). In general, cytokines elicit four functions- induction of gene expression, 
proliferation, differentiation, and survival (pro and anti-apoptotic) to co-ordinate effector 
functions of cells (Thomson 1991, Heinrich et al 1998). The role of cytokines is not 
however limited to the immune system and they are also involved in several 
developmental processes during embryogenesis.
1.14.1 Interleukins
The interleukins (IL) are members of the cytokine family, so named because they co­
ordinate intercommunications between leukocytes. Interleukins act as messenger 
molecules transmitting signals between non-haematopoietic stromal cells and cells of the 
immune system. There are currently 36 known interleukins, which belong to a number of 
families, each playing different roles depending on the context of their expression.
1.14.2 Interferons
Interferons are a family of closely related cytokines that possess potent anti-viral, anti­
microbial, tumoricidal and immunoregulatory activities (Biron 2001). Interferons are 
produced by a wide variety of cells in response to the presence of double-stranded RNA, 
a key indicator of viral infection. They assist the immune response by inhibiting viral
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replication within host cells, activating natural killer (NK) cells and macrophages, 
increasing antigen presentation to lymphocytes, and inducing the resistance of host cells 
to viral infection (Biron 2001). Interferons are classified into type I and type II according 
to their receptor specificity and sequence homology (Schroder et al 2004). Type I 
interferons are structurally related and bind a common heterodimeric receptor. This 
group includes IFN-a and IFN-|3, which are both important for viral immune responses 
(Schroder et al 2004). Interferon-y, the only type II interferon, is structurally unrelated to 
the type I interferons and binds a different receptor. This cytokine is similarly important 
for innate and adaptive immunity against viral and intracellular bacterial infections, as 
well as tumour control (Schroder et al 2004).
1.14.3 Tumour necrosis factor (TNF) super-family
The tumor necrosis factor super-family refers to a group of cytokines that control and 
orchestrate the immune and inflammatory responses (Bodmer et al 2002). Examples of 
these functions include the activation of immune precursor cells to fully competent 
effector cells, which is known to be dependent on several TNF family ligands, such as 
BAFF (B cell activating factor) and CD40L for B lymphocytes, and CD40L and RANKL 
(receptor activator for nuclear factor B ligand) for dendritic cells (Bodmer et al 2002). 
TNF can also regulate T cell activation, expansion and survival (Locksley et al 2001). 
Alternatively, some members of the TNF family (e.g. TNF, Fas ligand and TNF related 
apoptosis inducing ligand (TRAIL)) are pro-apoptotic and usually stimulate apoptosis 
through activation of the cysteine protease family of caspases (Locksley et al 2001). In 
this way, TNF members contribute to the function of cytotoxic effector cells and 
participate in the homeostasis of the lymphoid compartment by evoking activation- 
induced cell death in immune effector cells that have fulfilled their function (Locksley et 
al 2001, Bodmer et al 2002). Excessive or inappropriate control of TNF expression has 
been associated with acquired acute or chronic inflammatory conditions such as septic 
shock and rheumatoid arthritis (Bodmer et al 2002).
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1.15 Chemokines
Chemokines are a group of small structurally related molecules ranging from 8-14kDa, 
that regulate the trafficking of various leukocyte subsets via interactions with a subset of 
seven-transmembrane, G protein-coupled receptors (Baggiolini and Loetscher 2000). 
Inflammatory chemokines mainly act on neutrophils, monocytes, lymphocytes and 
eosinophils and are known to play a crucial role in host defence. Chemokines have also 
been shown to have a number of other roles that expand beyond the immune system such 
as their role in development and homeostasis (Zlotnik and Yoshie 2000). Chemokines 
can be divided into four main subsets determined by the arrangement of their two N- 
terminal cysteine residues. These subsets are named CXC chemokines (CXCL1, CXCL2 
etc), CC chemokines (CCL2, CCL5 etc), CX3C chemokines (CX3CLI, also termed 
fractalkine) or XC chemokines (Lymphotactin), depending on whether the first two 
cysteine residues are adjacent, or have amino acids separating them (Baggiolini et al 
1997, Baggiolini 1998). Fractalkine (CX3CLI), which has three amino acids separating 
the first two cysteine residues, is the only known membrane-bound chemokine, attached 
by a mucin stalk (Bazan et al 1997). Each chemokine nomenclature is then ended with 
an R referring to the receptor, or an L referring to the ligand. Table 1.4 summarises many 
examples of chemokines, their receptors and their functions.
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Receptor Ligands Cellular Distribution
CXCR1 CXCL6 , CXCL8 Neutrophils
CXCR2 CXCL1-3, CXCL5-8 Neutrophils
CXCR3 CXCL9, CXCL10, CXCL11 T cells (Thl)
CXCR4 CXCL12 Neutrophils, monocytes, T cells, B cells, 
DC, thymocytes
CXCR5 CXCL13 Memory B cells, follicular B-helper T 
cells, circulating memory T cells
CXCR6 CXCL16 T cells
CXCR7 CXCL11, CXCL12 Monocytes, B cells, T cells
CCR1 CCL3, CCL5, CCL8, CCL14-16, Monocytes, eosinophils, basophils,
CCL23 activated T cells
CCR2 CCL2, CCL7, CCL8, CCL13 Monocytes, basophils, activated T cells
CCR3 CCL5, CCL8, CCL11, CCL13, 
CCL24, CCL26
Eosinophils, basophils, Th2 cells
CCR4 CCL17, CCL22 T cells (Thl, Th2), memory T cells, 
thymocytes
CCR5 CCL3-5, CCL7, CCL13 Monocytes, Thl cells
CCR6 CCL20 T cells, B cells, immature DC
CCR7 CCL19, CCL21 Naive T cells, mature DC
CCR8 CCL1 Th2 cells
CCR9 CCL25 Memory T cells, B cells, immature 
thymocyte
CCR10 CCL27, CCL28 Memory T cells
XCR1 XCL1, XCL2 Neutrophils, B cells, T cells
CX3CR1 CX3CLI T cells, mast cells, monocytes
Table 1.4: A summary of chemokines receptors, their ligands and their cellular 
distribution.
1.16 Interleukin-6
The IL-6 family of cytokines include IL-6, leukemia inhibitory factor (LIF), oncostatin 
M (OSM), ciliary neurotrophic factor (CNTF), IL-11 and cardiotrophin-1 (CT-1). An 
overview of these cytokines is detailed in Table 1.5.
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Family
Member
Receptor Source Target Cells Functions
IL-6 IL-6R (CD 126) 
+ gpl30 
(CD 130)
Monocytes, 
T cells, 
Fibroblasts, 
Endothelial 
cells.
B, T, plasma 
cells
Thymocytes
Hepatocytes
Antigen specific 
immune responses. 
T and B cell 
growth, activation 
and differentiation. 
Acute phase protein 
production. 
Inflammatory 
reactions.
Fever.
OSM OSMRor LIFR, 
gpl30
T cells,
Monocytes/
Macrophages.
Endothelial
cells.
Mesothelial
cells.
Liver development. 
Haematopoiesis. 
Inflammation. 
Limits monocyte 
trafficking,
EL-11 IL-11R + gpl30 Bone marrow
stromal
fibroblasts.
Mesenchymal
cells.
Megakaryocytes.
Pre-adipocytes.
Haematopoietic
progenitors.
Synergistic actions 
with IL-3 and IL-4 
in haematopoiesis. 
Induction of acute 
phase proteins by 
hepatocytes.
LIF LIFR + gpl30 Bone marrow 
stromal cells. 
Fibroblasts. 
Endothelial 
cells.
Neural tissue. 
Leukemia cells. 
Monocytes.
Maintains 
embryonic stem 
cells.
Inflammation. 
Influences PMN 
recruitment.
CNTF CNRFRa, 
gpl30, LIFR
Glial cells Neuronal cell 
types.
Survival and 
differentiation of 
neural tissues. 
Reduces
inflammatory tissue 
damage.
OSM: Oncostatin M
LIF: Leukemia inhibitory factor
CNTF: Ciliary Neurotrophic Factor
Table 1.5: A table highlighting details o f  some members o f the IL-6 family o f cytokines. 
CT-1 (Cardiotrophin) and CLC (Cardiotrophin like cytokine) are also members of the 
IL-6 family, but are not described in this table.
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The IL-6 family cytokines exhibit pleiotropy and redundancy in biological activities and 
all share the common signal transducing receptor gpl30 (Taga and Kishimoto 1997). 
Interleukin (IL)-6 is a pleiotropic cytokine that regulates various aspects of the immune 
response, acute phase reaction, liver regeneration and haematopoiesis (Kishimoto, T. et al 
1989, 1995). The main producers of IL-6 are macrophages, DC, T cells, B cells, 
fibroblasts, endothelial cells, keratinocytes and most stromal fibrotic cells. IL-6 exerts a 
variety of effects during innate and acquired immunity, which can be defined as both pro- 
and anti-inflammatory. Following activation of TLR, IL-1 p and TNFa production 
induces a rapid release of IL-6 (Topley et al 1993), which subsequently stimulates the 
production of acute phase proteins in the liver, factors that are important for mediating 
the immune response to pathogens. IL-6 then plays a role in leukocyte recruitment, 
specifically the resolution of neutrophil infiltration and the recruitment of mononuclear 
cells (Hurst et al 2001, McLoughlin et al 2003 and 2005). IL-6 mediates these changes 
by the regulation of chemokine expression (McLoughlin et al 2005), and leukocyte 
apoptosis. In this respect, IL-6 rescues T cells from apoptosis by the regulation of anti- 
apoptotic regulators such as Bcl-2 and Bcl-XL (Atreya et al 2000, Teague et al 1997). 
Conversely, IL-6 deficiency is associated with impaired Caspase-3 activity in neutrophils, 
suggesting IL-6 may orchestrate the apoptotic clearance of neutrophils (McLoughlin et al
2003). By regulating leukocyte recruitment and apoptosis in this way, IL-6 has become 
widely known as a key regulator for the transition from innate to acquired immunity, 
characterised by the successful clearance of neutrophils, replacing them with a more 
sustained mononuclear cell population as the inflammatory episode evolves (Jones 2005).
In addition to its role in leukocyte trafficking and apoptosis, IL-6 is also important for the 
determination of B and T cell differentiation fate and function (Bettelli et al 2006, 
Veldhoen et al 2006, Dienz et al 2009). Recently, IL-6 has emerged as a key regulator of 
Thl7 cells, and it has become increasingly evident that this subset of T helper cells is 
involved in the development of autoimmune diseases (Betelli et al 2006). IL-6 in 
combination with TGF-p drives Thl 7 expansion and prevents the expansion of T-regs 
(Bettelli et al 2007, Veldhoen et al 2006, Pasare and Medzhitov 2003). This allows 
increased T cell activity and the onset of increased inflammation, which is damaging to
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the host, and characteristic of autoimmune disease (Langrish et al 2005, Bettelli et al 
2006).
IL-6 is an important growth factor for B cells, and is involved in the differentiation of 
proliferating B cells into antibody producing plasma cells. IL-6 has also recently been 
identified as a key promoter of B cell antibody production. IL-6 promotes the B cell 
helper capabilities of CD4+ T cells by inducing an increased production of IL-21 by these 
cells, which is required for IL-6 to promote B cell antibody production in vitro. This 
identifies IL-6 as a potential co-adjuvant to enhance humoral immunity (Dienz et al
2009).
Dysregulation of IL-6 signalling has been implicated in chronic inflammatory conditions, 
and sustained circulating levels of IL-6 have been documented extensively in 
autoimmune diseases (Jones et al 2001). In this respect, IL-6 deficient mice are resistant 
to the induction of a number of experimental autoimmune conditions (Nowell et al 2003, 
Mihara et al 1998, Kallen et al 2002), while agents that inhibit IL-6 , such as the blocking 
anti-IL-6 receptor antibody MRA (Atlizumab, Tocilizumab) have proven highly effective 
in the treatment of chronic inflammatory autoimmune diseases such as rheumatoid 
arthritis and Crohn’s disease (Choy et al 2002, Ito et al 2004). IL-6 has also recently 
been implicated in cancer, being the cause of between 15 and 20% of cancers (Schafer et 
al 2007, Rose-John et al 2006, 2009, Scheller et al 2006).
1.16.1 IL-6 signalling
IL-6 is able to signal via two different pathways (Figure 1.5). Classical signalling occurs 
when IL-6 binds to its cell surface bound cognate receptor known as IL-6R (CD 126). 
IL-6R is a non-signalling receptor, normally present only on hepatocytes and certain 
leukocyte subsets such as neutrophils, monocytes, and T and B lymphocytes. This 
complex then becomes associated with the signal transducing p-receptor gpl30 (CD 130), 
which acts as the signal transducing receptor for all IL-6 related cytokines (see Section 
1.16.3) (Rose-John et al 1994, Jones 2005).
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SIL-6R/IL-6
PM
sgp130
v
Signal
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Figure 1.5: Modes o f IL-6 signalling (A) Classical signalling occurs when IL-6 binds to its 
cognate surface bound IL-6R, which then associates with gpl30 dimers, and initiates 
the down stream signalling pathway. (B) Trans-signalling occurs independently of the surface 
bound IL-6R, whereby IL-6  binds to its soluble receptor, which then binds gpl30 as a 
complex, to initiate the downstream signalling pathway. This pathway can be blocked by 
soluble gpl30 (sgpl30), which binds and immobilizes the IL-6/sIL-6R complex.
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An alternative signalling pathway also exists whereby IL-6 signals via its soluble 
receptor. This pathway is referred to as IL-6 trans-signalling. The soluble receptor 
binds IL-6 with similar affinity to that of the cognate receptor, and is produced either by 
proteolytic shedding from the surface of cells by the sheddase Adamylsin and 
Disintegrin-associated Metalloprotease (ADAM)-17 and to a lesser extent ADAM-10, or 
by differential mRNA splicing. Both these mechanisms of sIL-6 generation exist in 
humans, however in mice, the soluble receptor is generated exclusively by shedding. In 
this mode of activation, IL-6 simply binds to its non-surface bound receptor, which then 
binds to gpl30 as a complex. This then activates the signalling pathway in exactly the 
same way as in classical signalling. This form of IL-6 signalling allows activation of cell 
types that do not express the surface bound IL-6R and since gpl30 is ubiquitously 
expressed, this includes most cell types, excluding red blood cells (Rose-John et al 1994, 
Jones 2005).
1.16.2 Intracellular signalling pathways of IL-6
In the case of both IL-6 classical signalling and IL-6 trans-signalling, the ligand bound 
IL-6R becomes associated with surface bound gpl30. Ligand-induced |3 subunit gpl30 
dimerisation then leads to the activation of JAK (Janus activated kinases), specifically 
JAK1, JAK2 and Tyk2 in IL-6 signalling, by tyrosine phosphorylation. JAK then 
phosphorylate gpl30 at the four C terminal tyrosine residues and this facilitates the 
recruitment of STATs (signal transducer and activation of transcription) 1 and 3, 
mediated by their SH2 domain. STAT1/3 bind to the phosphorylated YxxQ signalling 
motifs on gpl30, where they then become phosphorylated by JAKs. This 
phosphorylation leads to the formation of active ST AT dimers (STAT 1 and 3 
homodimers and less commonly, heterodimers), also mediated by their SH2 domains. 
These STAT dimers are subsequently transported to the nucleus where they activate gene 
expression (Figure 1.6) (Heinrich et al 2003).
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Figure 1.6: IL-6 signalling via the STAT and SHP2 pathways. Upon binding of IL-6 to its receptor, it becomes 
associated with gpl30 dimers. Gpl30 dimerisation leads to the activation of JAKs (Janus activated kinases), by 
tyrosine phosphorylation, which then phosphorylate gpl30 at the four C terminal tyrosine residues, facilitating 
the recruitment of STATs (signal transducer and activation of transcription) 1 and 3. The STATs then become 
phosphorylated by JAKs, which leads to the formation of active STAT dimers, which are subsequently 
transported to the nucleus where they activate gene expression (Heinrich et al 2003). IL-6 signalling also can 
activate the mitogen-activated protein kinase (MAPK) pathway. This occurs when activated JAKs tyrosine 
phosphorylate receptor bound SHP2, which then binds the adaptor protein growth factor receptor binding 
protein 2 (Grb2), which is constitutively associated with the GDP/GTP Ras exchange factor Sos, and GTP 
bound Ras triggers ERK activation, which leads into the MAPK pathway. Phosphorylated SHP2 can also bind 
with scaffolding proteins Gab 1/2 and phosphotidylinositol-3-kinase (PI3K) which leads to the activation of the 
AKT pathway (Heinrich et al 2003, Ernst and Jenkins 2004, Naugler and Karin 2008).
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As well as activating the STAT pathway, IL-6 signalling also can activate the mitogen- 
activated protein kinase (MAPK) pathway (Figure 1.6). This occurs when activated 
JAKs phosphorylate a further tyrosine residue (Y757 in mouse, Y759 in humans). 
Subsequently, these JAKS phosphorylate receptor bound SHP2 (a protein tyrosine 
phosphatase), which then binds the adaptor protein Growth factor Receptor Binding 
protein 2 (Grb2), which is constitutively associated with the Guanosine diphosphate 
(GDP)/Guanosine triphosphate (GTP) Ras exchange factor Son of Sevenless (Sos). GTP 
bound Ras triggers Extracellular signal Regulated Kinases (ERK) activation, which leads 
into the MAPK pathway. Phosphorylated SHP2 can also bind with scaffolding proteins 
Grb2 Associated Binding protein (Gab)-1/2 and phosphotidylinositol-3-kinase (PI3K), 
which leads to the activation of the AKT pathway (Heinrich et al 2003, Ernst and Jenkins 
2004, Naugler and Karin 2008). Signalling via the STAT1/3 pathway is associated with 
modulation of cellular differentiation, apoptosis and the Gl-S cell cycle transition 
(Yamanaka et al 1996, Fukada et al 1996), whereas the activation of the SHP2/ERK 
MAPK pathways is known to mediate cell cycle progression (Fukada et al 1996).
1.16.3 Regulation of IL-6 signalling
IL-6 trans-signalling is facilitated by the ligation of IL-6 to the soluble form of the 
receptor, which allows the regulation of cell types that do not express the cognate surface 
bound IL-6 receptor, through gpl30. However, due to the ubiquitous cellular expression 
of gpl30, IL-6 trans-signalling has the potential to stimulate all cell types in the body. 
Consequently it is important that this mode of IL-6 signalling is tightly regulated. This 
regulation is facilitated in a number of ways: 1) Regulation can be provided by a soluble 
variant of gpl30 (sgpl30), which is detected at high levels circulating in human sera 
(l-300ng/ml), and is known to counteract IL-6 signalling via its soluble receptor. 
Antagonism by sgpl30 only occurs once the IL-6/sIL-6R complex has formed and so it 
binds the complex as opposed to the individual components. Murine studies have 
demonstrated that sIL-6R levels increase before that of sgpl30 suggesting individual 
regulation of each protein, and although gpl30 shedding has been investigated as a 
source of sgpl30 in vitro, it is predicted that there is a more active role for differential 
mRNA splicing of the gpl30 gene in vivo (Jones 2008, Diamant et al 1997). 2) As part
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of the transcriptional events controlled by IL-6 , a series of negative regulators including 
suppressor of cytokine signalling (SOCS) 1 and SOCS 3 are induced. SOCS3 
counteracts STAT3 activation by interaction with a tyrosine residue that also directs 
SHP2 signalling. Specifically SOCS3 binds via its SH2 domain to tyrosine residue 757 
of gpl30 in mice and 759 in humans (Nicholson et al 2000, Schmitz et al 2000). 3) The 
third mode of regulation is facilitated by auto-antibodies specific for IL-6 . These exist in 
humans and are able to bind to and immobilise this cytokine in vivo (Suzuki et al 1994). 
4) IL-6 trans-signalling is also regulated by the rate of sIL-6 receptor production. 5) 
Regulation also occurs by the control of the balance between classical and 
trans-signalling and 6) the balance between IL-6 directed STAT1 and STAT3 signalling.
1.16.4 IL-6 in acute inflammation
As previously described, IL-6 is critically required for the resolution of innate immunity 
and the development of an acquired immune response (Jones 2005). In acute 
inflammation, this process is defined by a precise regulation of leukocyte recruitment and 
clearance, during which IL-6 is vital for the transition from a neutrophil to a mononuclear 
cell infiltrate (Jones 2005). This pattern of leukocyte infiltration is regulated by IL-6 and 
its soluble receptor, which suppresses neutrophil infiltration and promotes mononuclear 
cell recruitment and activation, through the modulation of inflammatory chemokine 
expression and apoptotic control processes (Hurst et al 2001, McLoughlin et al 2003, 
2005, Atreya et al 2000). This is discussed further in Section 1.20.6. IL-6 has also been 
shown to be a key regulatory signal in the development of Thl7 cells (Harrington et al 
2005, Betelli et al 2006, Veldhoen et al 2006). This subset of T helper cells produce the 
cytokines IL-17A and IL-17F, which are important for the innate immune response 
against extracellular bacteria (Bettelli et al 2007).
By directing and regulating the acute inflammatory response, IL-6 allows the successful 
clearance of the pathogen, and subsequent resolution of inflammation. This has been 
demonstrated effectively by Coles et al who has shown that IL-6 deficient mice exhibit 
impaired bacterial clearance during an experimental model of bacterial peritonitis (Coles 
et al unpublished). In support of this, it was recently shown that the reconstitution of
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IL-6 trans-signalling in IL-6 deficient mice subjected to bacterial infection, improved the 
rate of mortality and led to reduced neutrophilia and increased bacterial clearance in these 
mice (Onogawa 2005). This IL-6-driven outcome may be particularly relevant in septic 
shock, where IL-6 has proven to be protective (Barton et al 1993, Diao et al 2005). 
Finally, IL-6 deficient mice also display impaired viral clearance (Kopf et al 1994). 
Therefore, IL-6 is clearly important for the regulation of cellular immunity against 
infections. The protective properties displayed by IL-6 during infection must however be 
balanced against the detrimental aspects of IL-6 biology seen in chronic inflammatory 
disease. Dysregulation of this cytokine has been largely implicated in chronic 
inflammatory and autoimmune disease and this is discussed in more detail in Section
1.16.5.
1.16.5 IL-6 in chronic inflammation
As previously described, a pivotal role in the resolution of any inflammatory episode is 
the transition from innate to acquired immunity. Inappropriate regulation of this process 
can lead to a chronic inflammatory state, characterised by the retention of an activated 
mononuclear cell population within the affected tissue (Jones 2005).
Overproduction and increased signalling of IL-6 has been associated with chronic 
inflammatory and autoimmune conditions (rheumatoid arthritis, systemic lupus 
erythematosus, psoriasis, colitis, diabetes and various other inflammatory bowel 
diseases), which through an undefined dysregulation of chemokine-mediated recruitment 
and leukocyte apoptosis, is potentially detrimental (Grossman et al 1989, Swaak et al 
1989, Houssiau et al 1988, Naugler and Karin 2008). In this respect, increased levels of 
IL-6 in the synovial fluid within the inflamed joints of rheumatoid arthritis patients has 
been associated with joint pathology, with a series of in vivo studies using models of 
experimental arthritis having endorsed a role for IL-6 in joint destruction, leukocyte 
recruitment, apoptosis and T cell activation (Kallen 2002, Nowell et al 2003, Ohshima et 
al 1998, Alonzi et al 1998). The importance of IL-6 in chronic inflammatory diseases is 
reinforced by the fact that IL-6 deficient mice are resistant to the induction of 
experimental encephalitis, colitis, lupus nephritis and rheumatoid arthritis (Atreya, R. et
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al 2000, Nowell, M.A. et al 2003, Mihara, M. et al 1998). IL-6 deficient mice are also 
resistant to the induction of experimental chronic peritonitis and the associated membrane 
thickening, which has implications for peritoneal dialysis patients (see Sections 1.20.1-7) 
(Fielding et al 2009, submitted).
IL-6 trans-signalling is able to enhance production of several mononuclear cell 
chemoattractants from resident tissue cells, driving the recruitment of monocytic cells 
and lymphocytes to the inflammatory site (Jones, 2005). In addition to this, IL-6 also 
has anti-apoptotic effects on T cells, which can result in retention of mononuclear cells at 
sites of inflammation as observed in the lamina propria of Crohn’s disease patients, and 
the synovium of arthritic joints (Atreya et al 2000, Yamamoto et al 2000, Kikly et al 
2006, Nowell et al 2003, 2009). Both in vitro and in vivo studies have demonstrated the 
ability of IL-6 trans-signalling to ‘rescue’ T cells from apoptosis through a mechanism 
involving STAT3 driven expression of the anti-apoptotic regulators Bcl-2 and B c1 -x l  
(Teague et al, 2000; Atreya et al, 2000). In vivo blockade of IL-6R signalling by 
administration of an anti-IL-6R monoclonal antibody or soluble gpl30 therefore confers 
protection against these conditions, which are specifically associated with the IL-6 
mediated suppression of T cell apoptosis. This is important since inflammatory T helper 
cells such as the recently characterised Thl7 cells have been increasingly associated with 
the development of many autoimmune and chronic inflammatory conditions (Atreya et al 
2000, Yamamoto et al 2000, Kikly et al 2006, Nowell et al 2003, 2009).
These findings have led to the development of strategies that therapeutically inhibit IL-6 
responses, and a number of anti-IL-6 drugs are already available. The humanised 
blocking anti-IL-6 receptor antibody MRA (Tocilizumab, Atlizumab) is an example that 
has been shown to be highly effective in advanced clinical trials for the treatment and 
management of rheumatoid arthritis and Crohn’s disease (Choy et al 2002, Ito et al
2004).
It is important to remember that the detrimental consequences of IL-6 activity in chronic 
disease is balanced by its capacity to protect against septic shock (Barton et al 1993),
52
coordinate microbial clearance (Onogawa 2005, Coles et al unpublished) and to direct 
resolution of acute inflammation (Jones 2005). Completely blocking IL-6 signalling may 
have an undefined deleterious effect on the host’s ability to resolve bacterial infections. 
It is currently unknown what causes the conversion from a protective to a detrimental 
IL-6 biology.
1.17 Interleukin-10
IL-10 is a pleiotropic cytokine, which plays an important role in the early immune 
response, and displays suppressive activity toward a number of cell types in the immune 
system including macrophages, DC, neutrophils, eosinophils and Thl cells. IL-10 is 
important in regulating the severity and duration of inflammatory responses, making it 
important for obtaining the right balance between inducing the immune response to fight 
the pathogen, and inhibiting the immune response to prevent collateral tissue damage (Ho 
et al 1994).
IL-10 is produced by antigen presenting cells upon TLR-4 activation by LPS. This TLR 
induced production of IL-10 is also further increased by the presence of damaged cells, 
which usually arise during the inflammatory response (Byrne et al 2002). IL-10 is a 
potent stimulator of NK cells (Zheng et al 1996), which is important for the clearance of 
the pathogen and the acquisition of antigen from dead cells for cross priming by APC, 
which increases antigen availability and induces further activation of APC by induction 
of apoptosis/necrosis of damaged cells (Albert et al 1998). This facilitates the induction 
of an adaptive immune response, providing a link between innate and acquired immunity 
(Belardelli et al 2002). These combined allow IL-10 to contribute to the destruction of 
the pathogen, while limiting collateral tissue damage by simultaneously dampening the 
immune response, which it does in a number of ways discussed below.
IL-10 regulates the expression of cytokines, chemokines and co-stimulatory molecules on 
myeloid cells, having important effects on their ability to activate and sustain the 
inflammatory response (Moore et al 2001). In this respect, IL-10 suppresses the ability 
of APC to prime effector T cells by dampening the expression of inflammatory
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chemokines, co-stimulatory molecules and preventing further APC maturation (Moore et 
al 2001). IL-10 suppresses the release of monocyte inhibitory protein-la (MIP-la), 
MIP-lp, CCL2, CCL5 and KC (Berkman et al 1995, Marfaing-Koka et al 1996, 
Kopydlowski et al 1999, Olszyna et al 2000), TNF-a, IL -la, IL-lp, IL-6 and IL-8 by 
activated APC (Fiorentino et al 1991, de Waal Malefyt et al 1991, Moore et al 2001). 
IL-10 also inhibits the expression of MHCII, CD80 and CD86 on monocytes (de Waal 
Malefyt et al 1991, Ding et al 1993). In this respect, IL-10 indirectly inhibits T cell 
proliferation, by the suppression of antigen presenting cells (Chemoff et al 1995, de Waal 
Malefyt et al 1991). This is most likely a mechanism in place in order to restrict the 
extent of an inflammatory process, and prevent any collateral damage. By inhibiting 
APC maturation, IL-10 conserves their ability for antigen uptake and delays their 
migration to the draining lymph nodes. If the pathogen is not cleared in the early 
response, further signals are provided which lead to APC activation, maturation and the 
onset of the adaptive immune response (Brossart et al 2000).
Similar anti-inflammatory properties of IL-10 includes its ability to inhibit microbicidal 
activities in macrophages, and blocking IL-10 increases their killing capacity (Fleming 
and Campbell 1995). The same is true for neutrophils, where studies have shown that 
IL-10 inhibited bacterial phagocytosis and attenuated neutrophil microbicidal activity 
towards internalised bacteria (Laichalk et al 1996). In this respect, IL-10 plays a central 
role in facilitating bacterial outgrowth and dissemination.
Finally, IL-10 production by CD4+ T cells serves to halt the later phases of the 
inflammatory response when the pro-inflammatory stimuli induced by the pathogen is 
eliminated by the antigen specific effector mechanisms (Moore et al 2001). In particular 
IL-10 is thought to promote intracellular infection by disabling Thl responses and 
deactivating parasitised tissue macrophages (Murray et al 2002). In this respect, IL-10 
has been shown to induce anergy or non-responsiveness in T cells (Groux et al 1996).
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1.17.1 IL-10 signalling
The receptor for IL-10 has two subunits called IL-10 Receptor (R) a  and IL-10 Receptor 
(R) p. As the ligand-binding a  chains interact with IL-10 they dimerise and become 
associated with the two secondary p chains. Receptor assembly leads to activation of the 
Janus kinases JAK1 and Tyk2 and phosphorylation of tyrosine residues on the IL-10 Rl. 
This leads to the recruitment and phosphorylation of STAT3, which forms homodimers 
and translocates to the nucleus to activate a wide range of IL-10 -responsive genes 
(Figure 1.7) (Riley et al 1999, Ho et al 1993, 1994).
1.18 Interferon (IFN)^y
Interferon (IFN)-y co-ordinates a diverse array of cellular programs through the 
transcriptional regulation of immunologically important genes. It was at first thought that 
IFN-y was solely produced by CD4+ Thl lymphocytes, CD8+ cytotoxic T lymphocytes 
and NK cells, but further investigation has shown that B cells, NKT cells, and 
professional APC all produce IFN-y (Schroder et al 2004).
Initially, IFN-y orchestrates the trafficking of leukocytes by the up-regulation of adhesion 
molecule and chemokine expression. IFN-y and Nitric Oxide (NO) produced at the site 
of inflammation cause blood vessels in the vicinity to dilate thereby increasing “leaky 
vessels” and maximizing blood flow to the inflammatory site. IFN-y then up-regulates 
the expression of various chemokines such as MCP-1, M IP-la/p and RANTES, and also 
the expression of adhesion molecules ICAM-1 and VCAM-1, which in combination 
maximize trans-endothelial migration of leukocytes to the site of inflammation (Boehm et 
al 1997). IFN-y then has the ability to direct the activities of numerous cell types: IFN-y 
is an important stimulator of macrophages, inducing direct antimicrobial and antitumour 
mechanisms in these cells. IFN-y stimulation of macrophages increases pinocytosis and 
receptor-mediated phagocytosis, and enhances their microbial killing abilities by the 
induction of the NADPH-dependent phagocyte oxidase system (respiratory burst) and by 
priming for nitric oxide (NO) production (Decker et al 2002). IFN-y also up-regulates 
macrophage antigen processing and presentation pathways.
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Figure 1.7: IL-10 signalling pathway. The receptor for IL-10 has two subunits: IL-10 Rot and 
IL-10 Rp. As the ligand-binding chains interact with IL-10 they dimerise and become 
associated with two secondary chains. Receptor assembly leads to activation of the Janus 
kinases JAK1 and Tyk2 and phosphorylation of tyrosine residues on the IL-10 R a . This 
leads to the recruitment and phosphorylation of STAT3, which forms homodimers and 
translocates to the nucleus to activate a wide range of IL-10 -responsive genes (Riley et al 
1999, Ho et al 1993, 1994).
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IFN-y up-regulates many functions within the class I antigen presentation pathway to 
increase the number and diversity of peptides presented on the cell surface. Up- 
regulation of MHC I is important for the host response to intracellular pathogens and 
increases the likeliness of cytotoxic T cell recognition of foreign peptides thereby 
inducing cell mediated immunity (Schroder et al 2004). IFN-y also up-regulates MHC II 
presentation pathways thereby promoting peptide specific activation of CD4+ T cells 
(Mach et al 1996).
Finally, IFN-y is able to co-ordinate the transition from innate to adaptive immunity by 
aiding the development of Thl type responses, as well as directing B cell isotype 
switching, inducing immunoglobulin production, and regulating local leukocyte 
endothelial interactions (Schroder et al 2004). IFN-y is involved in the development of 
Thl responses and subsequent IFN-y secretion by these cells further skews the immune 
response towards a Thl phenotype. IFN-y facilitates this response by promoting Thl 
effector mechanisms such as innate cell mediated immunity by activation of NK cell 
effector functions, specific cytotoxic immunity by maximizing T cell:APC interactions to 
increase CD4+ differentiation (a result of increased antigen processing, presentation, and 
expression of co-stimulatory molecules) and macrophage activation (Boehm et al 1997).
1.18.1 Interferon (IFN)-y signalling
The receptor for IFN-y has two subunits, the IFN-y Ra ligand-binding chain and the 
IFN-y Rp signal-transducing chain. The receptor complex comes together and assembles 
before the ligand binds and IFN-y binds the receptor complex as a non-covalent 
homodimer. Ligand binding induces JAK2 autophosphorylation and activation, which 
allows JAK1 trans-phosphorylation by JAK2. The activated JAK1 then phosphorylates 
functionally important tyrosine residue 440 of each alpha chain to form two adjacent 
docking sites for the SH2 domains of STAT1. The recruited STAT1 pair is then 
phosphorylated near the N terminus at Y701, most likely by JAK2, inducing their 
dissociation from the receptor complex as a homodimer. The STAT1 homodimer then 
translocates to the nucleus to activate a wide range of IFN-y -responsive genes (Figure 
1.8) (Schroder et al 2004).
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Figure 1.8: IFN-y signalling pathway. The receptor for IFN-y has two subunits, IFN-y Roc, 
the ligand-binding chain and IFN-y Rp, the signal-transducing chain. The receptor complex 
comes together and assembles before the ligand binds and IFN-y binds the receptor complex 
as a non covalent homodimer. Ligand binding induces JAK2 autophosphorylation and 
activation, which allows JAK1 trans-phosphorylation by JAK2. The activated JAK1 then 
phosphorylates tyrosine residue 440 of each R Ot chain to form two adjacent docking sites for 
the SH2 domains of STAT1. The recruited STAT1 pair is then phosphorylated near the N 
terminus at Y701, most likely by JAK2, which induces their dissociation from the receptor 
complex as a homodimer. The STAT1 homodimer then translocates to the nucleus to 
activate a wide range of IFN-y -responsive genes (Schroder et al 2004).
1.19 Oncostatin M
Oncostatin M (OSM) is a pleiotropic cytokine of the interleukin-6 family and is produced 
by activated T cells and macrophages. OSM has been shown to drive the differentiation 
of megakaryocytes, inhibit tumour cell growth, induce neurotrophic peptides, and 
regulate cholesterol metabolism (Bruce 1992). In addition, OSM has also been 
implicated in wound healing and attenuation of the immune response, with evidence 
showing that OSM regulates the expression of IL-6 (Brown et al 1991), which has known 
potent pro-inflammatory capabilities. OSM can also regulate the expression of human 
acute phase proteins and protease inhibitors that have been implicated in modulating 
cytokine function and limiting tissue damage at sites of inflammation (Wallace et al 
1995).
OSM is produced late in the cytokine response and protects from LPS-induced toxicities 
(shown by its inhibition of bacterial LPS-induced TNF-a and septic lethality), promoting 
the re-establishment of homeostasis by cooperating with pro-inflammatory cytokines and 
acute phase molecules to alter and attenuate the inflammatory response. Additionally, in 
many murine models of chronic inflammatory disease such as rheumatoid arthritis and 
multiple sclerosis, OSM potently suppresses inflammation and tissue destruction 
(Wallace et al 1999, Wahl et al 2001). In contrast to this data however, OSM has been 
shown to be involved in tissue injury. Langdon et al showed that OSM may be involved 
in inflamed joint pathology, due to its apparent ability to regulate synovial fibroblast 
function (growth, and expression of MCP-1, IL-6 and tissue inhibitor metalloproteinase- 
1) in vitro, and its ability to cause increases in the synovial cell proliferation, infiltration 
of mononuclear cells, and increases in extracellular matrix deposition in joints in vivo 
resulting in the induction of a proliferative invasive phenotype of synovium in vivo in 
mice on overexpression (Langdon et al 2000).
Finally, OSM has been shown to have a role in monocytic cell trafficking during acute 
inflammation. Hams et al showed that OSM limits monocytic cell recruitment, shown by 
using a murine model of peritoneal inflammation in OSM-receptor p knock out mice,
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which exhibited enhanced monocytic cell trafficking. This was linked to the ability of 
OSM to inhibit IL-lp-mediated NF-kB activity and CCL5 expression (Hams et al 2008).
1.19.1 OSM signalling
OSM engages gpl30 to form a heterodimer with the OSMRp, upon which the 
intracellular signal is initiated. Gpl30 dimerisation with OSMRjJ leads to the activation 
of JAK (Janus activated kinases), specifically JAK1, JAK2 and Tyk2, by tyrosine 
phosphorylation. JAK then phosphorylates gpl30 at the four C terminal tyrosine residues 
and this facilitates the recruitment of STAT (signal transducer and activation of 
transcription) 1,3 and 5, mediated by their SH2 domain. STAT 1/3/5 bind to the
phosphorylated YxxQ signalling motifs on gpl30, where they then become 
phosphorylated by JAK. Phosphorylation occurs on a single tyrosine residue, which 
leads to the formation of active STAT dimers (STAT 1,3 and 5 homodimers and less 
commonly, heterodimers), also mediated by their SH2 domains. These STAT dimers are 
subsequently transported to the nucleus where they activate gene expression (Figure 1.9). 
OSM can also activate the mitogen-activated protein kinase (MAPK) pathway. This 
occurs when activated JAK tyrosine phosphorylate receptor bound SHP2 (a protein 
tyrosine phosphatase), which then binds the adaptor protein growth factor receptor 
binding protein 2 (Grb2), which is constitutively associated with the GDP/GTP Ras 
exchange factor Sos, and GTP bound Ras triggers ERK activation, which leads into the 
MAPK pathway (Figure 1.10) (Heinrich et al 2003).
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Figure 1.9: OSM signalling via the STAT pathway. Upon binding of OSM to its receptor, it 
becomes associated with gpl30. This leads to the activation of JAKs (Janus activated 
kinases), by tyrosine phosphorylation, which then phosphorylate gpl30, facilitating the 
recruitment of STATs (signal transducer and activation of transcription) 1,3 and 5. The 
STATs then become phosphorylated by JAKs, which leads to the formation of active 
STAT dimers, which are subsequently transported to the nucleus where they activate gene 
expression (Heinrich et al 2003).
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Figure 1.10: OSM signalling via the SHP2 pathway. Upon binding of OSM to its receptor, 
it becomes associated with gpl30. This leads to the activation of JAKs (Janus activated 
kinases), by tyrosine phosphorylation, which then phosphorylate gpl30. The JAKs then 
tyrosine phosphorylate receptor bound SHP2, which then binds the adaptor protein growth 
factor receptor binding protein 2 (Grb2), which is constitutively associated with the 
GDP/GTP Ras exchange factor Sos, and GTP bound Ras triggers ERK activation, which 
leads into the MAPK pathway. (Heinrich et al 2003, Ernst and Jenkins 2004).
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1.20 Established Renal Failure
End stage renal failure arising as a consequence of chronic renal disease is characterised 
by a 90% reduction in renal function as determined by the glomerular filtration rate 
(GFR). Patients with chronic renal disease have an abnormally low GFR. Causes of 
renal failure can include hypertension and cystic and interstitial renal diseases, but the 
majority of cases occur as a direct result of diabetic nephropathy, following longstanding 
diabetes mellitus.
The most effective and preferred treatment for end stage renal failure patients is kidney 
transplantation. However a lack of donor kidneys and transplant failure substantially 
limits the effectiveness of this treatment. Alternative treatment strategies involve the use 
of haemodialysis, which uses hydrostatic pressure to achieve ultra-filtration of fluids and 
solutes from the blood, or peritoneal dialysis to remove solutes from the blood.
1.20.1 Peritoneal dialysis
Peritoneal dialysis (PD) is an alternative therapy to haemodialysis, and is a more widely 
used therapy for patients with end stage renal failure. Peritoneal dialysis involves the use 
of a highly concentrated sugar solution to remove solutes from the blood utilising the 
semi permeable and highly vascularised peritoneal membrane as a dialysing surface, 
which separates the peritoneal capillary blood from the dialysate that is instilled into the 
peritoneal cavity through an implanted catheter (Venkat et al 2006).
1.20.2 Peritoneal dialysis technique
Dialysis fluid, which contains a high concentration of glucose, is instilled into the 
peritoneal cavity via an implanted catheter, which enters the skin in the right or left lower 
abdominal quadrant. Dialysate is left in the peritoneal cavity for 6-8 hours to equilibrate 
and then drained to allow fresh dialysate to be instilled. Removal of solutes from the 
blood relies on the creation of an osmotic gradient between the dialysate and the capillary 
rich peritoneal membrane by using varying concentrations of glucose in the dialysis fluid. 
During this time, solute transport occurs across the peritoneal membrane (Venkat et al 
2006). Water and small solutes including uremic metabolites move from the blood into
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the dialysate through the combination of osmotic pressure and hydrostatic ultrafiltration. 
This dialysis fluid is then drained from the peritoneal cavity and the cycle repeated 
approximately four times daily.
1.20.3 Peritonitis
Peritonitis, an inflammatory condition caused by bacterial infection, is a common 
complication with peritoneal dialysis and the biggest reason for treatment failure. It is 
defined by a dialysate leukocyte count of 105 cells/ml or more, with or without 
accompanying symptoms such as abdominal pain and fever and cloudy dialysate (Davies 
et al 1996). Repeated episodes of peritonitis are directly related to increased peritoneal 
fibrosis and increased susceptibility to further peritoneal infection.
The most common pathogens associated with peritonitis are gram-positive staphylococci, 
including Staphylococcus epidermidis and Staphylococcus aureus (Woo et al 2004). 
Most episodes of peritonitis are associated with catheter site infections caused by touch 
contamination during dialysis exchange. Episodes of peritonitis have been associated 
with the onset of ultrafiltration failure and can cause morphological changes in the 
membrane, characterised by cellular necrosis and a loss of the mesothelium (Di Paolo et 
al 1986). A loss of the filtration barrier and the function of the mesothelium leads to a 
loss of host defence, resulting in increased incidence of further infection. This increased 
susceptibility to peritonitis further compromises the host immune response, and 
ultimately, leads to treatment failure (Davies et al 1996).
1.20.4 The peritoneal membrane
The peritoneal membrane is composed of two distinct layers: an epithelial layer known as 
the mesothelium; and its underlying connective tissue known as the interstitium or the 
compact zone (Krediet et al 2000). These layers are separated by a discontinuous 
basement membrane, composed of proteoglycans, type IV collagen and glycoproteins, 
which supports the mesothelium (Nagy and Jackman, 1998). The compact zone acts as a 
cellular barrier preventing fibroblasts in the connective tissue making contact with the
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mesothelium. This zone is composed of extracellular matrix molecules including type I 
and III collagen, fibronectin and hyaluronic acid (Witz et al 2001).
The peritoneal membrane is highly vascularised to traffic molecules to and from tissues 
and organs of the abdominal cavity and a lymphatic system is also present, which is 
important for host defence within the peritoneum (Nagy and Jackman, 1998).
The mesothelium is composed of a monolayer of flattened mononuclear cells, which 
possess a luminal microvilli border to increase the surface area for exchange (Di Paolo et 
al 1986). The main function of the mesothelium is to maintain normal homeostasis 
within the peritoneal cavity, being involved in the transport of solutes and cells across 
serosal cavities, however they also play a role in regulating the inflammatory response 
after peritoneal infection or injury (Mutsaers et al 2004).
1.20.5 Peritoneal inflammation and the role of IL-6
Peritoneal inflammation can be characterised by an initial recruitment and subsequent 
clearance of neutrophils followed by the recruitment of a more sustained mononuclear 
cell infiltrate (Topley et al 1996) (Figure 1.11). Peritoneal inflammation, triggered by the 
presence of gram-positive bacteria, is driven by the early TLR-mediated activation and 
release of pro-inflammatory cytokines IL-1 and TNFa by “resident” peritoneal cells, 
usually monocytic cells such as macrophages. These pro-inflammatory cytokines signal 
the mesothelial cells, lining the peritoneal cavity, to produce an array of inflammatory 
mediators including CXCL1, CXCL2, CXCL5 and CXCL8, which are potent neutrophil 
activating CXC chemokines that promote neutrophil recruitment (Hurst et al 2001), and 
integrins such as CD62L, ICAM-1 and VCAM-1 in the mesothelium and endothelium of 
the surrounding blood vessels (Betjes et al 1993, Li et al 1998, Jonjic et al 1992). This 
initiates the strong adhesion of circulating neutrophils to the endothelium of blood vessels 
surrounding the site of inflammation and forms a chemotactic gradient down which 
neutrophils migrate into the peritoneal cavity where they form the initial response to the 
infection (Topley et al 1996). Upon entry into the peritoneal cavity, neutrophils are 
known to shed their surface bound IL-6R (McLoughlin et al 2004).
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Figure 1.11: Leukocyte infiltration into the murine peritoneal cavity following the 
induction o f inflammation. Upon induction of peritoneal inflammation, a 
characteristic infiltration of leukocytes can be observed. There is an initial influx of 
neutrophils which are cleared promptly, and followed by an infiltration of monocytic 
cells and lymphocytes.
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This shedding is performed by the sheddase ADAM-17 and is thought to be initiated by: 
1) C reactive protein (CRP) activation of neutrophils (produced in the liver in response to 
IL-6) (Jones et al 1999), 2) apoptosis of neutrophils (Chalaris et al 2007) and 3) by 
activation of neutrophils by CXCL1 and other chemoattractants (Marin et al 2001, 
McLoughlin et al 2004). This release of IL-6R facilitates the formation of the 
IL-6/sIL-6R complex, when the soluble receptor binds to exogenous IL-6 present in the 
peritoneal cavity having been secreted from the lining mesothelial cells (Topley et al 
1993). The formation of this complex facilitates trans-signalling and subsequent STAT 
activation in the mesothelial cell lining of the peritoneal cavity, which has been shown to 
differentially regulate inflammatory chemokine expression (notably the down-regulation 
of CXCL1 and up-regulation of CCL2 and CCL5 by mesothelial cells) (Hurst et al 2001, 
McLoughlin et al 2005) and modulate leukocyte apoptosis (in particular IL-6 directs 
caspase-3-mediated neutrophil apoptosis, but prevents T cell apoptosis) (McLoughlin et 
al 2003, Teague et al 1997, Atreya et al 2000). Consequently, IL-6 is essential for 
directing the transition from innate to acquired immunity (Figure 1.12) by defining the 
successful resolution and clearance of neutrophils, and the subsequent recruitment of 
mononuclear cells (Jones, S.A. 2005, Hurst et al 2001, McLoughlin et al 2004, 2005). 
Regulation of these activities may be critical for resolving bacterial infections since 
IL-6'7' mice show an impaired ability to control infections (Kopf et al 1994, Dalrymple et 
al 1995).
When challenged, IL-6 deficient mice exhibit impaired control of leukocyte infiltration 
and apoptosis. These mice exhibit increased neutrophil recruitment to the peritoneal 
cavity following acute inflammatory challenge, due to increased secretion of neutrophil 
chemoattractants, and also an impaired clearance of these cells resulting from impaired 
induction of apoptosis. These mice also exhibit impaired T lymphocyte trafficking into 
the cavity as a result of impaired chemokine secretion and receptor expression 
(McLoughlin et al 2004, 2005). In WT mice, IL-6 selectively governs T cell infiltration 
by regulating chemokine secretion (CXCL10, CCL4, CCL5, CCL11, and CCL17) and 
chemokine receptor (CCR3, CCR4, CCR5, and CXCR3) expression on the CD3+ 
infiltrate (McLoughlin et al 2005).
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Figure 1.12: Regulation by IL-6 signalling o f the early innate and late/adaptive 
arms of the immune system. The early innate immune response is regulated by IL-6 
trans-signalling, while the late/adaptive immune response is regulated by both 
classical and trans-signalling.
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Additionally, the IL-6/sIL-6R complex has been shown to be an inhibitor of apoptosis in 
T cells by inhibiting the down-regulation of anti-apoptotic regulator Bcl-2 (Teague et al 
1997). IL-6'a mice lacking this cytokine are more prone to T cell apoptosis, however this 
has not been proven in a model of peritonitis.
During initial cases of peritonitis, the influx of mononuclear cells effectively clears the 
pathogen and as a result, removes the stimulus for the production and release of pro- 
inflammatory cytokines. This then down-regulates the trafficking signals facilitating 
leukocyte infiltration into the cavity, and therefore leads to the resolution of the 
inflammatory response. In recurrent cases of peritonitis however, or in patients who have 
been undergoing PD for sustained periods of time, it is common to see a decreased 
clearance of pathogens during infection, and a constant up-regulation of pro- 
inflammatory cytokines, which lead to the onset of a chronic inflammatory state. This is 
characterised by an increased infiltration of neutrophils followed by a sustained influx 
and retention of mononuclear cells into the peritoneal cavity (Figure 1.13). The 
accumulation of leukocytes and the presence of elevated levels of cytokines in the 
peritoneal cavity have been shown to lead to loss of mesothelial integrity and thickening 
of the membrane. In cases of peritoneal membrane thickening, or ‘fibrosis’, the dialysing 
capacity of the membrane is compromised which can lead to treatment failure (Davies et 
al 1996, Selgas et al 2006).
1.20.6 Peritoneal dialysis associated fibrosis
Fibrosis is a pathological hallmark of many diseases, and is characterised by alterations in 
extracellular matrix deposition as a consequence of tissue damage or persistent 
inflammatory processes (Wynn et al 2007). Evidence has shown that exposure to bio­
incompatible peritoneal dialysis fluids during prolonged PD treatment in combination 
with repeated peritonitis episodes leads to long term changes in both peritoneal 
membrane structure and function. These include partial or complete loss of the 
mesothelium, a thickening of the submesothelial tissue due to deposition of collagen 
(fibrosis or sclerosis), hypervascularization in the submesothelial zone and alterations in 
the mesothelial cells such as multinucleation and reduced regenerative capacities
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(Davies et al 1996, Williams et al 2002, Di Paolo et al 1986, Devuyst et al 2002). 
Clinical evaluation of peritoneal biopsies have shown that the normal thickness of the 
submesothelial zone is approximately 50 pm compared to a thickness of 270 pm in 
peritoneal dialysis patients with active peritoneal fibrosis (Williams et al 2002).
Glucose and glucose degradation products in the dialysis fluid are responsible for 
stimulating transforming growth factor-(3 (TGF-P) production by mesothelial cells.
TGF-p is thought to be a key growth factor in the development of fibrosis in diabetic 
patients (Williams et al 2002), and increased peritoneal levels of TGF-p have been 
observed in PD patients (Williams et al 2002). TGF-P is a potent regulator of growth and 
differentiation of connective tissue cells and stimulates the conversion of fibroblasts to 
myofibroblasts during fibrogenesis (Roberts et al 1986). TGF-p also drives epithelial to 
mesenchymal transition (EMT) in the mesothelium. EMT is a process by which cells are 
diversified in complex tissues and by undergoing EMT, mesothelial cells are transformed 
into fibroblast like cells and acquire fibroblast capabilities with increased migratory, 
invasive and fibrogenic features (Selgas et al 2006). Epithelial to mesenchymal 
transition (EMT) is usually a normal physiologic process, during which local fibroblasts 
proliferate and secrete a non-rigid extracellular matrix rich in collagen type I and III, 
which is necessary for tissue repair under normal conditions. However if this process is 
uncontrolled, for example during PD when TGF-P levels are elevated, it can promote a 
fibrotic response and is well known to play a central role in the genesis of fibroblasts 
during organ fibrosis in adult tissues (Selgas et al 2006).
Glucose and glucose degradation products in the dialysis fluid are also responsible for 
stimulating vascular endothelial growth factor (VEGF) production by mesothelial cells. 
Local production of VEGF by transitional mesothelial cells in response to glucose 
products, appears to play a role in the processes leading to peritoneal angiogenesis 
(Selgas et al 2006). Peritoneal angiogenesis is one of the morphological membrane 
changes associated with fibrosis and is characterised by a progressive increase of
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capillaries and vasculopathy, which leads to increased small solute transport across the 
membrane (Selgas et al 2006).
Peritonitis has been shown to exacerbate and accelerate the process of fibrosis. The 
inflammatory response that occurs during peritonitis provides an alternative source of the 
pro-fibrotic growth factor TGF-p, as well as IL-1 and other pro-inflammatory cytokines, 
and the accumulation of these factors that arises as a result of repeated infections can 
contribute to the onset of membrane fibrosis and treatment failure (Davies et al 1996, 
Selgas et al 2006).
The combination of fibrosis, increased vasculopathy and loss of the mesothelium leads to 
a decrease in ultrafiltration (Di Paolo et al 1986). The major cause of ultrafiltration 
failure is the increased vascular peritoneal surface due to neoangiogenesis in the 
peritoneum. This combined with the increased distance between endothelium and 
dialysate due to sub-endothelial fibrosis, can lead to the increased transport of low 
molecular weight solutes, which makes maintaining an osmotic gradient over long 
periods very difficult (Buemi et al 2004).
1.21 IL-6 regulation of monocytic cells
The role of IL-6 in directing the successful transition from innate to acquired immunity 
and ultimately the resolution of the acute inflammatory response has been extensively 
reviewed in this Chapter (Jones 2005). Using an in vivo model of peritoneal 
inflammation (induced by i.p administration of a cell free supernatant derived from 
Staphylococcus epidermidis), which enables a comparison of the inflammatory 
trafficking and production of inflammatory mediators between WT and IL-6 '7' mice, it 
has been shown that IL-6 directs the successful resolution of neutrophil infiltration and 
subsequent recruitment of mononuclear cells via its control of chemokine production and 
apoptotic processes (Hurst et al 2001, McLoughlin et al 2005). However no 
observations have been made to suggest that IL-6 specifically regulates the recruitment 
and trafficking of monocytic cells (Hurst et al 2001, McLoughlin et al 2005). However 
these findings dealt with monocytic cells as a single population and did not discriminate
between the multiple monocytic cell subsets that are known to exist. Multiparameter 
flow cytometry can be used extensively to allow identification and discrimination of 
monocyte subpopulations with the use of antibodies against unique phenotypic markers. 
Using this technique, resident monocytic populations that reside in the peritoneal cavity 
have previously been characterised (Dioszeghy et al 2008). These studies have shown 
that the monocytic population in murine peritoneal cavity of wild type mice is comprised 
of approximately 50% macrophages and 2-5% dendritic cells. The remainder of the cells 
in the murine cavity are comprised of eosinophils, B and T lymphocytes. The resident 
macrophage and DC populations can be distinguished using flow cytometry by their 
distinct phenotypes of F4/80hlCD llbhl and F4/80mtCD llbhl respectively. These subsets 
have been extensively characterised individually by Dioszeghy et al 2008, and the 
surface marker expression of these populations is outlined in Table 1.6.
The protective roles played by IL-6 (directing microbial clearance and inflammatory 
resolution) are balanced against the detrimental effects exerted by this cytokine during 
chronic inflammatory disease. In this respect, studies using the same in vivo model have 
shown that IL-6 deficient mice subjected to repeated peritoneal inflammatory episodes 
remained resistant to the onset of the fibrosis normally associated with this condition, 
while WT controls exhibited thickening of the peritoneal membrane (Fielding et al 2009, 
submitted). These WT mice exhibit dramatically enhanced leukocyte trafficking upon 
repeated inflammatory episodes, which is thought to contribute to the characteristic 
membrane fibrosis. While the neutrophil and lymphocyte populations have been 
characterised in this model, little is known about the composition of the monocytic cell 
infiltrate and how IL-6 may regulate their migration.
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Surface marker Resident
macrophages
Resident DC
CDllb +++ +++
F4/80 +++ +
CD14 +++ +++
7/4 - -
Gr-1 - -
CDllc - ++
B220 - -
CD3 - -
CD4 +/- +
CD8 - -
CD83 - -
M-CSF-R + ++
GM-CSF-R ++ +++
Dectin-1 +/- ++
Dectin-2 - -
MR - ++
MARCO +/- +
SR-A + -
Siglecl +/- -
Syndecanl - +/-
TLR2 + +
CCR2 - -
CCR5 +/- ++
CCR6 - -
CXCR4 +/- +/-
CX3CR1 +/- +
CD62L +/- +/-
ICAM-1 +++ +++
CD49b - -
CD40 + +
CD80 + +
CD86 + +
MHC-II + +++
12/15-LOX + -
Table 1.6: Murine resident peritoneal macrophage and dendritic cell surface marker 
expression. Data have been assigned arbitrary symbols: + indicates low expression, ++ 
indicates intermediate expression, +++ indicates high expression, and -  indicates no 
expression. Adapted from Dioszeghy et al 2008.
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CHAPTER 2 
Materials and methods
2.1 Reagents
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. All 
chemicals were of analytical grade or higher.
2.2 Tissue culture
2.2.1.1 SV40 transformed human peritoneal mesothelial cells (HPMC)
SV40 transformed HPMC are derived from a primary HPMC cell line that has been 
transformed with a plasmid encoding a modified SV40 sequence which contains a 
deletion in the late region and a lbp insertion that disrupts the origin of replication site 
within the SV40 genome. This cell line retains many of the phenotypic properties of 
primary HPMC including morphology and the expression of cytokeratins 8 and 18 and 
vimentin (Fischereder et al, 1997).
2.2.1.2 SV40 HPMC growth conditions
SV40 HPMC were cultured in DMEM (Dulbecco’s modified medium) (Gibco, 
Invitrogen, Paisley, UK) with 10% (v/v) heat inactivated foetal calf serum (FCS) (Gibco, 
Invitrogen, Paisley, UK), supplemented with 2mM L-glutamine (Gibco, Invitrogen, 
Paisley, UK), lOOU/ml penicillin, lOOpg/ml streptomycin (Gibco, Invitrogen, Paisley, 
UK), 5p,g/ml transferrin, 5p,g/ml insulin and 0.4pg/ml hydrocortisone (Li et al, 1998). 
Cell monolayers were grown in T25 Falcon culture flasks (Beckton Dickinson, Oxford, 
UK) (incubated at 37°C, 5% CO2) until confluent.
2.2.1.3 Monolayer sub-culture
On reaching confluence in the primary culture flask, cells were transferred to T75 flasks 
before passage into appropriate culture vessels for experimental purposes at a 1:3 ratio. 
Sub-culture involved the use of trypsin to remove cells from the bottom of the plate. 
Growth medium was removed by aspiration and cells were washed with sterile PBS 
(Dulbecco’s phosphate buffered saline; 2.5mM KCL, 1.5mM KH2PO4, 137mM NaCl, 
8mM Na2HP04 pH7.4) (Gibco, Invitrogen, Paisley, UK) before trypsinisation with 0.1% 
trypsin/0.02% EDTA (ethylenediaminetetraacetic acid) (Gibco, Invitrogen, Paisley, UK) 
(w:v) diluted in sterile PBS. Cell detachment was monitored by light microscopy
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following brief incubation at 37°C. Once all cells had detached, lOmls of appropriate 
growth medium supplemented with 10% (v/v) FCS was added to neutralise the trypsin. 
The cell suspension was then transferred to a 50ml universal tube for centrifugation. 
Cells were spun at 600xg for 6 minutes, the supernatant removed and the cell pellet 
resuspended in FCS supplemented medium and transferred to the appropriate culture 
vessel and incubated at 37°C, 5% CO2.
2.2.1.4 Growth arrest and cell stimulation
At the beginning of each experiment, the growth phase of the cell population was 
synchronised by growth arresting the cells in serum free media containing appropriate 
culture supplements. In brief, the medium was removed, cells were washed with PBS to 
remove any residual FCS, and the media replaced with serum free medium. Cells were 
then incubated for 48 hours at 37°C, 5% CO2. For cell stimulation, cells were washed 
twice with serum free medium, prior to treatment with the desired stimulant/cytokine.
2.2.2.1 Isolation and culture of mouse peritoneal leukocytes
To collect total peritoneal leukocytes, healthy animals were sacrificed by Schedule 1. 
The peritoneal cavity was lavaged with 2ml ice cold sterile PBS. Cell numbers were 
determined using a Coulter counter. Leukocytes were then enriched through a magnetic 
sorting column (MACS column) (Miltenyi Biotech, Surrey, UK) selecting for CD llb+ 
cells (as described in section 2.2.2.2) prior to centrifugation (2000xg, 5 minutes) and 
resuspension in RPMI 1640 medium (Gibco, Invitrogen, Paisley, UK) supplemented with 
10% FCS, 2mM L-Glutamine, lOOU/ml penicillin, lOOp-g/ml streptomycin. Cells were 
subsequently stimulated in 12 well plates (2x l06 cells/well in 2mls media) for 2 hours 
with appropriate inflammatory mediators and stimulants (as described in the relevant 
Figure Legends). Culture supernatant samples were rendered cell-free by centrifugation 
and stored at -70°C for further cytokine analysis. Cells were collected by scraping for 
flow cytometric analysis.
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2.22.2 MACS purification of CD llb+ murine peritoneal leukocytes
Murine peritoneal cells were pelleted from lavage fluid by centrifugation (300xg, 10 
minutes). Cells were then resuspended in MACS buffer (PBS pH7.2, 0.5% BSA (Sigma, 
Poole, UK), 2mM EDTA) at a ratio of 90pl of buffer to every 107 total cells. Magnetic 
microbeads coated in anti-CDllb antibody (Miltenyi Biotech, Surry, UK) were then 
added at a ratio of lOpil beads to every 107 cells, and incubated at 4°C for 15 minutes. 
Cells were washed with 2 mis MACS buffer per 107 cells and centrifuged at 300xg for 10 
minutes. Supernatant was discarded and the pellet resuspended in 500pl MACS buffer 
(up to a maximum of 108 cells) or 3mls (>108 cells). A MACS column (Miltenyi 
Biotech, Surry, UK) was prepared by placing in the magnet and rinsing with the
O
appropriate volume of MACS buffer. For cell concentrations up to 2x10 , an MS column 
was used and rinsed with 500pi MACS buffer. For concentrations of up to 2x109 
labelled cells, an LS column was used and rinsed with 3mls of MACS buffer. The cell 
suspension was then applied to the column and allowed to run through, followed by three 
washes of either 500pl or 3 mis of MACS buffer as before. Finally bound cells were 
eluted from the column by removing from the magnetic field and applying either 1ml or 
5mls of MACS buffer, depending on column size.
2.2.2.3 MoFlo purification and culture of murine peritoneal macrophages and 
dendritic cells
Murine cells were collected by peritoneal lavage using cold sterile PBS (pH 7.4) as 
described in section 2.2.2.1. Peritoneal cells from between 10 and 30 age-matched mice 
of mixed sex were pooled and leukocytes were collected by centrifugation at 400g for 10 
minutes. Cells were resuspended in MACS buffer at a concentration of 20x106 cells/ml 
and to this was added 4ug/ml Fc block (CD16/CD32 FcyRl) (BD Pharmingen, Oxford, 
UK). These cells were then incubated at 4°C for 30 minutes. Anti-mouse F4/80 FITC 
(AbD Serotec, Oxford, UK) and CD lib  APC (BD Pharmingen, Oxford, UK) were then 
added directly to the cells at a 1/100 (2pg/ml) concentration before incubating for a 
further 1 hour at 4°C. Labelled cells were then sorted based on the expression of F4/80
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and CD lib , with the F4/80hl/CD llbhl population being resident macrophages and the 
F4/80int/CDl lbhl population being dendritic cells.
Cells were cultured in 24 well plates with or without SES (prepared as described in 
section 2.3.3) (1/50), human recombinant IL-6 (50ng/ml) (R&D systems, UK) and hyper 
IL-6 (30ng/ml) (Fusion protein comprising IL-6 bound to the soluble IL-6R. Donated by 
Stefan Rose-John, Christian-Albrechts, University of Kiel, Kiel, Germany) in RPMI + 
10% (v:v) FBS, 2mM L-Glutamine, lOOU/ml penicillin, lOOpg/ml streptomycin (v:v) at a 
concentration of 400,000 cells per well for the resident macrophages in 800pl volume of 
media, and 200,000 cells per well for resident dendritic cells in 400pi volume of media. 
After 20 hours of culture, supernatants were rendered cell free by centrifugation at 
2000rpm for 5 minutes, and stored at -80°C for cytokine determination by Luminex or 
protein array.
2.2.2.4 Isolation of murine peripheral blood leukocytes
Mice were sacrificed by schedule 1, and blood was extracted by cardiac puncture into a 
syringe primed with heparin (5,000U/ml) (LEO laboratories Ltd, Princes Risborough, 
Bucks, UK) as an anti-coagulant. All red blood cells were removed by hypertonic lysis 
(155mM NH4CI (BDH Chemicals, Poole, UK), 11.9mM NaHCOs (Fischer Scientific, 
Loughborough, UK), ImM EDTA) at room temperature (RT) for 5 minutes. This 
process was repeated as necessary, and each time leukocytes were collected by 
centrifugation (2000rpm 5 minutes).
2.2.2.5 Isolation of murine bone marrow leukocytes
Murine femurs and tibias were taken, and stripped. The ends were trimmed with sterile 
scissors, to expose the marrow. The bone marrow was then flushed from the bones using 
sterile PBS in a syringe with a needle. Bones were flushed until all cells had been 
recovered. Red blood cells were lysed as described in Section 2.2.2.4.
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2.3 Animal experiments
Experiments were performed in age matched 6-12 week C57/BL6 J wild type (WT), 
IL-6' \  IL-10'7', OSMR'\ IFN-y_/', gpl30Y757F/Y757F and gpl30Y757F/+ mice using a mixture 
of males and females. C57/BL6 J mice were bought from Charles River suppliers. 
Procedures were performed in accordance with Home Office approved project licence 
number PPL-30/2269.
2.3.1 Mice
WT C57BL6 mice were bought from Charles River Laboratories (Margate, UK).
IL-6’7' mice were generated as previously described (Kopf et al, 1994). Briefly, the IL-6 
gene was disrupted in the second exon (first coding exon) by insertion of a neomycin 
resistance (neoT) cassette, and loss of the WT alleles and IL-6 messenger RNA was 
confirmed by Southern blot analysis and reverse transcriptase PCR from 
lipopolysaccharide (LPS)-stimulated macrophages. OS MR'7' mice were generated as 
previously described (Tanaka et al 2003). Gpl30Y757F7Y757F and gpl30Y757F7+ mice were 
generated as previously described (Tebbutt et al 2002). IL-10'7' mice were from an in 
house colony, originally purchased from Jackson Laboratories, and were generated as 
previously described (Kuhn et al 1993). IFNy'7' mice were generated as previously 
described (Dalton et al 1993).
2.3.2 Determination of baseline leukocyte numbers
Differential cell counts and FACS analysis were performed on peripheral blood and 
peritoneal leukocytes from WT and IL-6 '7' animals. Peripheral blood was collected by 
cardiac puncture into syringes flushed with heparin (5,000U/ml) as an anti-coagulant. All 
red blood cells were removed by hypertonic lysis at room temperature (RT) for 5 
minutes. This process was repeated as necessary, each time leukocytes were collected by 
centrifugation (2000rpm 5 minutes). To collect peritoneal leukocytes, healthy animals 
were sacrificed by Schedule 1, and the peritoneal cavity was lavaged with 2 mis of ice 
cold sterile PBS pH 7.4. Cell numbers were determined using a Coulter counter. Slides 
for differential cell counting were prepared by cytospin (Thermo Fischer Scientific, 
Waltham, MA, USA) and stained with Wright GIEMSA (Sigma, Poole, UK) for 45
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seconds followed by washing in deionised water. Leukocyte subsets were counted 
according to cell morphology as visualised by light microscopy. Leukocytes numbers 
were also determined by flow cytometry using leukocyte markers as described in section 
2.4.
2.3.3 Preparation of a Staphylococcus epidermidis cell-free supernatant (SES)
A lyophilised cell free supernatant was prepared from a clinical isolate of Staphylococcus 
epidermidis. In brief, an inoculum of S. epidermidis was maintained on a dorset egg 
medium slope for cultivation and maintenance of stock culture (Oxoid Ltd, Basingstoke, 
Hampshire, UK). Using asceptic techniques, an agar plate (DST agar) (Oxoid Ltd, 
Basingstoke, Hampshire, UK) was inoculated with a loop of dormant S. epidermidis 
bacteria, and incubated at 37°C for 48 hours. A single colony was used to inoculate a 
volume of nutrient broth (Nutrient broth no.2) (Oxoid Ltd, Basingstoke, Hampshire, UK). 
The culture broth was incubated for 18-24 hours at 37°C with shaking (170rpm) until the 
cells reached the stationary phase of growth. Turbidity was checked by eye, and cultures 
were then centrifuged at 1800xg for 20 minutes at 20°C. Supernatants were discarded 
and pellets resuspended in 50mls of Tyrodes salts solution (1.8mM CaCl2*H2 0 , ImM 
MgCl2*6H20 , 2.6mM Kl, 137mM NaCl, 0.42mM NaH2P04, 5.5mM D-glucose, with 
12mM NaHCOs (Sigma, Poole, UK) and sterile filtered using a 0.2pm membrane). 
Bacteria were pelleted again at 1800xg for 20 minutes at 20°C. Supernatants were 
discarded and pellets resuspended in Tyrodes salts solution to an OD of 0.5 at 560nm, 
which corresponds to 5x108 cfu/ml. The bacterial suspension was then incubated at 37°C 
for 18-24 hours. After this period, bacteria was pelleted at 5000xg for 30 minutes at 
20°C, and following this the supernatant was collected and filtered through a 0.2pm filter 
to remove any remaining bacteria. The filtered supernatant was then dialysed against 5L 
deionised water at 4°C to remove excess salt (50-60mls of supernatant per dialysis tube, 2 
tubes per 5L of water). Fresh water was exchanged 3 times (every 8-12 hours). The 
dialysed supernatant was pooled and 10ml aliquots were prepared for freeze-drying. 
Lyophilised SES batches were stored at -70°C. Batches of SES were reconstituted in 
PBS (750pl) directly before use and filtered. All SES preparations were routinely stored 
for no more than 6 months.
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2.3.4 Determination of SES activity
A dose response bio-assay was used to validate each batch of SES prior to use in vivo. 
SV40 human peritoneal mesothelial cells (HPMC) were grown in 48 well plates to 
passage 2 (Sections 2.2.1.2-2.2.1.3), and then growth arrested once confluent for 48 hours 
in non-FCS-supplemented medium as described in Section 2.2.1.4. Cells were then 
stimulated for 24 hours with SES reconstituted in 2.5mls of appropriate serum free 
medium at the following dilutions: neat, 1/2, 1/10, 1/50, 1/100. Stimulation with 100 
pg/ml IL-ip (R&D systems, Abingdon, UK) was used as a positive control, and un­
stimulated cells as a negative control. All stimulations were in a volume of 300pl. 
Following 24 hours, supernatants were removed, and centrifuged at 2000rpm for 5 
minutes to pellet and remove any cells. The activity of the SES was then quantified by 
CXCL8 ELISA (BD biosciences, Oxford, UK) on the supernatants diluted 1/20. SES 
was considered suitable for use if the IL-8 levels produced from neat SES cultures was 
within 80% of that produced in response to IL-ip stimulation (Figure 2.1).
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Figure 2.1: Interleukin-8 production by SV40 cells following SES stimulation for 24 
hours.
2.3.5 Induction of peritoneal inflammation using Staphylococcus epidermidis cell-free 
supernatant
For each experiment groups of mixed sex, aged matched WT and certain genetically 
modified animals were used (IL-6"'\ IFN-y''', IL-10'\ gpl30Y757F/Y757F, gpl30Y757F/+, 
OSMR"). Inflammation was triggered in mice by intra-peritoneal (i.p) injection of SES 
(500pl). Dependent on the nature of the experiment, antibodies or cytokines were added 
to the SES prior to injection. These additions are stated in the Figure Legends in the 
appropriate Results Sections. At defined intervals (1 to 72 hours), mice were sacrificed 
by Schedule 1 and the peritoneal cavity lavaged with 2mls ice cold sterile PBS to collect 
the leukocytes. The leukocyte infiltrate was counted by direct counting (Coulter counter) 
(Section 2.3.2). Slides were prepared and stained for differential cell counts (Section 
2.3.2). Remaining leukocytes were stained for flow cytometric analysis of macrophage 
and dendritic cell specific (F4/80, CD1 lb and CDllc) markers (Section 2.4.2). Peritoneal 
lavage supernatants were rendered cell free by centrifugation and stored at -70°C for 
future analysis by ELISA (Section 2.5).
Samples of peritoneal membrane were taken for histology from mice after resolution of 
four episodes of SES-induced inflammation. Groups of five IL-6'7' and five WT mice 
received four consecutive injections of SES (500pl at weekly intervals) and were 
sacrificed 21 days after the final episode to allow for resolution. Sections of peritoneal 
membrane were removed and pinned flat in PBS, exposing the mesothelium. Sections 
were fixed overnight at 4°C in 10% neutral buffered formal saline (Sigma, Poole, UK) 
prior to embedding in paraffin. Fixed sections were cut (5-6pm thickness) and stained 
with haematoxylin and eosin (Sigma, Poole, UK). All histology was performed by 
Central Biotechnology Services, Cardiff University.
2.3.6 Preparation of a live Staphylococcus epidermidis inoculum for the live infection 
model
Bacteria ATCC S. epidermidis 12228 was maintained at room temperature on Agar 
slopes. An agar plate (prepared with Nutrient Broth # 2 (Oxoid Ltd, Baskingstoke, 
Hampshire, UK) was inoculated by aseptically transferring bacteria from a slope using a
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flame-sterilised loop. The agar plate was then incubated for 48 hours at 37°C checking 
for growth at 24 hours. lOmls of Nutrient Broth # 2 was then inoculated with a single 
colony of bacteria aseptically using a flame sterilised loop. The culture was incubated 
overnight for 24 hours in a shaking incubator at 37°C. This overnight bacterial culture 
was then used to inoculate a second culture, in a suitable volume of Nutrient Broth # 2 
(100 pi / 10 ml broth) to provide enough inoculum for the experiment planned. This 
culture was then incubated for 15 hrs in a shaking incubator and bacteria harvested from 
these log phase cultures. The bacterial broth suspension was pelleted at 4,000xg for 10 
minutes at room temperature and the supernatant carefully decanted taking care not to 
dislodge the pellet. The pellet was resuspended in 40 ml sterile PBS as a wash and this 
step was repeated a total of 3 times. Finally the bacteria were centrifuged at 4,000xg for
o
10 minutes at room temperature and resuspended in sterile PBS to a cell density of 5x10 
colony forming units (cfu) per inoculum (500pi). The inoculum was stored at 4°C or on 
ice until 5 minutes prior to injection.
2.3.7 Induction of peritoneal inflammation using a live infection model with 
Staphylococcus epidermidis
For each experiment groups of mixed sex, aged-matched WT and IL-6'7' animals were 
used. Peritoneal inflammation was achieved in mice by intra-peritoneal (i.p) injection of
o
5x10 cfu per mouse in a 500pl volume. At defined intervals (1-72 hours), mice were 
sacrificed by Schedule 1 and the peritoneal cavity lavaged with 2mls ice cold sterile PBS. 
The leukocyte infiltrate was assessed by direct counting (Coulter counter), differential 
staining and flow cytometric analysis with macrophage and dendritic cell specific 
markers (F4/80, CD llb and CDllc) (Sections 2.3.2 and 2.4.2). Lavage fluids were 
rendered cell free by centrifugation and stored at -70°C for analysis by ELISA as 
described in Section 2.5.
2.3.8 In vitro stimulation of inflammatory peritoneal leukocytes for intracellular 
cytokine staining
Inflammation was induced in WT, IL-6'7' and IL-10'7' mice by i.p injection SES (Section 
2.3.5). Mice were sacrificed by schedule 1 at 24, 48 and 72 hours and peritoneal
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leukocytes collected by lavage (Section 2.3.2). Cells were pelleted at 2000rpm for 5 
minutes, and resuspended in RPMI medium containing 10% FCS, 2mM L-glutamine, 
lOOU/ml Penicillin, lOOpg/ml Streptomycin, ImM sodium pyruvate (Gibco, Invitrogen, 
Paisley, UK) and 55pM p-mercaptoethanol (Gibco, Invitrogen, Paisley, UK), lx l06 cells 
were cultured in 96 well plates stimulated with 50ng/ml PMA (Phorbol 12-myristate 13- 
acetate (Sigma, Poole, UK), 500ng/ml Ionomycin (Sigma, Poole, UK) and 3pM 
Monensin (Sigma, Poole, UK), for 4 hours at 37°C, 5% CO2. Following this, cells were 
pelleted at 500xg for 3 minutes, and stained for flow cytometry (Section 2.4.3) to detect 
IL-17A, IFN-y and IL-10 producing CD4+ T cells.
86
2.4 Flow Cytometry
2.4.1 Use of Becton Dickinson FACS Calibur
Flow cytometric analysis allows information to be acquired on the relative size and 
granularity of cell samples, as well as enabling multi-parameter visualisation of defined 
cell marker expression using fluorochrome labelled antibodies.
2.4.2 Analysis of individual cell subsets utilising forward vs. side scatter
Size and granularity can be assessed using plots of forward scatter (FSC, reflects particle 
size) versus side scatter (SSC, reflects particle granularity), thus enabling individual cell 
subsets to be identified and analysed further. As cells pass though the laser beam, light is 
deflected and refracted by the cells in the stream. The scattered light is collected by the 
FSC and SSC photodiodes, which convert the light signal into electronic signals that are 
expressed as a plot of points on an axis corresponding to the morphology of the cells, as 
illustrated in Figure 2.1.
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Figure 2.2: Forward and side scatter profile of murine blood leukocytes indicating the separation of 
different subtypes of cells based on size and granularity. Side scatter is an indication of granularity 
whereas forward scatter is an indication of size. Due to the characteristics of individual leukocyte subsets, 
each can be gated for further analysis. R1 are neutrophils, which are relatively small but demonstrate 
granular morphology. R2 are monocytes, which are large, relatively granular cells. R3 are lymphocytes, 
which are smaller and less granular than neutrophils and monocytes.
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2.4.3 General protocol for staining cells with fluorochrome labelled antibodies for 
visualisation by flow cytometry
Murine cells were collected by centrifugation at 2000rpm for 5 minutes and then 
resuspended to a concentration of 2x107 cells/ml in Fc Block (4p,g/ml rat anti-mouse 
CD16/CD32 FcyRl monoclonal antibody (BD Pharmingen, Oxford, UK) in FACs buffer 
(5mM EDTA, 7.5mM NaFh (Sigma, Poole, UK), 0.5% BSA (USB Corporation, 
Cleveland, USA) in PBS pH 7.4). Cells were blocked for 30 minutes at 4°C before 
dilution to a concentration of between 2xl05 to 5xl05 cells/50p,l in FACS buffer. Cells 
(50pl per well) were transferred to a 96 well plate and 50pl of a 2X concentrated 
antibody mix in FACS buffer was added to each well as appropriate. Cells were stained 
with primary fluorochrome-conjugated or biotin-conjugated antibodies at 2pg/ml for 30- 
60 minutes at 4°C. Where necessary, cells were incubated for a further 30 minutes with 
the appropriate fluorochrome-conjugated secondary antibody or streptavidin conjugated 
fluorochrome for biotinylated antibodies. Following staining, cells were pelleted by 
centrifugation at 500xg for 3 minutes, and washed in 200pl FACS buffer to remove 
unbound antibodies. This step was repeated twice.
For intracellular staining, cells were permeabilised for 20 minutes following surface 
staining in BD cytofix/cytoperm (BD Pharmingen, Oxford, UK). Cells were washed 
twice in 200p,l BD cell perm/wash (BD Pharmingen, Oxford, UK) diluted 1/10 (v:v) in 
deionised water, and intracellular antibody (2pg/ml) staining performed for 45 minutes in 
BD cell perm/wash at 4°C. Cells were then washed twice in BD cell perm/wash and 
fixed in BD Cellfix (BD Pharmingen, Oxford, UK) diluted 1/10 (v:v) in deionised water.
Murine cells were analysed using a FACS Calibur flow cytometer. Data was acquired 
from 30,000-50,000 gated events and staining was compared to fluorochrome-conjugated 
isotype control antibodies. All antibody descriptions are shown in Table 2.1.
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Antibody Clone Isotype Fluorochrome Working
dilution
Source
F4/80 CI:A3-1 Rat
IgG2b
FITC 2 |Ag/ml AbD Serotec
CDllb Ml/70 Rat
IgG2b
APC 0.1 pg/ml BD
Pharmingen
CDllb Ml/70 Rat
IgG2b
PerCP-Cy5.5 0.5p,g/ml BD
Pharmingen
CDllc HL3 Hamster
Ig_Gl
PE 2 |jig/ml BD
Pharmingen
CDllc HL3 Hamster 
IgGl _
APC 4p,g/ml BD
Pharmingen
CD14 Sa2-8 Rat
IgG2a
PE 2(Lig/ml eBioscience
CD4 RM4-5 Rat
IgG2a
FITC
APC
PE
2p,g/ml Caltag
CD3 17A2 Rat
IgG2b
PE 2p,g/ml BD
Pharmingen
B220 RA3-6B2 Rat
IgG2a
FITC/PE/PerCPCy5.5 2 |ig/ml BD
Pharmingen
CD19 1D3 Rat
IgG2a
PE 2 pig/ml BD
Pharmingen
Gr-1 RB6-8C5 Rat
IgG2b
PE 2p,g/ml BD
Pharmingen
CD40 3/23 Rat
IgG2a
Biotin
PE
2 [xg/ml AbD Serotec 
BD
Pharmingen
CD80 B7-1 Hamster
IgG2
Biotin 2 (j,g/ml BD
Pharmingen
CD83 Michel-17 Rat
IgGl _
PE 2 |ig/ml eBiosciences
CD86 P03 Rat
IgG2b
Biotin 2p,g/ml BD
Pharmingen
CD206 MR5D3 Rat
IgG2a
Biotin 2 jig/ml R&D
systems
MHCII 2G9 Rat
IgG2a
Biotin 2 [i,g/ml BD
Pharmingen
TLR2 6C2 Rat
IgG2b
PE 2pg/ml eBiosciences
CCR3 83101 Rat
IgG2a
PE 2p,g/ml R&D
systems
CCR5 C34-3448 Rat
IgG2c
Biotin
PE
2 |Lig/ml BD
Pharmingen
CCR6 140706 Rat
IgG2a
PE 2(j,g/ml R&D
systems
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CCR7 4B12 Rat
IgG2a
Biotin 2pg/ml eBioscience
CXCR2 242216 Rat
IgG2a
PE 2pg/ml R&D
systems
CXCR3 220803 Rat
IgG2a
PE 2jAg/ml R&D
systems
CXCR6 221002 Rat
IgG2b
PE 2pg/ml R&D
systems
IL-6R D7715A7 Rat
IgG2b
PE 2pg/ml BD
Pharmingen
IL-6R BAF1830 Goat
IgG
Biotin 2 pg/ml R&D
systems
IL-10 JES5-
16E3
Rat
IgG2b
APC 2 pg/ml eBioscience
CD62L MEL-14 Rat
IgG2a
PE 2pg/ml BD
Pharmingen
NK1.1 PK136 IgG2a PE 2 p,g/ml eBioscience
IFNy XMG1.2 Rat
IgGl
FITC 2pg/ml Caltag
IL-17A TC11-
18H10.1
Rat
IgGl
PE 2 p,g/ml BD
Pharmingen
TNF-a MP6-
XT22
Rat
IgGl
APC 2p,g/ml BD
Pharmingen
IgGl R3-34 Rat FITC
PE
2 pg/ml BD
Pharmingen
IgGl G235-
5356
Hamster PE 2 p,g/ml BD
Pharmingen
IgGl G235-
5356
Hamster APC 4pg/ml BD
Pharmingen
IgG2a R35-95 Rat Biotin
PE
2 pg/ml BD
Pharmingen
IgG2b A95-1 Rat PE 2pg/ml BD
Pharmingen
IgG2c A23-1 Rat Biotin 2 pg/ml BD
Pharmingen
IgG polyclonal Goat Biotin 2 |j,g/ml Abeam
IgG2 Hamster Biotin 2p,g/ml BD
Pharmingen
CD16/CD32 2.4G2 Rat
IgG2b
N/A 4p,g/ml BD
Pharmingen
Table 2.1: Anti-mouse antibodies usedfor flow cytometry staining
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2.4.4 Analysis of receptor expression using single colour staining
When using a single fluorescent dye conjugated to a monoclonal antibody, histogram 
analysis can be used to gauge the relative distribution of a surface marker. The amount 
of fluorescent signal detected by the machine (electronic events) is proportional to the 
number of fluorochrome molecules. Specific alterations in the expression of cell markers 
can be calculated by monitoring the mean fluorescence units (MFU) associated with 
receptor expression. Markers can be placed on a histogram to specify a range of events 
for a single parameter. Negative isotype controls are used to place the marker for 
positive events. Any events to the right of the end of the negative isotype peak are 
considered to be positive. By utilising the statistics function on CellQuest Pro software, 
the geometric mean of the positive events and the negative events can be obtained, and 
the mean fluorescent intensity can then be calculated as the number given when the mean 
of the isotype control or negative events is subtracted from the mean of the cell marker or 
positive events. Calculation of the MFU enables the effect of cell stimulation on the 
relative receptor expression to be assessed.
2.4.5 Analysis of multiple receptors using more than one fluorochrome
More than one fluorochrome can be analysed simultaneously if the wavelengths required 
for excitation are similar and the peak emission wavelengths are far enough apart to be 
detected by separate detectors. However, the emission spectra of the fluorochromes used 
can overlap; this overlap can be compensated for by altering the optical filters within the 
machine. To set the correct compensation, control samples stained with negative isotype 
and positive controls for FITC (FL1), PE (FL2), PECy5 or PerCPCy5.5 (FL3) and APC 
(FL4) (see Table 2.2) were analysed to ensure no detection of fluorochromes in any other 
detector than that stated but that there was sufficient positive detection by the appropriate 
detector.
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Detector Fluorochrome Abbreviation
FL1 Fluoroscein / Fluoroscein 
isothiocyanate
FITC
FL2 Phycoerythrin PE
FL3 peridinin-chlorophyll- 
protein complex-cyanine 
5.5
PerCPCy5.5
FL4 Allophycocyanin APC
Table 2.2: Fluorochromes used for flow cytometric analysis within this report and 
associated detectors
Dot plots can be used to analyse two parameters together, enabling receptor expression to 
be determined on cell subsets based on additional expression of specific pan-leukocyte 
markers and further quantification of specific cell subsets.
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2.5 Enzyme-linked immunosorbent assays (ELISA)
Cell culture supernatants and murine peritoneal lavage fluids were assayed for cytokine 
and chemokine concentrations in accordance with the BD OptEIA™ (murine CCL2, 
CXCL1 (KC), IL-6, human CXCL8) or the R&D Systems Duoset (murine sIL-6R, 
CCL5) or the Antigenix America (murine CCL7) ELISA protocols. For specific 
antibody concentrations see Table 2.3.
Species Chemokine/
Cytokine
Primary 
capture Ab 
concentration/ 
dilution
Secondary 
detection Ab 
concentrations
Top
Standard
concentration
Limit of 
detection
Human CXCL8 * 1/250 1/250 200pg/ml 3.1pg/ml
Mouse CXCL1
(KC)*
2p,g/ml 200ng/ml lOOOpg/ml 15.1pg/ml
CCL2 1/250 1/250 lOOOpg/ml 15.1pg/ml
CCL3 * 2pg/ml 400ng/ml 500pg/ml 7.8pg/ml
CCL5 * 2pg/ml 400ng/ml 2000pg/ml 31.3pg/ml
CCL7 • 0.5pg/ml 200ng/ml lOOOpg/ml 15.1pg/ml
IL-6 1/250 1/250 2000pg/ml 31.3pg/ml
SIL-6R * 0 .8pg/ml lOOng/ml lOOOpg/ml 15.1pg/ml
IL-10 4pg/ml 800ng/ml 2000pg/ml 31.3pg/ml
Table 2.3: Antibody concentrations and standards for murine and human ELISA assays. 
* correspond to R&D sourced kits. CCL7 ELISA was sourced from Antigenix America. 
All other kits were sourced from BD.
Each ELISA assay was run according to the manufacturers protocol and although the 
methods were similar among kits, some variations existed in the buffers and other 
components. In brief, 96 well plates were coated with specific monoclonal capture 
antibody (1 OOpl) and incubated overnight at room temperature or at 4°C. For R&D 
ELISA kits, plates were coated in PBS, but for BD kits, plates were coated in 0.1M
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sodium carbonate buffer (8.4g NaHCC>3, 3.56g Na2C03 Sigma, Poole, UK). After each 
step the plate was washed in 0.05% (v:v) Tween20 (Sigma, Poole, UK) in PBS on a 
Jencons automatic plate washer (Jencons, West Sussex, UK). Plates were then blocked in 
PBS containing BSA (200pl per well), for one hour at room temperature. Composition 
of the blocking reagent varied between kits but was usually 3% (w/v) BSA in PBS for the 
BD OptEIA kits and 1% (w/v) BSA in PBS for the Duoset kits (R&D systems). Plates 
were washed once again and standards and test samples were added for a 2 hour 
incubation at room temperature. Samples and standards were diluted appropriately in 
reagent diluent (blocking reagents as described earlier). Each well was washed again 
prior to the addition of detection antibody (specific biotinylated monoclonal antibody and 
streptavidin-horseradish peroxidase (HRP) conjugate) (lOOpl per well), which was 
incubated in wells for 1 hour at room temperature, or two hours for R&D kits, with a 
separate streptavidin-HRP step for 20 minutes. Wells were once again washed prior to 
the final step, which was the addition of Tetramethyl Blue (Sureblue TMB (3,3’,5,5’- 
tetramethylbenzidine) substrate) (Insight Biotechnology, Middlesex, UK) (100pi per 
well). Colour development was monitored by eye and once the required blue colour 
change was acquired, the reaction was stopped by addition of 2M H2SO4 (sulphuric acid) 
(Fischer Scientific, Loughborough, UK) 50pil per well. Absorbance changes were 
measured at 450nm (MRX Revelation, Dynex Technologies, Worthing, West Sussex, 
UK) and concentrations were deduced using the logarithmic relationship between the 
standards and their absorbances.
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2.6 Luminex Bio-Plex Cytokine Assay
Luminex is a multisphere based multiplex system that allows detection of multiple 
cytokines/chemokines in a single well, and is ideal for multi-parameter analysis on 
precious and limited samples. The Bio-Plex cytokine assay was run according to the 
manufacturers protocol (Biorad, Hertfordshire, UK). In brief, fluorochrome labelled 
beads specific for 23 mouse cytokines (see Table 2.4) were diluted to the advised 
working concentration and aliquoted into a pre-wetted 96 well filter bottom plate 
(50pl/well). Beads were washed twice in lOOpl of wash buffer provided with the kit. 
Wash buffer was removed between each step by vacuum filtration. Standards and 
samples were then added. Standards were diluted down the plate, with a 1/4 dilution 
between each well. Culture supernatants were added neat due to the top standard for each 
cytokine being at a very high concentration. The plate was then incubated on a shaker 
rotating at l,100rpm for 30 seconds and then at 300rpm for 30 minutes at room 
temperature. The beads were then washed three times in wash buffer as previously 
described, and this was followed by the addition of a biotin conjugated detection antibody 
cocktail (25pi per well). The detection antibody was diluted in accordance with the 
manufacturers protocol in detection antibody diluent provided with the kit. The plate was 
then incubated for 30 minutes at room temperature with shaking as previously described. 
The beads were once again washed three times as before, and PE-conjugated streptavidin, 
(diluted as advised in Bio-Plex assay buffer) added (50pl per well). The plate was then 
incubated for 10 minutes at room temperature with shaking as previously described. 
Finally the beads were washed three times, and resuspended in 125 pi of Bio-Plex assay 
buffer provided. Plates were then placed on a shaker for 30 seconds (l,100rpm) and 
immediately read on a pre-calibrated Bio-Plex system. This system works similarly to a 
FACS calibur in that it acquires a defined number of beads and then determines sample 
concentration of each cytokine relative to the standard based on the PE signal in each 
well.
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Streptavidin conjugated PE
Analyte
Biotinylated detection antibody
Capture antibody
Microsphere with
unique fluorescence 
for discrimination
Figure 2.3: A diagram to depict the mechanism o f the Bioplex assay. Capture antibodies 
specific for individual cytokines or chemokines are immobilised on the surface of 
microspheres, which possess a fluorescence unique to that soluble factor. Once the 
analyte has bound the capture antibody/microsphere complex, this is then incubated with 
a biotinylated detection antibody, which is subsequently conjugated to streptavidin PE. 
The plate reader can distinguish between different cytokines/chemokines according to 
their fluorescent microsphere, and quantify the levels of the analyte by measuring the PE 
fluorescence.
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Cytokine/Chemokine Top Standard 
concentration (pg/ml)
IL-la 30998
IL-ip 20063
IL-2 74458
IL-3 30331
IL-4 66096
IL-5 24998
IL-6 17664
IL-9 23886
IL-10 108315
IL-12 (p40) 17376
IL-12 (p70) 15270
IL-13 53744
IL-17 50593
Eotaxin 49383
G-CSF 40736
GM-CSF 58435
IFN-y 37387
KC 31953
MCP-1 35748
MIP-la 31252
MIP-ip 27058
RANTES 16902
TNF-a 77425
Table 2.4: Cytokines/chemokines detected in the Bioplex luminex assay, and their top 
standards used
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2.7 Proteome Profiler Arrays
Proteome profiler arrays (R&D Systems, Abingdon, UK) were used for parallel 
determination of the relative levels of selected cytokines and chemokines. Each kit 
contained four blots with capture antibodies for multiple cytokines and chemokines 
spotted in duplicate onto the surface. The membranes were blocked in array buffer 
provided for 1 hour on a rocking platform, and following this, cell free culture 
supernatants, that had previously been incubated for 1 hour with a detection antibody 
cocktail, were incubated with the membranes overnight at 4°C. Each membrane was then 
washed three times in 20mls of array wash buffer provided for 10 minutes with gentle 
rocking. The blots were then incubated with streptavidin-HRP for 30 minutes at room 
temperature, followed by three washes as described above. Finally a chemiluminescent 
substrate was incubated with the blots, in this case ECL western blotting detection 
reagents (GE Healthcare UK, Buckinghamshire, UK), for three minutes and blots were 
then developed for 10 minutes with X ray film.
2.8 Statistical analysis
In vivo experiments were performed on groups of five animals for each time point. In 
vitro experiments were performed to n=>2. Statistical analyses were performed using the 
Student’s Mest, with a p value of <0.05 considered significant. All data represent mean 
values +/- SEM.
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CHAPTER 3
Phenotypic characterisation of resident peritoneal mononuclear subsets: Defining
the involvement of ST AT activating cytokines
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3.1 Introduction
Resident macrophages and dendritic cells (DC) reside as homeostatic sentinels in the 
peritoneal cavity of both mice and humans where they are likely to undergo phagocytosis 
of apoptotic cells, antigen sampling, and the induction of peripheral tolerance to self 
molecules (Steinman et al 2000). However during infection, these cells act as the first 
line of defence, and act to co-ordinate the anti-microbial immune response (Dunn et al 
1985). Resident macrophages and DC undergo a degree of turnover, particularly the DC, 
which are continually replenished. This is associated with their trafficking through the 
tissues into the lymphatic system and subsequent migration to the T cell area of the 
lymph nodes (Kamath et al 2000). This suggests that these populations are regularly 
replenished from the haematopoietic pool to maintain resident populations within the 
peripheral tissues.
It is well documented that gpl30 mediated STAT3 signalling is critical for normal 
haematopoiesis, with evidence showing that mice exhibiting hyperactive STAT3 
signalling and impaired SOCS3 regulation of gpl30 signalling, display multiple 
hyperproliferative haemopoietic abnormalities (Jenkins et al 2002, 2005). Subsequent 
investigations showed that these mice also exhibit elevated myelopoiesis in the bone 
marrow, attributable to an increase by either IL-6 or IL-11 in the STAT3 driven 
impairment of TGF-fJ signalling (Jenkins et al 2007). Further studies have also 
illustrated that IL-6 is an important secondary cytokine in GM-CSF (Granulocyte 
macrophage colony stimulating growth factor) induced monocytopoiesis (Jansen et al 
1992), and is required as an accessory cytokine to promote mono-DC haematopoiesis 
from normal progenitors (Santiago-Schwartz et al 1995). In contrast however, IL-6, 
Leukemia inhibitory factor (LIF) and ciliary neurotrophic factor have been reported to 
selectively inhibit the proliferation of committed macrophage-lineage progenitor cells 
indicating that gpl30 activating cytokines may act as negative physiological regulators of 
mononuclear phagocyte differentiation or expansion (Clutterbuck et al 2000).
Since peripheral blood monocytes are a common precursor of macrophages and DC, 
there have been many contradictory studies demonstrating how IL-6 can regulate
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macrophage or dendritic cell differentiation from monocytic cell precursors. In this 
respect, IL-6 has been shown to switch the differentiation of monocytes from dendritic 
cells to macrophages upon contact with fibroblasts, which occurs when monocytes cross 
the endothelium (Chomarat et al 2000). It is thought that IL-6 secretion by activated 
fibroblasts induces an up-regulation of M-CSF receptor expression on monocytes 
allowing an autocrinal activation of monocyte to macrophage differentiation by M-CSF 
(Chomarat et al 2000). In contrast however, Jenkins et al showed that the IL-6 family 
cytokines inhibited M-CSF-stimulated macrophage formation by the down-regulation of 
the M-CSF receptor gene c-fms (Jenkins et al 2004). The findings by Chomarat et al 
were supported by work from Mitani et al, who showed that IL-6 inhibited differentiation 
of monocytes to DC by promoting their differentiation towards macrophages, however 
this inhibition was reversed upon addition of TNF-a, LPS, IL-ip, CD40L or TGF-p 
(Mitani et al 2000). Similarly, Mentrier-Caux et al showed that IL-6 or M-CSF inhibited 
the differentiation of DC from CD34+ progenitor cells, and redirected the differentiation 
of these cells towards a macrophage lineage (Mentrier-Caux et al 1998). Finally Bleier et 
al showed that the number of bone marrow derived DC from IL-6 deficient mice 
generated in vitro was significantly greater than that of WT mice, however, no difference 
was observed in the number and subtype composition of DC in the absence of IL-6 in 
vivo (Bleier et al 2004).
Whilst much of the work discussed so far infers that signalling by IL-6 promotes 
macrophage differentiation, there is work that supports a role for IL-6 in the promotion of 
dendritic cell differentiation. Brasel et al established that blocking IL-6 function reduced 
the number of DC generated in Flt-3 ligand-supplemented murine WT bone marrow 
cultures (Brasel et al 2000). Santiago-Schwartz et al showed that when CD34+ 
progenitor cells were cultured with GM-CSF, TNF-a and stem cell factor (SCF), the 
proportion of DC generation was markedly enhanced by the presence of IL-6, and 
consequently reduced by the addition of blocking antibodies to IL-6 (Santiago-Schwartz 
et al 1995). Similarly, Bernhard et al showed that hyper IL-6 (an IL-6/sIL-6R fusion 
protein) in combination with SCF (Stem cell factor) and GM-CSF, promoted the
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expansion and differentiation of DC from CD34+ precursor cells from both bone marrow 
and peripheral blood stem cells (Bernhard et al 2000).
Given the contrasting data, Jenkins, B.J. suggests that differences in the transcriptional 
programming of immature and committed haematopoietic progenitors to respond to 
gpl30 signalling, affect the ability of IL-6 family cytokines to determine the 
differentiation fate of these cells (Jenkins et al 2004). In light of this, the aim of this 
Chapter was to determine whether cytokine directed ST AT signalling regulates the 
number of resident peritoneal macrophages and DC present in mice, and how it may 
potentially affect the phenotype of these cells.
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3.2 Materials and methods
3.2.1 Isolation of basal resident peritoneal macrophages and dendritic cells
WT, IL-6'7', IL-10'7*, gpl30Y757F/Y757F, OSMR'7' and IFN-y'7* mice were sacrificed by 
schedule 1 and peritoneal leukocytes recovered by lavage as described in Section 2.2.2.1. 
Each of these strains are on a C57/BL6 background, except for the gpl30Y757F/Y757F mice, 
which are on a mixed SV29/C57/BL6 background. For this reason, separate WT 
littermate controls, which had the same mixed background, were used for experimental 
comparisons against the gpl30Y757F/Y757F mice.
3.2.2 Flow cytometric analysis of basal resident peritoneal macrophages and 
dendritic cells
Resident peritoneal macrophages and DC were labelled with anti-F4/80 FITC and anti- 
CDllb APC in combination with antibodies against a variety of macrophage and DC 
markers conjugated to either biotin or PE as described in Section 2.4.3. Details of the 
antibodies used are found in Table 2.1. Cell numbers were quantified by taking the flow 
cytometry gated population percentages and multiplying them by the total cell number.
3.2.3 MoFlo purification and culture of murine peritoneal macrophages and 
dendritic cells
Basal resident peritoneal leukocytes were collected by lavage from WT and IL-6*7' mice 
(Section 2.2.2.1). Cells were labelled with anti-F4/80 FITC and anti-CDllb APC 
conjugated antibodies as described in Section 2.2.2.3. Resident macrophage and DC 
populations were isolated on the MoFlo sorter based on their differential expression of 
these two antigens. Resident macrophages and DC were gated and sorted according to 
their F4/80hl CD1 lbhl and F4/80mt CDllbh‘ phenotypes respectively. These populations 
were then individually cultured as described in Section 2.2.2.3, in the presence or absence 
of SES (as prepared in Section 2.3.3) at a 1/50 concentration or with 50ng/ml human 
recombinant IL-6 (R&D systems, UK). Cells were cultured for 20 hours and the 
supernatants removed and rendered cell free by centrifugation as described in Section 
2.2.2.3. Supernatants were frozen at -70°C until required for cytokine quantification by 
either luminex or protein array.
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3.2.4 Assays for cytokine/chemokine quantification of macrophage and DC culture 
supernatants
Culture supernatants were analysed on a Bioplex assay (BioRad), which could detect and 
quantify a panel of 23 murine cytokines/chemokines (see Section 2.6). The 
cytokines/chemokines measured are detailed in Table 2.4. Culture supernatants were also 
run on a protein profiler array (R&D Systems), which was used as an alternative method 
to the Bioplex assay for the semi-quantification of cytokines/chemokines. This was 
performed as described in Section 2.7 to verify results obtained from the bioplex assay.
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3.3 Results
3.3.1 Resident macrophages, DC and infiltrating monocytes have distinct 
phenotypes
Resident peritoneal macrophages and DC have been extensively characterised by 
Dioszeghy et al 2008, who showed that these subpopulations are easily identified by their 
differential expression of F4/80 and CD1 lb. In this respect, antibodies against these two 
markers were used to identify resident peritoneal macrophages and DC as well as 
infiltrating monocytes. Labelling of peritoneal leukocytes with anti-F4/80 and anti- 
CDllb revealed three distinct populations of monocytic cells (Figure 3.1). Resident 
peritoneal macrophages were defined as F4/80hl CDllbhl, and resident DC as F4/80int 
CD llbhl. Both these populations were present in the murine peritoneal cavity of 
unchallenged naive WT mice. Upon induction of peritoneal inflammation, a third 
infiltrating population of monocytes was observed. These infiltrating cells were defined 
as F4/80int C D llbint (Figure 3.1).
3.3.2 WT, IL-67, IL-107, IFNy 7, OSMR7 and gpl30Y757F7Y757 mouse total peritoneal 
leukocyte numbers
To determine differences in baseline leukocyte cell numbers in WT, IL-6 '7',
IL-10'7', IFNy'7', OSMR'7' and gpl30Y757F7Y757 mice, peritoneal leukocytes were recovered 
by lavage, and the total leukocytes were counted using a coulter counter (Figure 3.2 and
3.5 A). WT, IL-6 '7', IL-10'7', IFNy'7', and OSMR'7' mice had equivalent numbers of total 
peritoneal leukocytes. Gpl30Y757F7Y757 mice, (which exhibit hyperactive STAT 1/3 
signalling and impaired SOCS3 regulation of gpl30 signalling as well as aberrant SHP2 
signalling) had significantly more total peritoneal leukocytes compared to the WT mice.
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InflammationBaseline
C D llb
R1 Resident peritoneal 
macrophages
F4/80hi/C D llbhi
R2 Resident peritoneal dendritic 
cells
F4/80int/CDl lb*1'
R3 Inflammatory/ infiltrating 
monocytes
F4/80'",/CDl lb""
Figure 3.1: F4/80 and C D llb  staining highlights three subpopulations o f monocytic cells. 
(A) Basal “resident” peritoneal leukocytes were labelled with anti F4/80 and anti CD1 lb 
highlighting the presence of two populations of monocytic cells. The F4/80hl/CDl lbhl 
cells have been identified as resident macrophages, and the F4/80‘nt/CDl lbhl cells have 
been identified as resident dendritic cells (Dioszeghy et al 2008). (B) Staining of 
peritoneal leukocytes present during SES induced peritonitis (12 hours) highlighted the 
presence of F4/80,nt/CDl lb ,ntinfiltrating monocytes. (C) Summary of the phenotypically 
distinct monocytic cell subsets.
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Figure 3.2: Total peritoneal leukocyte counts for WT, IL-6"A, OSMR"A IL-lfr7', IFN-yA 
and gpl30Y757F/Y757F mice. Peritoneal leukocytes were recovered by peritoneal 
lavage from WT, IL-6*7', OSMR"7', IL-10"7"and IFN-y7" mice. Total cells were counted 
using a coulter counter.
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3.3.3 Signalling by cytokines via the ST AT pathway regulates resident peritoneal 
macrophage and dendritic cell numbers
To investigate whether ST AT signalling regulates the proportion of resident monocyte 
populations, baseline levels of peritoneal macrophages and DC were recorded in a variety 
of mice deficient in cytokines that signal via the STAT pathway. The number of resident 
peritoneal macrophages present in the peritoneal cavity at baseline was plotted for WT, 
IL-6’7’, OSM-R7*, IL-10'7" and IFN-y7' mice. No significant differences were observed 
between the WT and any of the genetic strains (Figure 3.3). However the number of 
resident peritoneal macrophages present in the gpl30Y757F/Y757F mice was significantly 
greater than the number of macrophages present in the WT mice (Figure 3.5 B). The 
total cell number in gpl30 mice is significantly higher than in WT mice (Figure
3.5 A), meaning that although the total number of resident macrophages was significantly 
greater in the gpl30Y757F/Y757F mice, the proportion of these cells was equivalent in both 
strains.
Comparable analysis of the resident DC population in each of the 6 strains examined 
revealed that there were significantly fewer resident peritoneal DC present in the IL-67' 
mice, but significantly more of these cells in the IFN-y7' mice (Figure 3.4). The number 
of resident DC in OSMR7' and IL-107' mice remained equivalent to the numbers 
observed in WT mice. Gpl30Y757F/Y757F mice also showed no significant difference in the 
number of resident peritoneal DC compared to WT mice (Figure 3.5 C).
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Figure 3.3: IL-6, OSM, IL-10 and IFNy driven ST AT signaling does not determine 
the resident macrophage population size. (A) Resident peritoneal macrophages 
were recovered by peritoneal lavage, and were identified by labelling with 
antibodies against F4/80 and CD1 lb. (B) This population size was determined in 
various knock out mice by taking into account the flow cytometry population gated 
percentage and applying this to the total cell number recovered from the peritoneal 
cavity.
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Figure 3.4: IFN-y mediated STAT1 signalling and IL-6 mediated Shp2 signalling 
plays a role in regulating the resident dendritic cell population size. (A) Resident 
peritoneal DC were recovered by peritoneal lavage, and were identified by labelling 
with antibodies against F4/80 and CD1 lb. (B) This population size was determined 
in various knock out mice by taking into account the flow cytometry population 
gated percentage and applying this to the total cell number recovered from the 
peritoneal cavity. (*** P < 0.001)
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Figure 3.5: Hyperactive gpl30 mediated STAT1/3 signalling appears to play a role 
in regulating the resident macrophage population size, but does not plays a significant 
role in determining the resident dendritic cell population size. Resident peritoneal 
leukocytes were recovered by peritoneal lavage, and counted (A) . Resident 
macrophages and DC were identified by labelling with antibodies against F4/80 and 
CD1 lb. The resident macrophage (B) and resident dendritic cell (C) population sizes 
were determined in WT and gpl30Y757F/Y757 mice (which display hyperactive STAT1/3 
signaling) by taking into account the flow cytometry population gated percentage and 
applying this to the total cell number recovered from the peritoneal cavity. (* P <
0.05, **P<  0.01)
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3.3.4 Phenotypic analysis of resident peritoneal macrophages and DC
Resident macrophages and DC were characterised using antibodies against pan markers 
associated with the phenotype of these cell types in the six murine strains, by flow 
cytometry (Figure 3.6). Wild type resident peritoneal macrophages expressed F4/80, 
CD1 lb, MHCII, CD80, CD86, ICAM-1, Scavenger RA, CD40, TLR2, IL-6R, CCR3 and 
CCR5. Wild type resident DC expressed F4/80, CDllb, MHCII, CD80, CD86, CD40, 
ICAM-1, TLR-2, Mannose receptor (MR), CCR3, CCR5 and IL-6R (Figure 3.6).
The expression of these characteristic macrophage and DC markers by resident peritoneal 
macrophages and DC was generally equivalent in the different genetic strains (Figures
3.7 & 3.8 respectively). The exceptions were resident macrophages from gpl30Y757F/Y757F 
mice and IL-10'7" mice, which expressed more CCR5 and MHCII respectively than WT 
littermates (Figure 3.7 B&C). Finally, IL-6"7' mice expressed lower levels of CCR5 on 
their resident DC compared to WT mice (Figure 3.8 B).
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Figure 3.6: Expression o f macrophage and dendritic cell markers by WT 
resident peritoneal macrophages (Rl) and dendritic cells (R2). Resident 
macrophage and DC populations were identified by flow cytometry by 
labelling with anti F4/80 FITC and anti CD1 lb APC, and pan markers were 
measured using PE conjugated antibodies. Flow cytometry histogram plots are 
representative of four independent experiments.
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A Resident peritoneal macrophage expression of pan markers.
Marker WT IL -6 7 OSMR7 IL-107 IFN-y7" WT Gpl30Y757F7Y757F
F4/80 +++ +++ +++ +++ +++ +++ +++
C D llb +++ +++ +++ +++ +++ +-H- +++
C D llc - - - - - - -
MHCII + + + ++ + + +
MR - - - - - - -
TLR2 ++ ++ ++ ++ ++ ++ ++
CD80 + + + + + + +
CD83 - - - - - - -
CD86 + + + + + + +
ICAM-1 +++ +++ +++ +++ +++ +++ +++
CD40 ++ ++ ++ ++ ++ ++ ++
SR-A + + + + + + +
CCR3 + + + + + + +
CCR5 +/- +/- +/- +/- +/- +/- +
IL-6 R +/- +/- +/- +/- +/- +/- +/-
WT gpl30Y757F/Y757F
CCR5
WT IL-10 - / -
E E
MHCII
Figure 3.7: Characterisation o f resident peritoneal macrophages in WT, IL-6'7', OSMR'7', IL-KL7',
IFN- y7~ and gpl30Y757F/Y757F mice. (A) Peritoneal leukocytes were recovered by lavage, and labelled 
with antibodies against F4/80 and CD1 lb, to identify the macrophages, and an array of macrophage/DC 
markers. (B) CCR5 expression in WT and gpl30Y757F7Y757F resident macrophages. (C) MHC II 
expression on WT and IL-10'7' resident macrophages. -, +, ++, +++ refer to no expression, low, medium 
and high expression respectively, as gauged by the relative intensity of staining defined from the 
histogram plot. Data is representative of four independent experiments.
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A Resident peritoneal dendritic cell expression of pan markers.
Marker WT IL-6'7' OSMRv' IL-10_/' IFN-y7' WT Gpl30Y757F/Y757F
F4/80 + ++ ++ ++ ++ ++ ++
CDllb +++ +++ +++ +++ -H -+ +++ +++
CDllc ++ ++ ++ ++ ++ ++ ++
MHCII +++ -H-+ +++ +++ +++ +++ +++
MR + + + + + + +
TLR2 ++ ++ ++ ++ ++ ++ ++
CD80 + + + + + + +
CD83 - - - - - - -
CD86 + + + + + + +
ICAM-1 +++ +++ +++ +++ +++ +++ +++
CD40 + + + + + + +
SR-A - - - - - - -
CCR3 + + + + + + +
CCR5 + + + + + ++ ++ ++ ++
IL-6 R + + + + + + +
B WT IL-6
CCR5
Figure 3.8: Characterisation o f  resident peritoneal dendritic cells in WT, IL-6"A, 
OSMR-', IL-10-'-, IFN- f - a n d  g p l3 0 Y757F/Y757F mice. (A) Peritoneal leukocytes were 
recovered by lavage, and labelled with F4/80 and CD1 lb, to identify the resident DC, 
and a number o f macrophage/DC markers. (B) CCR5 expression in WT and IL-6' '  
resident DC. +, ++, +++ refer to no expression, low, medium and high expression 
respectively, as gauged by the relative intensity o f staining defined from the histogram 
plot. Data is representative of four independent experiments.
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3.3.5 Cytokine/chemokine production by resident macrophages and DC, in response 
to SES and IL-6
To study the activity o f resident monocytic cells upon inflammatory stimulation, 
cytokine/chemokine production by resident peritoneal macrophages and DC from WT 
and IL-6"7" mice was measured using a Bioplex assay and a proteome profiler array. Non 
stimulated resident macrophages and DC produced basal levels o f cytokines/chemokines. 
Macrophages produced IL - la , IL -ip , IL-6, IL-9, IL-10, IL-12 (p40 and p70), IL-13, G- 
CSF, GM-CSF, CXCL1, CCL2, CCL3, CCL4, CCL5 and TN F-a (Figure 3.9 & 3.10). 
The production o f these cytokines/chemokines was however comparable between WT 
and IL-6'7* mice, with the exception o f IL-6, which was absent in the IL-6'7' mice. In 
response to SES stimulation, production o f all the cytokines/chemokines tested increased 
significantly, and also led to a low level o f production o f IL-2 and IL-3. SES stimulation 
induced equivalent changes in cytokine/chemokine production in macrophages from both 
WT and IL-6*7' mice. Interestingly, IL-6 stimulation o f these resident macrophages did 
not induce any changes in cytokine or chemokine production in IL-6"7* mice. The same is 
true for WT macrophages, however since this population is likely to respond to autocrinal 
IL-6, no effect was expected by further IL-6 stimulation o f these cells.
WT resident DC produced basal levels o f IL -la , IL -lp , IL-6, IL-9, IL-10, IL-12 (p40 and 
p70), IL-13, G-CSF, GM-CSF, CXCL1, CCL2, CCL3, CCL4, CCL5 and TN F-a in un­
stimulated culture (Figure 3.11 & 3.12). Again, cytokine and chemokine production was 
significantly increased in the resident DC population challenged with SES. IL-6'7* mice 
lacked IL-6, GM-CSF and TN F-a, but were comparable to WT in their release o f the 
other cytokines/chemokines tested. The production o f GM-CSF and TN F-a by IL-6'7' 
resident DC was however rescued upon stimulation with IL-6 (Figure 3.11). However 
these values were below the limit o f detection and so no real conclusions could be made 
from these results. No other regulation was observed in response to IL-6 stimulation in 
IL-6'7' resident DC, or in WT resident DC as was expected given their basal expression of 
IL-6 in un-stimulated culture.
This data was confirmed by protein array (data not shown).
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Figure 3.9: Resident peritoneal macrophages produce basal levels o f cytokines in 
culture which increases upon SES stimulation but not IL-6 stimulation. Resident 
peritoneal macrophages were purified from pooled lavages based on their 
expression of F4/80 and CD1 lb. Cytokine production was measured by Bioplex 
assay. (A) Cytokine production by WT resident peritoneal macrophages in culture, 
un-stimulated, SES 1/50, recombinant (r)IL-6 50ng/ml, SES+hrIL-6. (B) Cytokine 
production by IL-6'7' resident peritoneal macrophages in culture, un-stimulated, SES 
1/50, rIL-6 50ng/ml, SES+rIL-6. Data represents a single experiment following 
20hrs of culture. . .  n
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Figure 3.10: Resident peritoneal macrophages produce basal levels o f  
chemokines in culture which increases upon SES stimulation but not IL-6 
stimulation. Resident peritoneal macrophages were purified from pooled lavages 
based on their expression of F4/80 and CD1 lb. Chemokine production was 
measured by Bioplex assay. (A) Chemokine production by WT resident 
peritoneal macrophages in culture, un-stimulated, SES 1/50, recombinant (r)IL-6 
50ng/ml, SES+rIL-6. (B) Chemokine production by IL-67' resident peritoneal 
macrophages in culture, un-stimulated, SES 1/50, rIL-6 50ng/ml, SES+rIL-6. 
Data represents a single experiment following 20hrs of culture.
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Figure 3.11: Resident peritoneal DC produce basal levels o f cytokines in culture 
which increases upon SES stimulation but not IL-6 stimulation. Resident peritoneal 
DC were purified from pooled lavages based on their expression of F4/80 and 
CD1 lb. Cytokine production was measured by Bioplex assay. (A) Cytokine 
production by WT resident peritoneal DC in culture, un-stimulated, SES 1/50, 
recombinant (r)IL-6 50ng/ml. (B) Cytokine production by IL-67' resident peritoneal 
DC in culture, un-stimulated, rIL-6 50ng/ml. Data represents a single experiment 
following 20hrs of culture.
119
10001 Unstimulated
CXCL1 CCL2 CCL3 CCL4 CCL5
B
1000-
£
CXCL1 CCL2 CCL3 CCL4 CCL5
Figure 3.12: Resident peritoneal DC produce basal levels o f  chemokines in 
culture which increases upon SES stimulation but not IL-6 stimulation. Resident 
peritoneal DC were purified from pooled lavages based on their expression of 
F4/80 and C D llb . Chemokine production was measured by Bioplex assay. (A) 
Chemokine production by WT resident peritoneal DC in culture, un-stimulated, 
SES 1/50, recombinant (r)IL-6 50ng/ml. (B) Chemokine production by IL-6_/' 
resident peritoneal DC in culture, un-stimulated and rIL-6 50ng/ml. Data 
represents a single experiment following 20hrs of culture.
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3.4 Discussion
Based on work published by a collaborating group (Dioszeghy et al 2008), we were able 
to use F4/80 and C D llb  labelling of total resident peritoneal cells to identify distinct 
populations of resident peritoneal macrophages and dendritic cells. These resident 
macrophage and DC populations were defined by their phenotypes F4/80h,CD llbhl and 
F4/80,ntCDl lbhl respectively. The data shown in this Chapter suggest that STAT 
signalling via IL-6, OSM, IFN-y, and IL-10 does not regulate the number of resident 
macrophages found in the mouse peritoneal cavity under baseline conditions. It must be 
said however that it would be difficult to detect small variations in the resident 
macrophage population due to their large number (between 1.5xl06 and 6xl06 cells) 
present at any one time within the cavity. Gpl30 mice however possessed
significantly increased numbers of resident macrophages as compared to their littermate 
controls. These mice also exhibited a global increase in the number of peritoneal 
leukocytes indicating that hyperactive STAT signalling in these mice contributes to 
haematopoiesis in general, giving rise to the increased numbers of macrophages 
observed.
The studies described here have however shown that IL-6 directed STAT1/STAT3 or 
SHP-2 signalling and IFN-y directed STAT1 signalling regulates the number of resident 
DC present in the peritoneal cavity of naive mice, in a positive and negative manner 
respectively. IL-6 is able to signal either via the STAT pathway or the SHP2 pathway (as 
detailed in Chapter 1, Section 1.16.2). To distinguish which IL-6-mediated signalling 
pathway may contribute to the regulation of DC numbers, this population was analysed in 
gpl30Y757F/Y757F mice, which exhibit hyperactive STAT1/STAT3 signalling, and impaired 
SHP2 signalling (Tebbutt et al 2002). Given that the gpl30Y757F/Y757F mice did not 
exhibit any increase in the number of resident DC present in the peritoneal cavity (as 
would be expected if the regulation was STAT1/STAT3 regulated), this positive 
regulation by IL-6 of the proportion of resident peritoneal DC is likely acting via the 
SHP2 mediated ERK MAP kinase pathway. Therefore, the evidence given in this chapter 
supports a role for the IL-6 mediated MAP kinase pathway in promoting resident DC 
numbers shown by the significantly reduced numbers of these cells in IL-6’7’ mice. To
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confirm these observations, it would have been elegant to test this notion further in 
gpl30iSTAT: aSTAT mice, which retain SHP2 signalling capacity, but lack STAT1/STAT3 
signalling capacity (Ernst et al 2001). However due to breeding difficulties within the 
colony we were unable to test this further. The apparent positive regulation of resident 
peritoneal DC numbers by IL-6 demonstrated by these findings, supports work by 
Santiago-Schwartz et al 1995, Bernhard et al 2000, and Brasel et al 2000, who all 
showed evidence to suggest that IL-6 drives DC differentiation. Conversely, it contrasts 
many reports of IL-6 skewing the differentiation of monocytes from macrophages to DC. 
The data shown in this Chapter, inferring a role for IL-6 in the regulation of the number 
of resident DC, is also supported by the fact that no decrease in resident peritoneal 
macrophages was observed in IL-6'7' mice suggesting that IL-6, in this case, is not 
regulating macrophage numbers, but does appear to be dictating DC numbers.
Studies in this Chapter also revealed a role for IFN-y in the suppression of resident DC 
numbers. This negative regulation of resident peritoneal DC numbers by IFN-y supports 
previous work by Delneste et al who showed that in humans, IFN-y switches monocyte 
differentiation from dendritic cells to macrophages, by up-regulation of autocrine IL-6 
and M-CSF production (Delneste et al 2003). In this respect, IL-6 has been shown to 
enhance M-CSF receptor expression and signalling (Chomorat et al 2000), which in turn 
drives macrophage differentiation (Becker et al 1987). It therefore follows that in the 
absence of IFN-y, monocyte differentiation into DC would predominate, as was 
demonstrated in the findings discussed here.
Since WT, IL-6'7' and IFN-y'7' mice possessed equivalent total peritoneal leukocyte 
numbers, the differences observed in DC numbers in these mice indicate that SHP2 and 
STAT1 responses driven by IL-6 and IFN-y '7' respectively, contribute to the regulation of 
the DC population alone, and do not regulate the global haematopoiesis of all cell types. 
In this respect, while the data supports a clear role for IL-6 and IFN-y in determining 
resident peritoneal DC numbers, it does not allow us to draw any conclusions on the 
mechanism by which they do this. These cytokines may either regulate the rate of 
homeostatic migration to the peritoneal cavity and local differentiation of these DC from
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their precursors, or the rate of egress from the peritoneal cavity, and further experimental 
work would be required to determine the nature of this response.
No differences were observed in the number of resident DC in OSMR'7' and IL-10'7' mice 
indicating that the regulation of STAT signalling by these particular cytokines does not 
regulate the resident peritoneal DC population size. It has been previously reported that 
in humans, IL-10 prevents differentiation of monocytes to DC and instead promotes their 
maturation to macrophages (Allavena et al 1998), but no evidence of this was seen in the 
murine model in these studies.
To define a role for IL-6 in regulating resident monocytic cell activity, macrophages and 
DC were cultured in the presence of IL-6 as well as inflammatory stimulus SES, to 
determine how the activity of these cells are regulated upon inflammatory challenge. 
Cytokine and chemokine production in WT and IL-6'7' resident macrophages and DC was 
up-regulated upon SES stimulation and this is consistent with findings by Dioszeghy et al 
2008, who showed similar up-regulation of cytokine and chemokine production in WT 
resident macrophages and DC using the same bioplex assay (Dioszeghy et al 2008). IL-6 
stimulation of IL-6'7' resident macrophages showed no effect on cytokine and chemokine 
production. The level of IL-6R expression on these cells is very low (refer to Figure 3.6), 
which may explain why no response is seen from these cells. However, resident DC, 
which express higher levels of IL-6R, also did not appear to respond to IL-6 stimulation. 
Where differences were seen upon IL-6 stimulation, the measured levels were below the 
limit of detection of the assay, so no conclusions could be made from these results. 
These data clearly demonstrate that while the activity of resident macrophage and DC 
populations is potently initiated and up-regulated by an inflammatory stimulus (e.g. SES), 
the activity of these cells does not appear to be regulated in any way by the presence of 
IL-6. This is striking given the known impact of IL-6 on monocyte activity (Bleier et al 
2004, Hedge et al 2004, Pasare et al 2003).
The absence of activity of resident peritoneal DC in response to IL-6 stimulation is 
further investigated in Chapter 4.
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CHAPTER 4
The regulation of IL-6 receptor on m urine resident peritoneal dendritic cells
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4.1 Introduction
In addition to its role as a regulator of dendritic cell haematopoiesis and differentiation, 
IL-6 also controls dendritic cell activation, maturation and trafficking (Park 2004, 
Kitamura et al 2005, Hedge et al 2004). Following microbial invasion or tissue 
destruction, resting immature DC, which possess diverse recognition systems for 
monitoring danger signals, become activated and undergo maturation (Kaisho et al 2001). 
DC maturation is associated with the loss of antigen capturing ability and the acquisition 
of an antigen presenting ability. This maturation is coupled with the migration of DC 
from the peripheral tissue, to the lymph nodes where they are able to present antigen, and 
activate T cells (Novak and Beiber 2007, Ueno et al 2007, Wu and Dakie 2004, Foti et al 
1999). Work by Park et al showed that IL-6 plays a major role in maintaining DC in an 
immature state. Specifically, IL-6*7' mice had increased numbers of mature DC indicating 
that IL-6 blocks DC maturation in vivo. In this respect, IL-6 activation of STAT3 was 
required for the suppression of LPS-induced DC maturation, with DC mediated T cell 
activation being enhanced in IL-6'7' mice and suppressed in gpl30 knock in mice (Park et 
al 2004). Taken together these data indicate that IL-6 acts as an immunosuppressive 
cytokine for DC differentiation/activation/maturation and suggests that IL-6 continuously 
stimulates resting/immature DC in the steady state (Park et al 2004).
A key indicator of DC maturation is the induction of intracellular trafficking of MHCII 
vesicles and increased surface expression of MHCII. Work by Kitamura et al has shown 
that IL-6-STAT3 signalling suppresses MHCII expression on DC by suppressing both 
MHCII ap  dimer subunits and associated MHCII-adaptor molecules. Regulation of these 
processes is associated with an attenuation of T cell activation (Kitamura et al 2005). 
This work supports findings by Park et al who showed that IL-6 STAT-3 mediated 
signalling suppressed LPS-induced surface expression of MHCII (Park et al 2004).
Upon activation and maturation of DC, they migrate through the lymphatic system to the 
lymph nodes where they present antigen and activate T cells. This migration is 
chemokine mediated, and the predominant chemokine receptor for this process is CCR7 
(Ohi et al 2004, Forster et al 1999, Sozzani et al 1998). DC maturation is accompanied
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by a rapid inhibition of responsiveness to chemoattractants present at the sites of 
inflammation by down regulation of the relevant chemokine receptors (Sozzani et al 
1998). This permits the maturing DC to leave the peripheral tissues, at which point an 
up-regulation of CCR7 allows a co-ordinated migration of DC towards the 
chemoattractants CCL19 and CCL21 expressed in the lymph nodes (Sozzani et al 1998, 
Ohi et al 2004, Forster et al 1999). The induction of CCR7 is regarded as a crucial 
integral part of the maturation process, as it confers responsiveness to CCL19, the 
chemoattractant produced in the T cell zone of the secondary lymphoid organs, and 
secondary lymphoid tissue chemokine CCL21. These chemokines are responsible for the 
homing of T cells and DC to secondary lymphoid tissue (Moser and Loetscher, 2001). 
IL-6 has been shown to inhibit CCR7 up-regulation on LPS matured DC, adding another 
immunosuppressive property to the growing list attributed to IL-6. Hedge et al showed 
that IL-6 does this by inhibiting nuclear factor-xB regulation of CCR7 transcription. This 
results in impaired chemotaxis of matured DC to CCR7-activating chemokines CCL19 
and CCL21, required for recruiting DC to lymphoid tissues in vivo (Hedge et al 2004).
In contrast to these findings, IL-6 has been shown to be vital for the function of fully 
matured DC within the lymphoid organs. Bleier et al showed that IL-6'7' bone marrow 
derived DC (BMDC) and splenic DC induced significantly less allogenic T cell 
stimulation than their WT counterparts. Dendritic cells also produced high levels of IL-6 
upon microbial stimulation, indicating that IL-6 is important for their function in 
activating T cells (Bleier et al 2004). Finally, IL-6 secretion by DC upon TLR 
stimulation has been shown to block the immunosuppressive activities of regulatory T 
cells (Pasare and Medzhitov 2003) thereby promoting pro-inflammatory T cell responses. 
Therefore IL-6 plays either an immunosuppressive role or a proinflammatory role on 
antigen presenting cells depending on their maturation state and tissue localisation.
The aim of this Chapter was to determine the effect of IL-6 on the activity of resident 
peritoneal dendritic cells, and to investigate possible activation induced changes in DC 
IL-6 receptor expression.
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4.2 Materials and methods
4.2.1 Isolation of basal resident peritoneal macrophages and dendritic cells
WT, IL-6'7', IL-10'7', gpl30Y757F7Y757F, OSMR'7' and IFN-y'7‘ mice were sacrificed by 
schedule 1 and peritoneal leukocytes were recovered by lavage as described in Section 
2 .2 .2 . 1.
4.2.2 MACS purification of C D llb+ murine peritoneal leukocytes
CD llb+ murine peritoneal leukocytes were purified by MACS column separation using 
anti-CD l ib  antibodies conjugated to magnetisable particles (Section 2.2.2.2.). The 
CD1 lb+ fraction of cells largely consists of macrophages and DC.
4.2.3 Culture of C D llb+ murine peritoneal leukocytes
2xl06 peritoneal leukocytes were incubated in 12 well plates for 2 hours at 37°C with 
SES (reconstituted in 750pl media and sterile filtered), PMA 50ng/ml, Ionomycin 
500ng/ml, TAPI (TG-ase activating protease inhibitor) lOOpM or PMA in combination 
with TAPI (Section 2.2.2.1). Cells were removed by scraping and centrifuged at 
2000rpm for 5 minutes to collect the cells for flow cytometric analysis (see Section 
4.2.6).
4.2.4 Induction of peritoneal inflammation with Staphylococcus epidermidis (SES)
Lyophilised SES was prepared as described in Section 2.3.3 and reconstituted in 750^1 
sterile PBS. Mice were injected i.p with a 500p,l aliquot of SES (Section 2.3.5). At 
defined intervals, groups of mice (n=5, mixture of males and females) were sacrificed 
and peritoneal leukocytes recovered by lavage as described in Section 2.3.2.
4.2.5 Induction of bacterial peritonitis by administration of Staphylococcus 
epidermidis
Experiments were performed as outlined in Section 2.3.7. Mice were injected i.p with 
5xl08 colony forming units (cfu) of live Staphylococcus epidermidis (prepared as 
described in section 2.3.6). At defined intervals, groups of mice (n=5, mixture of males
127
and females) were sacrificed by schedule 1 and peritoneal leukocytes recovered by lavage 
(Section 2.3.2).
4.2.6 Flow cytometric analysis of resident peritoneal dendritic cells
Freshly isolated and cultured resident peritoneal macrophages and DC were labelled with 
anti-F4/80 FITC and anti-CD l ib  APC, and PE or Biotin conjugated antibodies against 
either IL-6R, MHC II, CD83, CCR5, CCR3, CCR6 or CCR7 as described in Section 
2.4.3. Resident peritoneal macrophages and DC from in vivo experiments were labelled 
with anti-F4/80 FITC, anti-CDl lb  PerCP Cy5.5, anti-CDl lc APC, and anti-IL-6R PE as 
described in section 2.4.3. Details of the antibodies used are found in Table 2.1. 
Receptor expression was quantified by calculating the mean fluorescent intensity as 
described in Section 2.4.5.
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4.3 Results
4.3.1 Changes in IL-6R levels on cultured resident dendritic cells
Due to the lack of IL-6 responsiveness of resident DC, observed in the previous Chapter 
(Section 3.3.5), it was decided to investigate the levels of the IL-6 receptor on this 
population during culture. Total C D llb+ leukocytes, which included all resident 
macrophages and DC, were isolated by MACS separation, and established in culture. 
Cells were recovered two hours later and analysed by flow cytometry using antibodies 
against F4/80, C D llb  and IL-6R. In contrast to resident peritoneal DC, resident 
peritoneal macrophages showed very low expression of IL-6R, and therefore it was not 
possible to determine any changes in IL-6R levels on this population. However 
prolonged culture of resident DC led to an almost complete loss of IL-6R expression on 
the cell surface (Figure 4.IB). This down regulation in IL-6R coincided with a 
significant increase in both CD83 and MHC II expression (Figure 4.1 C&D). This up- 
regulation of maturation markers was indicative of dendritic cell activation. The down 
regulation of IL-6R observed was not ligand dependent since a comparable loss in IL-6R 
was also noted in resident DC from IL-6_/' mice (Figure 4.2).
To determine if the loss of IL-6R on resident DC was a result of shedding, these cells 
were cultured in the presence of a variety of cell stimulators, and also the IL-6R sheddase 
inhibitor TAPI. Down-regulation of the receptor was quantified by calculating the mean 
fluorescent units (Figure 4.2). Down-regulation of IL-6R upon PMA, SES and 
ionomycin stimulation of resident DC was only marginally greater than that induced by 
culture alone, therefore culture induced activation alone was enough to mediate an almost 
complete loss of IL-6R on these cells. The addition of TAPI to these cultures only 
partially inhibited the down-regulation of IL-6R, returning the levels of IL-6R on these 
cells to that seen in cells in un-stimulated culture (Figure 4.2).
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Figure 4.1: WT resident dendritic cells down-regulate their IL-6R upon culture, 
coinciding with an up-regulation o f  CD83 and MHC II. (A) Freshly isolated and 
cultured resident peritoneal DC were labelled with anti F4/80 and CD1 lb, and were 
subsequently identified by their phenotype F4/80intCDl lbhl. (B) Flow cytometry 
histogram plots gated on resting and cultured resident dendritic cells (F4/80intCDl lb w) 
from 30,000 total events, measuring IL-6R levels. Representative histogram plots for 
(C) CD83 levels and (D) MHC II levels. Data is representative of 3 separate 
experiments. 130
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Figure 4.2: WT and IL-6v' mice exhibit a down regulation o f IL-6 receptor on their 
resident DC in vitro both spontaneously in culture and upon stimulation with PMA, 
ionomycin and SES. A) Representative flow cytometry histograms displaying the down 
regulation of IL-6R on WT and IL-6'7' murine resident peritoneal dendritic cells, based 
on 2-8 individual experiments. (B) Plots of the mean fluorescent units (MFU) taken 
from histogram plots, to represent down regulation of IL-6R from resident DC upon 
culture, and stimulation with PMA (50ng/ml), ionomycin (500ng/ml), SES (1/2) and 
with the addition of protease inhibitor TAPI (lOOpM) in WT and (C) IL-6-7'mice .
(* P <  0.05, ***/>< 0.001).
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4.3.2 IL-6R level changes on resident dendritic cells in vivo upon activation of SES 
and S.epidermidis induced inflammation
To determine if resident DC down-regulated their IL-6R in vivo, peritoneal inflammation 
was induced either by i.p administration of SES, a cell free supernatant derived from a 
clinical isolate of S.epidermidis, or a live isolate of S.epidermidis. As a control, some 
mice were treated with PBS alone. Peritoneal cells were recovered by lavage after one 
and three hours and flow cytometry was performed using antibodies against F4/80, 
CD lib , C D llc and IL-6R to determine receptor levels in the resident DC population 
(Figure 4.3). Analysis of resident DC from both WT and IL-6'7" mice showed that 
inflammatory activation with either SES or live bacteria triggered a down-regulation of 
IL-6R on the resident DC population (Figure 4.3 A). No such changes were observed 
following PBS administration (Figure 4.3 B). Calculating the mean fluorescent units to 
quantify receptor level changes showed that IL-6'7' mice appeared to down-regulate their 
IL-6R at a slower rate than WT mice, which was particularly evident in mice 
administered with SES (Figure 4.4 C&D). Most WT mice exhibited a complete 
disappearance of the IL-6R from their resident DC by one hour post induction of 
inflammation. In IL-6'7’ mice however, the receptor was not completely down-regulated 
on resident DC by 1 hour, but was completely absent from the cell surface by 3 hours 
(Figure 4.4).
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Figure 4.3: IL-6R is down-regulated on resident peritoneal dendritic cells in vivo.
(A) Peritoneal inflammation was established in WT mice by i.p injection of either 
5xl08 cfxi Staphylococcus epidermidis or 500pl of SES. Some mice received 500pl 
of PBS as a control. IL-6R was measured on F4/80mtCDl lbhlCDl lc+ resident DC.
(B) IL-6R was measured on F4/80hlCDl lbhl resident macrophages. Plots are 
representative from a total of 5 mice per time point.
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Figure 4.4: WT and IL-61- mice exhibit a down regulation o f IL-6 receptor on their 
resident DC in vivo upon induction o f peritoneal inflammation.
Peritoneal inflammation was established in WT and IL-6'7' mice by i.p injection of 
either 5x108 cfu Staphylococcus epidermidis or 500pl of SES. Resident DC 
(F4/80intCD llbhiCDllc+) were labelled with anti IL-6R, 1 and 3 hours following 
induction of peritoneal inflammation and changes in the mean fluorescent units were 
plotted for (A) WT mice that received live Staphylococcus epidermidis (B) IL-6'7' that 
received live Staphylococcus epidermidis, (C) WT mice that received SES. (D) IL-6'7' 
mice that received SES. (** P < 0.01, *** P < 0.001).
4.3.3 Regulation of CCR7 expression on resident dendritic cells
IL-6 has been shown to impair CCR7 up-regulation on maturing dendritic cells, and as a 
result impairs chemokine driven trafficking of DC to the draining lymph nodes following 
activation (Hedge et al 2004). To determine whether the down-regulation of 
IL-6R observed on resident peritoneal DC was associated with a concomitant increase in 
CCR7, expression of this receptor was measured on resident DC before and after 
activation. CD1 lb+ peritoneal leukocytes, pooled from four mice, were cultured for two 
hours with or without SES stimulation, and flow cytometry performed using antibodies 
against F4/80, CD l ib  and CCR7 as well as IL-6R, CD83 and MHC II as controls. 
Resident DC from both WT (Figure 4.5) and IL-6'7' (data not shown) mice exhibited the 
previously observed down-regulation of IL-6R and corresponding up-regulation of CD83 
and MHC II, but they did not show any expression of CCR7, both in the resting state, and 
following culture induced activation. This was irrespective of prior SES activation.
4.3.4 Regulation of monocyte chemoattractant receptors on resident dendritic cells
Since resident DC did not up-regulate CCR7 upon activation, alternative chemokine 
receptors were addressed with the aim of determining the mechanism by which resident 
DC migrate to the draining lymph node following activation. Resting, and culture 
activated (with and without SES) resident peritoneal DC from WT (Figure 4.6) and IL-67' 
(data not shown) mice were analysed by flow cytometry using antibodies against CCR3, 
CCR5 and CCR6. Resting resident DC did not express CCR6 basally, but did express 
CCR3 at a very low level, and CCR5 at a more moderate level. Upon activation in 
culture resident DC from both WT and IL-67' mice did not up-regulate any of these three 
chemokine receptors (Figure 4.6).
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Figure 4.5: Resident peritoneal DC do not exhibit an up-regulation o f  CCR7 upon culture.
(A) Wild type CD1 lb+ MACS enriched peritoneal cells, pooled from 4 mice, were labelled with 
anti F4/80 and CD1 lb, and resident DC were identified and gated as F4/80,ntCDl lbhl. This was 
followed by subsequent flow cytometry analysis. (B) Expression of IL-6R, CD83, MHCII and 
CCR7 on resting resident peritoneal DC from naive WT mice. (C) Expression of IL-6R, CD83, 
MHC II and CCR7 on resident peritoneal DC following un-stimulated culture for two hours.
(D) Expression of IL-6R, CD83, MHC II and CCR7 on resident peritoneal DC following 
stimulation with SES in culture for two hours. (E) Positive control for CCR7 antibody, staining 
of CD4+ splenocytes. FACS plots are representative of two independent experiments.
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Figure 4.6: Resident peritoneal DC do not up-regulate chemokine expression upon 
stimulation in culture. (A) Wild type CD1 lb+ MACS enriched peritoneal cells, pooled 
from four mice, were labeled with anti F4/80 and CD1 lb, and resident DC were 
identified and gated as F4/80,ntCDl lb hl. This was followed by subsequent flow 
cytometry analysis. (B) Expression of CCR3, CCR6 and CCR5 on resting resident 
peritoneal DC from naive WT mice. (C) Expression of CCR3, CCR6 and CCR5 on 
resident peritoneal DC following un-stimulated culture for two hours. (D) Expression 
of CCR3, CCR6 and CCR5 on resident peritoneal DC following stimulation with SES 
in culture for two hours. FACS plots are representative o f two independent 
experiments
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4.4 Discussion
Data presented in this Chapter supports a hypothesis that resident peritoneal DC down- 
regulate their IL-6 receptor upon activation, as part of the maturation process. The down- 
regulation of the IL-6R observed, coincided with the maturation of the resident DC 
population, and was linked with an increase in the DC activation markers MHCII and 
CD83. This activation-induced loss of IL-6R on resident DC goes some way to explain 
the lack of IL-6 responsiveness observed in vitro, where IL-6 failed to activate this cell 
population (data presented in Chapter 3). A number of studies have shown that the 
activation of T cells is associated with a reduced expression or complete loss of IL-6R 
resulting in IL-6 insensitivity (Teague et al 2000, Nowell et al 2009, Briso et al 2008). 
Similarly, an activation-induced loss of membrane bound IL-6R expression on DC is 
likely to abrogate IL-6 signalling, accounting for a down-regulation in IL-6 
responsiveness by these cells. This would assume that these activated DC also lack 
responsiveness to IL-6 trans-signalling via the soluble receptor. The potential activation 
of resident DC by IL-6 trans-signalling is still unclear and due to a lack of an appropriate 
antibody we were unable to examine potential changes in the signalling receptor gpl30.
The data shown in this Chapter fits nicely with what is already known about IL-6 and its 
immunosuppressive role on DC. IL-6 is currently believed to maintain resting DC in an 
immature state where they reside in the periphery (Park et al 2004). Once activated by a 
microbial stimulus, DC undergo maturation (Kaisho et al 2001). This process is an 
essential event that enables the activated DC to migrate to the lymph node where they can 
present antigen to T cells. The down-modulation of IL-6R on activated DC would 
therefore be predicted to remove the inflammatory constraint imposed upon DC by IL-6. 
This receptor down-regulation doesn’t affect their ability to produce IL-6 however (as 
shown in Chapter 3, IL-6 production by resident DC increases upon SES stimulation), 
allowing the DC to effectively suppress T regulatory cells and activate T helper cells by 
the production of IL-6, without responding to IL-6 themselves (Pasare and Medzhitov 
2003, Park et al 2004).
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Support for this conclusion is derived from data relating to the IL-6 control of MHC II. 
As previously stated, the studies discussed here showed that resident peritoneal DC up- 
regulated MHCII upon activation in vitro. Based on data presented by Kitamura et al, 
IL-6 has been shown to act as a negative regulator of MHC II expression (Kitamura et al 
2005), and the results presented in this Chapter would appear to support these findings. It 
could be speculated that the down regulation of IL-6R on these resident DC upon 
activation renders them unresponsive to IL-6R and therefore allows the up-regulation of 
MHCII on the cell surface. This would increase the antigen presenting capacity of these 
cells, and define their maturation from immature antigen capturing cells, to matured 
antigen presenting cells. However since an equivalent up-regulation of MHCII was 
observed in IL-6'7' DC, these studies would suggest that the increase in expression of this 
receptor was IL-6 independent. Further experiments would need to be performed to 
determine if the up-regulation of MHCII on these activated resident DC is attributed to 
the inability of IL-6 to stimulate these cells upon the loss of the receptor.
Previous studies have shown that IL-6 negatively regulates CCR7 expression, the 
chemokine receptor required for migration of matured DC to the lymph nodes (Hedge et 
al 2004). It was therefore hypothesised that upon down-regulation of the IL-6R on 
resident peritoneal DC, CCR7 expression would be increased due to the removal of the 
immunosuppressive effects of IL-6 on these cells. Unfortunately it was not possible to 
show an up-regulation of CCR7 or other potential chemokine receptors CCR3, CCR5 and 
CCR6 in vitro. It is conceivable that the initial migration of maturing resident peritoneal 
DC is attributed to an alternative chemokine, and the up regulation of CCR7 may occur at 
a later stage, perhaps during the transit into the lymphatic system at which point the cells 
become unrecoverable by peritoneal lavage. To determine this, CCR7 expression would 
need to be measured in resident DC upon induction of peritoneal inflammation in vivo. 
An alternative explanation could be that the resident DC in culture are being subjected to 
suppression by IL-6 trans-signalling, which allows IL-6 to signal via its soluble receptor 
even in the absence of IL-6R on the cells surface. This is unlikely however due to the 
absence of CCR7 observed on activated resident DC from IL-6"7* mice. Resident DC
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from these mice do not secrete IL-6, and therefore are unable to produce the IL-6/sIL-6R 
complex required for trans-signalling in these cultures. Finally it is conceivable that the 
resident DC do not home to the lymph nodes upon activation in the same way that many 
other DC subtypes have been observed to do. The peritoneal cavity is known to be rich 
in B1 cells, which are involved in both the innate and the adaptive immune response 
(Itakura et al 2005). The resident peritoneal DC are established antigen presenting cells 
(Dioszeghy et al 2008), and it is conceivable that this subset may remain in the peritoneal 
cavity upon activation, to present antigen to and activate the resident B1 cells, triggering 
their roles in innate and adaptive immunity. This would provide an adequate explanation 
for the lack of expression of lymph homing chemokine receptors by the resident DC, and 
support a potential new role for these cells in triggering a local and more rapid adaptive 
immune response.
The next Chapter investigates the role of IL-6 in the trafficking of monocytic cell 
populations during acute inflammation.
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CHAPTER 5
The role of IL-6 in the trafficking of monocytic cells during an in vivo model of
peritoneal inflammation
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5.1 Introduction
Bacterial peritonitis is an underlining complication of end-stage renal failure patients 
receiving peritoneal dialysis. This form of treatment uses the peritoneal membrane as a 
dialysing barrier, across which waste products can be removed from the blood into a 
dialysis fluid (Venkat et al 2006). Commensal bacteria are often introduced into the 
peritoneal cavity via the catheter port as a result of skin contact that occurs when 
attaching or detaching bags, resulting in an inflammatory episode. The most common 
bacterial infections associated with these episodes of peritonitis are either Staphylococcus 
aureus or Staphylococcus epidermidis (Woo et al 2004). Repeated episodes of peritonitis 
affect the integrity of the peritoneal membrane, causing thickening of the membrane and 
compromising its ability to act as a dialysis membrane (Davies et al 1996, Williams et al 
2002, Di Paolo et al 1986, Devuyst et al 2002). Ultimately these inflammation-induced 
changes to the tissue architecture lead to treatment failure. IL-6_/" mice exhibit a 
remarkable protection from chronic inflammation, and are protected from a number of 
other immunological disorders such as rheumatoid arthritis and Crohn’s disease 
(Grossman et al 1989, Swaak et al 1989, Houssiau et al 1988, Naugler and Karin 2008). 
This has lead to IL-6 being of huge interest as an important therapeutic target with anti- 
IL-6 based therapies currently being used to treat these chronic inflammatory disorders 
(Scheinecker et al 2009). Consequently, it is important to understand how IL-6 
contributes to the control of the inflammatory process, and affects disease progression. A 
number of roles currently exist for IL-6 in controlling leukocyte recruitment and 
activation. For instance IL-6 is centrally required to direct the transition from innate to 
acquired immunity (Jones 2005). IL-6 does this by balancing both the suppression of 
neutrophil recruitment and concomitantly promoting the infiltration of mononuclear cells 
during acute inflammation. These IL-6 directed outcomes are mediated through a control 
of inflammatory chemokine production and apoptosis (Hurst et al 2001, McLoughlin et 
al 2003, 2004, 2005, Teague et al 1997, Atreya 2000). Although IL-6 has been well 
established as a key regulator of chemokine expression, neutrophil trafficking, apoptosis 
and T cell survival, the role it plays as a regulator of monocytic cells is less well defined.
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During acute peritoneal inflammation, leukocyte recruitment is characterised by an initial 
infiltration of neutrophils, which are later replaced by a more sustained population of 
mononuclear cells (Topley et al 1996). Based on data obtained from cytospins of 
peritoneal leukocytes differentially stained for neutrophils, lymphocytes and monocytes, 
IL-6 does not appear to play a role in the inflammatory trafficking of monocytic cells 
(McLoughlin et al 2005). This method is however limited and does not allow a more 
phenotypic evaluation of specific monocytic subsets. It is well established that a number 
of monocytic cell subsets exist, distinguished by their unique phenotypic cell surface 
markers, that potentially perform very different functions in an inflammatory context. In 
the peritoneal cavity of naive mice, two populations of resident monocytic cells have 
been characterised, and are defined as a resident macrophage population 
(F4/80hl/CDl lchl) which comprises around 50% of the total resting leukocyte population, 
and a resident dendritic cell population (F4/80lnt/CD llbh7CDllc+) which constitutes 
approximately 5% of the total resting leukocyte population (Dioszeghy et al 2008). 
These populations were extensively characterised in Chapters 3 and 4 of this thesis. 
Resident tissue macrophages and DC are regarded as sentinels of the innate immune 
system, and the front line of host defence (Dunn et al 1985). Recent work has shown that 
specific ablation of the resident peritoneal macrophages, followed by induction of 
peritoneal inflammation, results in an impaired neutrophil infiltration as a consequence of 
reduced neutrophil activating CXC chemokine expression (Specifically KC (CXCL1) and 
MIP-2 (CXCL2)). This indicates that the resident macrophages are essential for the 
initiation and orchestration of acute peritoneal inflammation (Cailhier et al 2005).
Upon induction of the inflammatory response, an infiltrating population of 
F4/80+/CDl lbhl monocytes are recruited to the peritoneal cavity (Dioszeghy et al 2008). 
Within the circulating blood, two subpopulations of monocytes exist. The 
“inflammatory” subset migrates to inflamed tissue where it can trigger immune 
responses, while the “resident” subset, with a longer life, migrates to non-inflamed 
tissues to replenish the resident populations (Geissman et al 2003). Upon infiltration to 
the site of infection, the ‘inflammatory’ monocytes are thought to differentiate into 
macrophages or DC to help combat the infection (Randolph et al 1998, Gordon and
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Taylor 2005). The resident blood monocyte population have recently been assigned 
another function in that they also ‘patrol’ healthy tissues by crawling on the resting 
endothelium lining the blood vessels and can rapidly invade tissues upon infection. Once 
in the tissue, they help to trigger the immune response in combination with the resident 
macrophages and DC (Auffrey et al 2007).
In summary, the resident peritoneal macrophage and DC populations have been 
implicated in the initiation and orchestration of the acute inflammatory response (Cailhier 
et al 2005), while the recruited inflammatory monocytes are thought to be important for 
replenishing the macrophage and DC populations and maintenance of the immune 
response (Gordon and Taylor 2005, Geissman et al 2003, Randolph et al 1998). There is 
also evidence dictating that all these monocytic subsets described have antigen presenting 
abilities and are important in driving the adaptive immune response (Dioszeghy et al 
2008, Randolph et al 2008).
Since little is known about the potential role of IL-6 in regulating the monocytic cell 
subsets described here, the studies outlined in this Chapter aimed to investigate the 
potential role of IL-6 in governing the inflammatory trafficking of monocytic cell subsets 
using an in vivo model of peritoneal inflammation.
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5.2 Materials and methods
5.2.1 Induction of peritoneal inflammation with Staphylococcus epidermidis (SES) 
Lyophilised SES was prepared as described in Section 2.3.3 and reconstituted in 750pl 
sterile PBS. Inflammation was induced in groups of WT and IL-6'7' mice (n=5 per group, 
mixture of males and females) by i.p administration of SES (Section 2.3.5). At defined 
intervals during the inflammatory response (0, 1, 3, 6, 12, 15, 18, 24, 48 and 72 hours) 
mice were sacrificed and the leukocyte infiltrate collected by peritoneal lavage.
5.2.2 Cytospin analysis of the leukocyte infiltrate
Cytospin samples of peritoneal leukocytes were prepared and stained with Wright 
Giemsa stain and the composition of the inflammatory infiltrate was determined by 
differential cell counting (Section 2.3.2). The identification of each leukocyte subset was 
based on their morphology as visualised by light microscopy (Picture 5.1).
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Picture 5.1: Murine blood leukocytes visualised by light microscopy following Giemsa staining. 
Neutrophils are large and have multi-lobed nuclei. Monocytes are very large, and possess a 
kidney shaped nucleus. Lymphocytes are small, with very little cytoplasm and a large nucleus, 
which stains darker than that o f the monocyte and neutrophil.
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5.2.3 Flow cytometry
Peritoneal leukocytes were labelled with antibodies against the macrophage and dendritic 
cell markers F4/80, CD1 lb, and CD1 lc and analysed on a FACS calibur (Section 2.4.3). 
Details of the antibodies used are found in Table 2.1. Macrophages were defined as 
F4/80hlCDl lbhl, dendritic cells as F4/80,nt/CDl lbhl and infiltrating monocytes as 
F4/80intCDl lbmt. Cell numbers were quantified by taking the flow cytometry population 
gated percentages and multiplying by the total cell number.
5.2.4 ELISA quantification of cytokine and chemokine levels
Peritoneal lavage fluids were rendered cell free by centrifugation and stored at
-70°C. Supernatants were analysed by ELISA for IL-6, CCL2, CCL3, CCL5 and CCL7
and CXCL1 (KC) as described in Section 2.5.
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5.3 Results
5.3.1 Comparison of leukocyte trafficking in WT and IL-6'7" mice following SES 
induced inflammation
To define the profile of leukocyte recruitment arising following SES challenge, 
differential cell counts were performed on cytospin preparations obtained at defined 
intervals following SES administration. Mice exhibited an initial transient infiltration of 
neutrophils which begun as early as one hour after SES challenge and peaked 12 hours 
post SES administration. This population was then cleared, and replaced with a more 
sustained population of monocytic cells and lymphocytes (Figure 5.1). As previously 
observed (Hurst et al 2001, McLoughlin et al 2004), IL-6'7' mice showed an enhanced 
peritoneal infiltration of neutrophils (approximately 2-fold higher than WT mice at 6 and 
12 hours), which were retained for longer within the peritoneal cavity (Figure 5.1 A). 
Comparative analysis in WT and IL-6'7' mice did however emphasise that lymphocyte 
trafficking was unaffected by the absence of IL-6. Lymphocyte trafficking was 
characterised by an initial decrease in number during the first 3 hours after SES 
challenge, followed by a re-emergence of this population which was retained over the 
remainder of the time course (Figure 5.IB). Similarly, monocyte trafficking was also 
unaffected by the absence of IL-6. Monocyte trafficking was characterised by an initial 
decrease in number during the first 3 hours, followed by a substantial influx of these 
cells, which were retained throughout the remainder of the time course (Figure 5.1C).
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Figure 5.1: Neutrophil, monocyte and lymphocyte trafficking following the induction 
of SES induced inflammation. Peritoneal inflammation was induced by i.p 
administration of SES and peritoneal leukocytes were collected by lavage at defined 
intervals. (A) Differential cell counts were performed and the number of neutrophils 
calculated at each time point. (B) The number of lymphocytes calculated at each time 
point. (C) The number of monocytes calculated at each time point. (D) IL-6 levels 
were measured in lavage supernatants by ELISA as a control to confirm the absence of 
IL-6 in IL-6'7' mice. Values represent the mean ±  SEM, n=5-15 mice per time point, 
* * P < 0 . 0 1 .
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5.3.2 The role of IL-6 in directing the inflammatory trafficking of resident-like 
macrophages
To tease apart potential differences in the inflammatory trafficking of defined monocytic 
populations, flow cytometry was used to monitor SES induced changes in F4/80+CDl lb+ 
cell trafficking. Such analysis identified two distinctly defined populations characterised 
as resident-like F4/80hlCDl lbhl macrophages, and infiltrating F4/80mtCDl lbint 
monocytes, which emerge following inflammatory activation (Figure 3.1). The aim of 
this experiment was to determine whether the trafficking of these populations during 
acute inflammation was regulated by IL-6. Prior to SES activation, the resident 
monocytic population was predominantly F4/80hlCD llbhl. SES stimulation however 
triggered an early exodus of the F4/80hlCDl lbhl resident macrophage population from the 
peritoneal cavity, decreasing dramatically during the first three hours of inflammation 
(Figure 5.2). This coincided with a marked influx of F4/80mtC D llbint monocytic cells 
(See Section 5.3.3). However as inflammation progressed, flow cytometry affirmed the 
re-emergence of a resident-like F4/80hlCD llbhl macrophage population. This profile of 
cell emigration and recruitment was evident in both WT and IL-6"7' mice, with only minor 
differences observed between them. The emigration of the resident-like macrophage 
population from the peritoneal cavity did appear to be impaired in the IL-6"7" mice, 
demonstrated over the first 12 hours, and they also appeared to re-emerge at a faster rate 
in the IL-6'7" mice, demonstrated by the differences observed at 48 hours (Figure 5.2). 
However an analysis of the rate of clearance (WT: 3.1xl05 cells/hr, IL-6'7': 3x105 cells/hr) 
and rate of re-emergence (WT: 1.7xl04 cells/hr, IL-6'7': 1.7xl04 cells/hr) showed that WT 
and IL-6'7' exhibited equivalent resident macrophage trafficking profiles.
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Figure 5.2: IL-6 regulation o f resident-like macrophage trafficking following SES 
induced peritonitis. Peritoneal inflammation was induced by i.p administration of SES 
and peritoneal leukocytes were collected by lavage at defined intervals. (A) Peritoneal 
leukocytes were labelled with anti F4/80 and CD1 lb and the macrophages identified 
by their F4/80h,CDl lbhl phenotype. (B) The number of resident-like macrophages, defined 
by the indicated gates (Panel A) were calculated at each time point by taking the flow 
cytometry gated percentage and multiplying by the total cell number. Values represent the 
mean ±  SEM, n=5-15 mice per time point,* P < 0.05, ** P < 0.01.
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5.3.3 The role of IL-6 in directing the inflammatory trafficking of infiltrating 
monocytes
Infiltrating monocytes were phenotypically identified as F4/80int/C D llbint. To 
extrapolate the infiltration of these cells, their number was calculated at each time point 
(Figure 5.3). Infiltrating monocytes began to appear in the peritoneal cavity at 3 hours, 
reaching a peak at 12 hours. This population was then retained in the peritoneal cavity, 
and were still present at 72 hours. No significant differences were observed in the 
trafficking of infiltrating monocytes in WT and IL-6'7' mice, apart from at 48 hours, when 
there was a slight elevation in the number of monocytes in WT mice.
5.3.4 IL-67' mice exhibit a temporal appearance of a C D llc+ monocytic like 
population during inflammation
To study the trafficking of resident F4/80int/CD llbh7CDllc+ dendritic cells, the number 
of these cells was extrapolated from FACS data at each time point following SES 
administration (Figure 5.4). SES stimulation in both WT and IL-6'7' mice triggered an 
early clearance of the resident DC population during the first 3 hours, which was 
followed by a subsequent re-emergence of this population that was retained for the 
duration of the time course tested. The re-emergence of this DC like population was 
greatly enhanced in IL-6'7' animals, peaking at 12 hours (Figure 5.4). This enhanced re- 
emergence of the DC population was temporal, with their numbers becoming equivalent 
to WT mice towards the end of the time course. The DC population present in WT and 
IL-6'7' mice after 12 hours of SES was further analysed based on forward and side scatter 
properties. This mode of analysis gave information on the size and granularity of these 
cells (Figure 5.5). This identified two separate populations of DC-like cells present in 
IL-6'7* mice, which were distinguishable as being either relatively small, or larger and 
more granular. These were subsequently referred to as F4/80,oCDl lbhlCDl lc+ resident­
like or monocyte-like DC respectively. WT mice possessed the smaller resident-like 
population of DC, but lacked the larger monocyte-like DC population (Figure 5.5). The 
data outlined in Figure 5.5 therefore supported the notion that IL-6 suppresses 
development of a novel CD1 lc+ monocyte-like DC population.
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Figure 5.3: IL-6 regulation o f infiltrating monocytes following SES induced peritonitis. 
Peritoneal inflammation was induced by i.p administration of SES. Peritoneal leukocytes 
were collected by lavage at defined intervals. (A) Peritoneal leukocytes were labelled 
with anti F4/80 and CD1 lb and monocytes were subsequently identified by their 
phenotype F4/80mtCDl lbint. (B) The number of infiltrating monocytes within the 
defined gates (Panel A) were calculated at each time point by taking the flow cytometry 
gated percentage and multiplying by the total cell number. Values represent the mean ±  
SEM, n=5-15 mice per time point, * P < 0.05.
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Figure 5.4: IL-6 regulation o f DC trafficking. Peritoneal inflammation was 
induced by i.p administration of SES and peritoneal leukocytes were collected by 
lavage at defined intervals. (A) Peritoneal leukocytes were labelled with anti F4/80 and 
CD1 lb and cells that were positive for F4/80 and CD1 lb were labelled for CD1 lc.
Cells that resided in this F4/80intCDl lbh,CDl lc+ gate were defined as DC.
(B) The number of F4/80intCDl lbhiCDl lc+ DC within the defined gate (Panel A) 
was calculated at each time point by taking the flow cytometry gated percentage and multiplying 
by the total cell number. Values represent the mean ±  SEM, n=5-15 mice per time point, 
* * / >< 0.01.
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Figure 5.5: IL-6mi ce  possess a novel C Dl l c + monocytic population at 12 hours 
following induction o f inflammation. Peritoneal inflammation was induced by i.p 
administration of SES. Peritoneal leukocytes were collected by lavage after 12 hours and 
were labelled with anti F4/80, CD1 lb  and CD1 lc. (A) Cells that were high for CD1 lb, 
low and medium for F4/80 and positive for CD1 lc were gated and analyzed by their 
forward and side scatter properties. (B) Forward and side scatter analysis of 
F4/80,oCDl lbhlCDl lc+ peritoneal DC. (C) Back gating of the high forward and side 
scatter population revealing information on exact F4/80 and CD1 lb expression by these 
cells.
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To evaluate the trafficking properties of these two separate populations, the number of 
resident-like and monocyte-like DC were individually plotted for each time point 
(Figures 5.6 and 5.7). This showed that the trafficking of the resident-like DC population 
was equivalent in WT and IL-67' mice (Figure 5.6). In this respect, SES challenge led to 
an initial clearance of these cells over the first 3 hours, only to return later in the time 
course. The monocyte-like DC population however, exhibited a more temporal increase 
and showed a transient profile of detection (between 6-18 hours post SES challenge). 
This temporal appearance was more exaggerated in IL-67' mice, which possessed 
significantly more of these cells at 6 and 12 hours than WT mice (Figure 5.7).
5.3.5 The appearance of a C D llc+ monocytic population in IL-67' mice does not 
appear to be chemokine driven
To determine whether the appearance of the monocyte-like DC population seen in SES 
challenged IL-67' mice was attributable to alterations in chemokine expression, CXCL1 
(KC), CCL2, CCL3, CCL5 and CCL7 levels were measured in the peritoneal lavage 
supernatants at each time point by ELISA.
CXCL1 (KC) is a known neutrophil chemo-attractant. When measured, this chemokine 
could be temporally detected at the 1 hour time point, and was quickly cleared by 3 
hours. The production of this chemokine was significantly enhanced in IL-67' mice as 
compared to the WT mice, with significantly more CXCL1 being produced in these mice 
at 1 hour (Figure 5.8).
Known monocyte chemo-attractants CCL2, CCL3, CCL5 and CCL7 all exhibited a 
temporal production in WT and IL-67' mice, with CCL2 and CCL5 peaking at 3 hours 
and CCL3 peaking at 6 hours. CCL7 peaked at 3 hours in WT mice, whilst IL-67' mice 
exhibited a delayed kinetic, with CCL7 peaking at 6 hours in these mice. This was 
followed by a complete clearance of the chemokine by 72 hours. The production of 
CCL2, CCL3 and CCL5 were all significantly impaired in IL-67' mice (Figure 5.9).
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Figure 5.6: Trafficking o f resident-like DC following SES induced peritonitis. 
Peritoneal inflammation was induced by i.p administration of SES. Peritoneal 
leukocytes collected by lavage at defined intervals. (A) Peritoneal leukocytes were 
labelled with anti F4/80 and CD1 lb and CD1 lc. Cells that were high for CD1 lb, low 
and medium for F4/80 and positive for CD1 lc were gated and analyzed by their 
forward and side scatter properties to identify the resident-like DC that display a 
F4/80loCDl lbhlCDl lc+phenotype and reside in the low FSC/SSC gate. (B) The 
number of resident-like DC was calculated at each time point by taking the flow 
cytometry gated percentage and applying that to the total cell number. Values 
represent the mean ±  SEM, n=5-15 m i^.
CDllc FSC
B
“o
O
D
CD
CD
Ooco
***
5
WT
IL-6-/-
0
r
0
i i
10 20 30 40 50 60 70 80
Time (hours)
Figure 5.7: Trafficking o f monocyte-like DC following SES induced peritonitis. 
Peritoneal inflammation was induced by i.p administration of SES. Peritoneal 
leukocytes were collected by lavage at defined intervals. (A) Peritoneal leukocytes were 
labelled with anti F4/80 and CD1 lb and CD1 lc. Cells that were high for CD1 lb, low 
and medium for F4/80 and positive for CD1 lc were gated and analysed by their forward 
and side scatter properties to identify the monocyte-like DC that display a 
F4/80'°CD1 lbh,CDl lc+ phenotype and reside in the high FSC/SSC gate. (B) The 
number of monocyte-like DC was calculated at each time point by taking the flow 
cytometry gated percentage and applying that to the total cell number. Values represent 
the mean ±  SEM, n=5-15 mice per time point, ** p  < 0.0 !,***/>< 0.001.
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Figure 5.9: Mononuclear chemo-attractant production in the peritoneal 
cavity following SES induced inflammation. Peritoneal inflammation was induced by 
i.p administration of SES. (A) CCL2 (B) CCL3, (C) CCL5, (D) and CCL7 levels were 
quantified by ELISA in cell-free lavage supernatants. Values represent the mean ±  
SEM, n=5-15 mice per time point, * P <  0.05, ** P < 0.01.
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5.4 Discussion
As has previously been reported by the group, data presented in this Chapter highlights a 
role for IL-6 in the regulation of neutrophil trafficking (Hurst et al 2001). This 
conclusion is based on differential cell count data, which showed an enhanced influx of 
neutrophils in IL-6"7’ mice. IL-6 is essential for directing the transition from innate to 
acquired immunity by directing the successful resolution of neutrophil infiltration during 
inflammation, and the subsequent recruitment of mononuclear cells, which is critical for 
the successful resolution of acute inflammation (Jones, S.A. 2005). Upon entry to the 
peritoneal cavity, neutrophils shed their surface IL-6 receptor (McLoughlin et al 2004). 
The release of IL-6R from neutrophils facilitates IL-6 trans-signalling in the 
mesothelium, which differentially regulates inflammatory chemokine expression (notably 
the down-regulation of CXCL1 and up-regulation of CCL2 and CCL5 by mesothelial 
cells), and modulates leukocyte apoptosis (in particular IL-6 directs caspase-3-mediated 
neutrophil apoptosis), thereby driving a switch from a predominantly neutrophil rich 
environment to a more sustained mononuclear cell recruitment (Hurst et al 2001, 
McLoughlin et al 2003 McLoughlin et al 2004, McLoughlin et al 2005). In the absence 
of IL-6, CXCL1 production by the mesothelial cells is prolonged and the onset of 
neutrophil apoptosis is delayed resulting in increased recmitment and retention of these 
cells (Hurst et al 2001, McLoughlin et al 2003 and 2004).
It is also documented, but not seen in this study, that IL-6'7' mice exhibit impaired 
lymphocyte infiltration during inflammation, specifically T lymphocytes (McLoughlin et 
al 2005, Jones et al 2009, J.Immunol, under revision). This is attributed to IL-6 which 
selectively governs T cell infiltration by regulating chemokine secretion (CXCL10, 
CCL4, CCL5, CCL11, and CCL17) and chemokine receptor (CCR3, CCR4, CCR5, and 
CXCR3) expression on the CD3+ infiltrate (McLoughlin et al 2005). Additionally, the 
IL-6/sIL-6R complex has been shown to be an inhibitor of apoptosis in T cells by 
inhibiting the down-regulation of anti-apoptotic regulator Bcl-2 (Teague et al 1997).
IL-6‘7‘ mice lacking this cytokine are therefore likely to be more prone to T cell apoptosis. 
Regulation of these activities may be critical for resolving bacterial infections since
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IL-6'a mice show an impaired ability to control infections (Kopf et al 1994, Dalrymple et 
al 1995, Coles et al unpublished). This regulation of T lymphocyte trafficking by IL-6 
was not supported by the data presented in this Chapter, however the differential cell 
counting method utilised did not allow a discrimination between T and B lymphocytes, 
therefore the data represents the trafficking profile of the total lymphocyte population. 
Multi-parameter flow cytometry, which was used by both McLoughlin et al and Jones et 
al, allows the trafficking of B and T lymphocyte trafficking to be analysed individually 
providing an explanation as to why differences were not seen in these studies described 
here. In this respect, a flow cytometric analysis of CD4+ T lymphocytes during SES 
induced peritonitis is outlined in Chapter 8.
The data presented in this Chapter showed that IL-6 does not regulate the inflammatory 
trafficking of resident-like macrophages. Although an impaired clearance of these 
macrophages was observed in IL-6'7' mice during the initial stages, naive mice (Oh time 
point) began with a larger number of resident macrophages, and these cells were cleared 
and re-emerged at an equivalent rate to that of WT mice. It is currently unknown what 
causes the initial exodus of this population, but a number of explanations are possible. 
Firstly cells could adhere to the peritoneal membrane as a result of activation, meaning 
that they would not be recovered in the peritoneal lavage. A review of adhesion 
molecules present on the surface of these cells would shed light on this. Secondly, these 
cells may undergo apoptosis, whilst their homing to the lymphatic system or omental 
milky spots may represent an alternative explanation (Rangal-Moreno et al 2009). 
Further work would be needed to confirm this. The reappearance of this population is 
likely a result of replenishment from the infiltrating monocytes, and there is currently no 
evidence to show that the original population might be returning to the peritoneal cavity 
upon resolution of the inflammatory episode. To address this, experiments were 
performed utilising a fluorescent marker to label resident leukocytes prior to induction of 
inflammation in an attempt to distinguish between resident macrophages and newly 
recruited cells. Whilst the resident like macrophage population remained labelled 
throughout the time course following the induction of inflammation, this could not be 
attributed to their retention in the peritoneal cavity since newly recruited cells may
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become labelled by the phagocytic uptake of labelled apoptotic resident cells. Therefore 
alternative experiments would be required to try to conclusively answer this question.
The initial egress of the resident macrophage population, which was observed following 
the induction of inflammation, coincided with a recruitment of infiltrating monocytes 
from the circulation. These cells are known to enter the peritoneal cavity during 
inflammation where they differentiate into either macrophages or DC to replenish the 
resident populations and also contribute to the immune response against the pathogen 
(Geissman et al 2003, Randolph et al 1998, Aufffey et al 2007). In this respect they form 
an important support to the resident DC and macrophages, which initiate the immune 
response, but are unable to clear the infection alone (Ajuebor et al 1999, Cailhier et al 
2005). Although IL-6 did not drive the trafficking of these infiltrating monocytes, shown 
by the data in this Chapter, the absence of IL-6 enabled the appearance of a monocyte­
like CD llc+ DC population of cells. This population was characterised by an 
F4/80loCDl lbhlCDl lc+ phenotype and are large and granular cells. This DC population, 
which is not observed in WT mice, may conceivably represent a novel inflammatory DC 
subset. Inflammatory DC appear as a consequence of inflammation or microbial stimuli. 
An example of an inflammatory DC is the tumour-necrosis factor and inducible nitric- 
oxide sythase-producing DC, also termed Tip DC, which were first discovered in mice 
infected with Listeria monocytogenes (Serbina et al 2003, Wu and Lui 2007 and Wu and 
Dakie 2004). Another example of inflammatory DC are the monocyte-derived DC, 
which are derived from Grl+ monocytes, and are thought to be essential for antimicrobial 
immunity (Lopez-Bravo and Ardavin 2008). It is possible that the CD llc+ monocyte­
like DC observed in these current studies may have differentiated from infiltrating 
monocytes. It is documented that IL-6 switches the phenotype of monocytes from DC to 
macrophages by facilitating the M-CSF (Macrophage colony stimulating factor) 
regulation of macrophage differentiation (Chomarat et al 2000). Although a base line 
appraisal of resident peritoneal DC numbers supports the notion that IL-6 favours DC 
formation, (Chapter 3), it is possible that the reverse is true under inflammatory 
conditions where the absence of IL-6 may enable an increased differentiation into 
dendritic cells. The functional significance of this population is of interest given that
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IL-6'7' mice exhibit protection to various autoimmune diseases and this novel population 
of cells could contribute to that protection. It has been published that IL-6'7' mice have 
increased numbers of mature DC in the spleen and lymph nodes indicating that IL-6 
blocks DC maturation in vivo (Park et al 2004). In this respect, it could be speculated 
that the emerging population of CD llc+ monocyte-like DC seen in IL-6'7' mice, may 
undergo increased maturation and a subsequent trafficking to secondary lymph nodes 
where they can mediate antigen presentation. Alternatively, it has also been published 
that IL-6*7' mice have increased numbers of bone marrow derived DC with reduced 
function (Bleier et al 2004). An attenuated function by the C D llc+ monocyte-like DC 
may be important for the protective phenotype exhibited by this strain as this may act to 
dampen down the immune response and thereby prevent the development of chronic 
inflammatory conditions. This concept will be discussed in Chapter 6.
The appearance of the CDllc+ monocyte-like DC population in IL-6*7' mice does not 
appear to be chemokine driven, given that the monocytic chemokines measured were 
either equivalent or significantly lower in IL-6'7* mice compared to WT. While it is 
possible that an alternative chemokine is responsible for the trafficking of these cells, it 
may also be possible that the trafficking of these cells is chemokine independent and 
regulated in another way. This has been seen previously in work by Dioszeghy et al who 
also showed an increased inflammatory trafficking of monocyte/macrophages in mice 
that coincided with a significantly impaired monocyte chemokine production in these 
mice (Dioszeghy et al 2008). The studies described in this Chapter did however show 
significantly elevated levels of the neutrophil activating chemokine KC in IL-6'7' mice. 
Interestingly, work by Huo et al has shown that KC is able to trigger monocyte arrest on 
the early atherosclerotic endothelium thereby promoting their recruitment in vivo (Huo et 
al 2001). This is an important finding and could provide an explanation as to the 
emergence of the monocyte like DC subset in IL-6'7' mice described here.
This novel monocyte-like DC population is studied in a repeat inflammatory model in 
Chapter 6, and its regulation is studied in more detail in Chapter 7.
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CHAPTER 6
The role of IL-6 in the trafficking of monocytic cells in an in vivo repeat model of
inflammation
164
6.1 Introduction
During an acute infectious episode, leukocyte infiltration is tightly regulated to ensure 
both clearance of the invading microbe and successful resolution of the inflammatory 
response to prevent damage to the host tissue. IL-6 is essential for defining leukocyte 
recruitment and clearance during acute peritoneal inflammation (Hurst et al 2001, Jones 
2005, Fielding et al 2008) via its control of signalling events that occur through the 
transcription factors STAT1 and STAT3, which appear to be critical for inflammatory 
resolution (McLoughlin et al 2005, Fielding et al 2008). In this respect, IL-6 deficient 
mice have an impaired ability to clear bacterial infections, suggesting a central role for 
IL-6 in cellular immunity against infection (Kopf et al 1994, Coles et al unpublished). 
These protective properties of IL-6 however are balanced against the detrimental effects 
of IL-6 biology seen in chronic inflammatory disease (Jones 2005). Chronic 
inflammation arises through an inappropriate control of the inflammatory response and is 
exacerbated by the prolonged retention of activated leukocytes within the affected tissue 
(Jones 2005). IL-6 plays a significant role in the emergence of a chronic inflammatory 
state, given its heightened levels in a number of chronic inflammatory diseases, and a 
capacity to direct mononuclear cell trafficking and prevent normal apoptotic processes in 
effector T cells, including Thl7 and Thl cells (Jones 2005, McLoughlin et al 2005, 
Atreya et al 2000, Yamamoto et al 2000, Kikly et al 2006). In this respect, IL-6'7' mice 
exhibit a marked protection from chronic inflammation, and are resistant to experimental 
models of rheumatoid arthritis, systemic lupus erythematous, psoriasis and Crohn’s 
disease (Grossman et al 1989, Swaak et al 1989, Houssiau et al 1988, Naugler and Karin 
2008).
Persistent or recurrent episodes of bacterial peritonitis are a common complication in 
renal failure patients receiving dialysis treatment, and dramatically affect the integrity of 
the peritoneal membrane, giving rise to fibrotic thickening and scarring of the membrane 
(Davies et al 1996, Williams et al 2002). Fibrosis is characterised by alterations in 
extracellular matrix deposition as a consequence of tissue damage or persistent 
inflammatory processes (Wynn et al 2007). This compromises the dialysing capacity of
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the membrane and ultimately these inflammation-induced changes to the tissue 
architecture lead to treatment failure (Davies et al 1996, Williams et al 2002).
The induction of tissue damage is a key marker of chronic disease pathology. The 
underlining tissue damage that can lead to fibrosis is associated with the damage or 
apoptosis of cells within the inflamed tissue such as resident stromal and parenchymal 
cells (Shimizu et al 1995). Inflammatory macrophages have been well documented to 
play a major role in the induction of tissue damage, and this is indicated by a strong 
correlation between macrophage influx and apoptosis of resident tissues (Tesch et al 
1999). Macrophages induce tissue damage via a number of mechanisms, which include 
their ability to release a variety of cytokines and free radicals such as nitric oxide, and 
oxygen radicals such as hydrogen peroxide, all of which have been shown to induce 
apoptosis and oxidative damage within target tissues (Duffield et al 2000, Duffield et al 
2001, Kipari et al 2002, Duffield et al 2001). Macrophages also release TGF-p (Khalil et 
al 1996, Bissell et al 1995, Letterio and Roberts 1998), which is known to drive epithelial 
to mesenchymal transition (EMT), transforming mesothelial cells to fibroblasts, which, 
when uncontrolled, can lead to overproduction of extracellular matrix and tissue fibrosis 
(Selgas et al 2006). Recent work has shown that dendritic cells also express high levels 
of inducible nitric oxide synthase (Serbina et al 2003), and can induce cell death (Stary et 
al 2007). It therefore follows that dendritic cells may also contribute to tissue injury 
during chronic disease.
Given that both macrophages and dendritic cells have the potential to induce tissue 
damage, the aim of this Chapter was to determine whether recurrent or persistent 
inflammation caused changes in the recruitment of the defined peritoneal mononuclear 
subsets that have been characterised in Chapters 3-5, and if IL-6 modulated any of these 
outcomes.
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6.2 Materials and methods
6.2.1 Recurrent induction of SES induced peritoneal inflammation
SES induced peritoneal inflammation was established in groups of WT and IL-6'7' mice 
(n=5 per group, mixture of males and females) as previously described in Section 2.3.5. 
However to mimic the incidence of recurrent peritonitis in humans, mice were 
sequentially activated with a maximum of four rounds of SES induced inflammation, 
which were triggered at seven day intervals. At defined intervals (0, 1, 3, 6, 12, 15, 18, 
24, 48 and 72 hours) during the first and fourth episode, groups of mice were sacrificed 
and the peritoneal lavage sample collected. A further group of mice, that had received 
four sequential injections of SES as described above, were maintained until day 49 to 
allow complete resolution of the inflammatory response, and their peritoneal membranes 
were collected for histological analysis. These were compared to age matched controls, 
which had received no SES (see Diagram 6.1 for an overview).
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Diag. 6.1: Schematic depicting the recurrent model of peritoneal inflammation.
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6.2.2 Cytospin analysis of leukocyte infiltrate
Cytospins of peritoneal leukocytes from lavage samples were stained with Wright 
Giemsa stain and the composition of the inflammatory infiltrate examined by differential 
cell counting (Section 2.3.2).
6.2.3 Flow cytometric analysis of leukocyte infiltrate
Multi-parameter flow cytometry (Section 2.4.3) using defined surface markers (F4/80, 
CD1 lb and CD1 lc) was used to assess changes in F4/80hlCDl lbhl resident macrophages, 
F4/80intC D llb int monocytes and F4/80intC D llbhiC D llc+ DC. Cell numbers were 
quantified by taking the FACS gated population percentages and multiplying by the total 
cell number.
6.2.4 ELISA quantification of cytokine and chemokine levels in lavage supernatants
Peritoneal lavage supernatants were analysed by ELISA for CCL2, CCL5 and CCL7 as 
described in Section 2.5.
6.2.5 Histological analysis of peritoneal membranes
Histological evaluation of peritoneal membranes was performed on fixed and paraffin 
embedded sections (Section 2.3.5). Tissue sections (5-6pm) were cut and stained with 
haematoxylin and eosin. The thickness of the mesothelium was measured by light 
microscopy and QWin software. Measurements were taken in pm and an average was 
taken from a number of measurements across the membrane.
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6.3 Results
6.3.1 Peritoneal membrane thickening as a result of repeated inflammatory episodes
Repeated peritoneal inflammatory episodes is associated with increased tissue damage 
and peritoneal fibrosis (Davies et al 1996, Williams et al 2002, Fielding et al 2009, 
submitted). To mimic these processes, WT and IL-6'7' mice were challenged with four 
consecutive rounds of SES induced inflammation. At day 49, the peritoneal membrane 
was collected and histologically analysed (Figure 6.1). Evaluation of the membrane 
structure revealed two distinct cellular regions consisting of an underlining area of 
muscle and a thin mesothelial layer. Analysis of the membrane revealed that WT mice 
exhibited increased thickening of the mesothelium following four episodes of SES 
induced peritoneal inflammation. IL-6'7' mice however exhibited no histological changes 
in the mesothelium integrity and remained comparable with non-treated WT controls.
6.3.2 Recurrent peritoneal inflammation results in increased retention of leukocytes
A chronic inflammatory state is often associated with a retention of activated 
mononuclear cells, which are known to affect fibrosis and the underlining tissue damage 
(Jones 2005, Duffield et al 2000, Duffield et al 2001, Kipari et al 2002, Duffield et al 
2001, Stary et al 2007, Gordon 2003, Deodhar et al 1997). Therefore the retention of 
leukocytes was analysed in a recurrent inflammatory model to determine whether 
repeated inflammation controlled leukocyte recruitment and how IL-6 may affect the 
retention of leukocytes in the peritoneal cavity once the inflammatory episodes have 
resolved. To analyse the peritoneal leukocyte composition during a recurrent 
inflammatory model, WT and IL-6'7' mice were administered with SES and the 
inflammatory infiltrate profiled prior to the induction of the first and fourth round of 
peritoneal inflammation. As seen in Figure 6.2, these baseline measurements showed 
that prior inflammatory episodes gave rise to a retention of inflammatory leukocytes in 
WT and IL-6'7' mice (Figure 6.2 A). Specifically, increased numbers of monocytes, 
lymphocytes and neutrophils were found in the peritoneal cavity prior to the fourth 
episode of inflammation (Figure 6.2 B). Wild type mice exhibited a greater retention of 
monocytes and lymphocytes prior to the fourth inflammatory episode, compared to 
IL-6 '7'mice (Figure 6.2B).
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Figure 6.1: WT but not IL-6"A mice exhibit peritoneal membrane thickening 
following repeated inflammatory episodes. Peritoneal inflammation was 
induced by i.p administration of SES. WT and IL-6'7' mice received four 
consecutive rounds of inflammation, at 7 day intervals, and were then 
maintained to day 49 to allow complete resolution. Peritoneal membranes 
were then recovered, sectioned and stained for histological analysis. 
Membrane thickness was observed and measured at multiple points along a 
5pm membrane section by light microscopy in (A) WT and (B) IL-6'7* mice. 
Representative pictures of membranes are shown. n=5.
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were performed to determine monocyte, lymphocyte and neutrophil numbers. 
Values represent the mean ±  SEM, n=4-5 mice per time point, * P <  0.05, 
**P<0 .01 .
171
f6.3.3 Recurrent inflammation results in increased leukocyte infiltration in WT mice
To determine whether IL-6 regulates the inflammatory trafficking of leukocytes in this 
recurrent inflammatory model, trafficking of neutrophils and mononuclear cells were 
monitored by differential cell counting in WT and IL-6"7" mice during the first and fourth 
inflammatory episodes (Figure 6.3).
During the fourth episode of inflammation WT mice exhibited a significantly increased 
recruitment of neutrophils compared to that observed during the first episode (Figure 6.3 
A). This was coupled with an enhanced retention or delayed clearance of neutrophils in 
these mice compared to the first episode. As shown in Figure 6.3 B, WT mice also 
exhibited a significant increase in the recruitment of monocytic cells into the peritoneal 
cavity during the fourth inflammatory episode as compared to the first. This was 
particularly evident at 48 hours, at which point there was a 2 fold increase in the number 
of monocytes present compared to the first inflammatory episode. Similarly, WT mice 
also exhibited a significant increase (2.5 fold) in lymphocyte trafficking at 48 hours upon 
repeated SES challenge (Figure 6.3 C).
The leukocyte trafficking observed in IL-6’7" mice following repeated SES challenge 
showed few changes from that observed in a single inflammatory episode. Neutrophil 
trafficking in IL-6"7" mice remained unchanged from the first episode (Figure 6.3 A). 
This resulted in the neutrophil trafficking profiles for WT and IL-6"7" mice being 
equivalent during the fourth episode, contrasting that seen during the first episode. 
Similarly, IL-6"7' mice did not display an enhanced trafficking of monocytic cells, and 
their migratory patterns remained equivalent to that seen during a single inflammatory 
episode (Figure 6.3 B). Finally IL-6"7" mice exhibited only a small increase (1.5 fold) in 
lymphocyte trafficking at 48 hours during the fourth inflammatory episode (Figure 6.3 
C).
172
Episode 1
A
Episode 4
Neutrophils
5- * *
WT
IL-6
i i
0 10
r i
30 40
"T
5020 60 70 80
to
CD
.Co.
2
3
©z
r T TT T T T
Time (hrs)
10 20 30 40 50 60 70 80
Time (hrs)
B
Monocytic cells 12.5i
o  10.0- o  10.0- 
x
7  7.5-T  7.5-
O 2.5-
r
0
nr~ r
20 30
t   r-
60 70
T -T-
6040 50 80
■ T
20 30
T T
0
Time (hrs) Time (hrs)
Lymphocytes
to©
X
C0
©
>»aoJZa
Eir
T Tr T ▼ T T
10 20 30 40 50 60 70 80
Time (hrs)
o 5-
_i
 r   i ■ i i i
40 50 60 70 80
T -
20
T-
30
r T
Time (hrs)
Figure 63: Repeated episodes o f peritoneal inflammation resulted in increased infiltration of 
all leukocyte types in WT mice. Peritoneal inflammation was established by i.p injections of 
SES. Mice received either one or four injections (7 days apart). Peritoneal leukocytes were 
recovered by lavage and cytospins prepared for differential cell counts. (A) Neutrophil 
numbers determined by differential cell counting. (B) Monocyte numbers determined by 
differential cell counting. (C) Lymphocytes numbers determined by differential cell counting. 
Values represent the mean ±  SEM, n=5-15 mice per time point, * P < 0.05, ** P < 0.01,
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6.3.4 The effect of repeated inflammatory episodes on chemokine production
To determine if increased levels of inflammatory chemokines resulted in the increased 
and retained inflammatory infiltrate observed in WT mice, ELISAs were performed to 
measure chemokine levels in the lavage fluids (Figure 6.4).
As seen in Chapter 5, CCL2 levels were significantly impaired in IL-6’7' mice during the 
first episode of SES induced inflammation. This was not observed during the fourth 
episode, with WT and IL-6'7' mice exhibiting equivalent levels of CCL2 in the peritoneal 
cavity (Figure 6.4 A). CCL5 and CCL7 production in WT and IL-6'7' mice during the 
fourth inflammatory episode remained equivalent to that seen during the first episode 
(Figure 6.4 B&C).
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Figure 6.4: Mononuclear chemo-attractant production in the peritoneal cavity lavage fluids 
in WT and IL-6'/_ mice during the first and fourth inflammatory episodes.
Peritoneal inflammation was established by i.p injections of SES. Mice received either one 
or four injections (7 days apart). Peritoneal fluids were recovered by lavage and centrifuged 
to remove leukocytes. Chemokines were then measured by ELISA (A) CCL2 production in 
WT and IL-6'7' mice during episodes 1 and 4. (B) CCL5 production in WT and IL-6'7' mice 
during episodes 1 and 4. (C) CCL7 production in WT and IL-6'7' mice episodes 1 and 4. 
Values represent the mean ±  SEM, n=5-15 mice per time point.
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6.3.5 Regulation of resident like macrophage trafficking during a recurrent 
inflammatory model
As previously discussed, macrophages have the potential to contribute to tissue injury 
during chronic inflammation (Duffield et al 2000, Duffield et al 2001, Kipari et al 2002, 
Duffield et al 2001), as well as their potential to drive EMT by their production of TGFp 
(Khalil et al 1996, Bissell et al 1995, Letterio and Roberts 1998, Selgas et al 2006). 
Since WT mice exhibit membrane fibrosis upon repeated episodes of inflammation, while 
the IL-6'7’ mice remain protected, resident macrophage trafficking was analysed in these 
mice to assess whether IL-6 plays a role in the trafficking/retention of this subset during a 
recurrent inflammatory model. To do this, the leukocyte infiltrate was further analysed at 
each time point by multi-parameter flow cytometry to identify changes in the trafficking 
of specific monocytic cell subsets as a consequence of repeated inflammatory episodes. 
The trafficking of resident like macrophages, identified as F4/80hl C D llbhl, was 
monitored and the number of these cells present in the peritoneal cavity of WT and IL-6"7' 
mice during the first and fourth inflammatory episodes was plotted at each time point 
(Figure 6.5 A&B). Resident-like macrophages were retained in the peritoneal cavity of 
WT mice prior to induction of the fourth inflammatory episode, exhibited by a 2.3 fold 
increase in the number of peritoneal resident-macrophages in the base line (0 hr) group. 
During both the first and fourth inflammatory episodes, the resident like macrophages 
exhibited a defined trafficking pattern characterised by an initial clearance followed by a 
subsequent re-emergence of this population at the later time points within the 
inflammatory response. The rate of clearance (WT: 9x105 cells/hr, IL-6'7':1.4xl06 
cells/hr) and re-emergence (WT: 1.9xl04 cells/hr, IL-6’7’: 2.9x104 cells/hr ) of the 
macrophage population was significantly accelerated during the fourth inflammatory 
episode as compared to the first (clearance WT: 3.1xl05 cells/hr, IL-6’7’: 3xl05 cells/hr, 
re-emergence WT: 1.7xl04 cells/hr, IL-6'7’: 1.7xl04 cells/hr). Interestingly the emerging 
macrophage population re-established itself to numbers equivalent to those seen at the 
beginning of the inflammatory episode, following both single and repeated SES 
challenge. As seen during the first episode, there were no differences observed between 
WT and IL-6'7’ mice (Figure 6.5).
176
AWT
IL-6
CD
W om 0) O
O)CO
£ 2'
ft*
r TT T T T T 1
0 10 20 30 40 50 60 70 80
Time (hours)
B
CDo
X
tf>0)o>CO
oCO
2
r T T TT T T T
0 10 20 30 40 50 60 70 80
Time (hours)
Figure 6.5: IL-6 does not regulate resident like macrophage trafficking in a 
single inflammatory episode or a recurrent inflammatory state. Peritoneal 
inflammation was established by i.p injection of SES. Groups of mice 
received either one (A) or four (B) sequential inflammatory episodes. 
Peritoneal leukocytes were collected by lavage and labelled with F4/80 and 
CD1 lb. Resident macrophage were identified based on their phenotype 
F4/80hlCDl lb hl, and their number plotted at each time point by taking the 
flow cytometry gated percentage and multiplying by the total cell number. 
Values represent the mean ±  SEM, n=5-15 mice per time point, * P<  0.05, 
** PcO.Ol.
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6.3.6 Regulation of infiltrating monocyte cell trafficking during a recurrent 
inflammatory model
Peritoneal infiltration of F4/80mt CD1 lb int monocytes was monitored in WT and IL-6'7' by 
flow cytometry following a single and repeated SES activation (Figure 6.6 A&B). 
Monocyte recruitment into the peritoneal cavity began one hour after the induction of the 
fourth inflammatory episode, compared to 3 hours as was observed during the first 
episode. Monocytes continued to infiltrate the cavity, reaching a peak at 18 hours, 
followed by a subsequent clearance of this population. WT mice exhibited an enhanced 
magnitude of infiltration during the fourth inflammatory episode, which was particularly 
evident at 48 hours when the number of monocytes present was 2.8 fold higher than that 
observed during the first episode. Subsequently the clearance of these cells was faster 
(1.6xl05 cell/hr in the fourth episode compared to 3.3xl04 cells/hr in the first episode). 
This confirmed data obtained from differential cell counting for this group, which 
highlighted an enhanced monocyte infiltrate in WT mice.
The absence of IL-6 did not alter the recruitment or infiltration of monocytes, with IL-6'7' 
mice exhibiting an equivalent pattern and magnitude of infiltrating monocyte trafficking 
during the fourth episode to that seen in the first episode.
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Figure 6.6: IL-6 regulates infiltrating monocyte trafficking in a single inflammatory 
episode and a recurrent inflammatory state. Peritoneal inflammation was 
established by i.p injection of SES. Groups of mice received either one (A) or four 
(B) sequential inflammatory episodes. Peritoneal leukocytes were collected by 
lavage and labelled with anti F4/80 and anti CD1 lb. Infiltrating monocytes were 
identified based on their phenotype F4/80,ntCDl lbmtand their number plotted at 
each time point by taking the flow cytometry gated percentage and multiplying by 
the total cell number. Values represent the mean ±  SEM, n=5-15 mice per time 
point, * P < 0.05, ** P < 0.01.
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6.3.7.1 Regulation of dendritic-like cell trafficking during a recurrent inflammatory 
model
Reports have suggested that dendritic cells have the capacity to contribute to tissue 
damage based on their ability to express high levels of inducible nitric oxide synthase 
(Serbina et al 2003), and to induce cell death (Stary et al 2007). In this respect, the 
inflammatory trafficking of DC was monitored in a single and recurrent inflammatory 
model to determine if regulation by IL-6 contributed to the retention and recruitment of 
these cells, and subsequent tissue damage observed in this model. The trafficking of 
dendritic cells, defined as F4/80mtCDl lbhlCDl lc+, were monitored by flow cytometry 
and the number of these cells present in the peritoneal cavity of WT and IL-6'7' mice was 
plotted at each time point during the first and fourth inflammatory episodes (Figure 6.7 
A&B).
Dendritic-like cells were retained in the peritoneal cavity of WT mice prior to induction 
of the fourth inflammatory episode, exhibited by a 2.3 fold increase in the number of 
peritoneal resident DC in the base line (0 hr) group (Figure 6.7 B). Following the 
induction of the fourth inflammatory episode, the DC population exhibited a brief 
clearance, followed by a recruitment of cells, which were retained for the remainder of 
the time course. The magnitude of infiltrating DC in the fourth episode was significantly 
enhanced in WT mice, with 2.5 fold more DC-like cells being present in the peritoneal 
cavity at 48 hours.
As was observed during the first inflammatory episode (Figure 6.7 A), IL-6'7' mice 
exhibited an enhanced infiltration of DC-like cells compared to the WT mice during the 
fourth episode, and this was particularly evident at 6 and 12 hours. The number of DC- 
like cells present in the peritoneal cavity of IL-6'7* mice at these time points however, was 
equivalent to the number present at the same time points during the first inflammatory 
episode indicating that their infiltration was not enhanced as a result of repeated SES 
activation. In this respect, these IL-6'7' mice also did not exhibit the enhanced infiltration 
of DC at 48 hours that was observed in WT mice.
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Figure 6.7: IL-6 regulates DC trafficking in a single inflammatory episode and 
a recurrent inflammatory state. Peritoneal inflammation was established by i.p 
injection of SES. Groups of mice received either one (A) or four (B) sequential 
inflammatory episodes. Peritoneal leukocytes were collected by lavage and 
labelled with anti F4/80, CD1 lb  and CD1 lc. Total DC were identified based on 
their phenotype F4/80intCDl lbhlCDl lc+ and their number plotted at each time 
point by taking the flow cytometry gated percentage and multiplying by the 
total cell number. Values represent the mean ±  SEM, n=5-15 mice per time 
point,
* * P < 0 . 0 1 .
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6.3.7.2 Regulation of resident- and monocyte-like DC trafficking during a recurrent 
inflammatory model
Prior investigation outlined in Section 5.3.4 revealed that the inflammatory DC 
population was comprised of two phenotypically distinct F4/80,oC D llbhlCD llc+ subsets, 
being distinguishable based on low (resident-like) and high (monocyte-like) forward and 
side scatter properties. The number of these cells present in the peritoneal cavity of WT 
and IL-6’7' mice was therefore plotted at each time point following induction of a single 
and recurrent inflammatory episodes (Figure 6.8 and 6.9).
Resident-like DC were retained in the peritoneal cavity of mice prior to induction of the 
fourth inflammatory episode, exhibited by a 1.8 fold increase in the number of peritoneal 
resident-like DC in the base line (0 hr) group (Figure 6.8 B). During the fourth 
inflammatory episode, the trafficking of these cells followed a similar pattern to that 
exhibited during the first episode, characterised by an initial clearance followed by a 
recruitment of this population at the later time points. The infiltration of this subset in 
WT mice was significantly enhanced when compared to that observed during a single 
inflammatory episode, with a 2.5 fold increase in the number of these cells present at 48 
hours.
Monocyte-like DC were also retained in the peritoneal cavity of mice prior to induction 
of the fourth inflammatory episode, exhibited by a 4 fold increase in the number of 
peritoneal monocyte-like DC in the base line (0 hr) group (Figure 6.9 B). During the 
fourth inflammatory episode, the trafficking of these cells was equivalent to that observed 
during the first episode, characterised by a temporal increase in the number of these cells, 
followed by their clearance during the later time points. The infiltration of the monocyte­
like DC population peaked at 6 hours during the fourth episode, 6 hours earlier than that 
seen during the first episode. As was observed during the first episode, IL-6'7' mice 
exhibited an increased recruitment of monocyte-like DC compared to the WT mice. 
Interestingly however, the number of recruited monocyte-like DC during the fourth 
episode was no higher than the number recruited during one inflammatory episode 
indicating that their infiltration was not enhanced as a result of repeated SES activation.
182
in
o
Q
©JX
c
©■o
’55©
B
WT
IL-6-/-
2-
1“
0
0 10 20 30 40 50 60 70 80
Time (hours)
inO
X
o
Q
©
c©■o
©
©a:
T T T Tr T T T
10 20 30 40 50 60 70 80
Time (hours)
Figure 6.8: IL-6 does not regulate resident like DC trafficking in a single 
inflammatory episode but does during a recurrent inflammatory state. 
Peritoneal inflammation was established by i.p injection of SES. Groups of 
mice received either one (A) or four (B) sequential inflammatory episodes. 
Peritoneal leukocytes were collected by lavage and labelled with F4/80,
CD1 lb and CD1 lc. Resident like DC were identified based on their 
phenotype F4/80,oCDl lbhlCDl lc+ and their low forward and side scatter 
properties, and their number plotted at each time point by taking the flow 
cytometry gated percentage and multiplying by the total cell number. Values 
represent the mean ±  SEM, n=5-15 mice per time point, * P < 0.05.
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Figure 6.9: IL-6 regulates monocyte like DC trafficking in a single 
inflammatory episode and a recurrent inflammatory state. Peritoneal 
inflammation was established by i.p injection of SES. Groups of mice received 
either one (A) or four (B) sequential inflammatory episodes. Peritoneal 
leukocytes were collected by lavage and labelled with F4/80, CD1 lb  and 
CD1 lc. Monocyte like DC were identified based on their phenotype 
F4/80,oCDl lbhiCDl lc+ and their high forward and side scatter properties, and 
their number plotted at each time point by taking the flow cytometry gated 
percentage and multiplying by the total cell number. Values represent the 
mean ±  SEM, n=5-15 mice per time point, * P < 0.05 ** P < 0.01, *** P < 
0.001.
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6.4 Discussion
Studies described here were performed to determine whether repeated activation altered 
mononuclear cell trafficking and recruitment during peritoneal inflammation, and 
whether IL-6 modulated these outcomes. The rationale for doing this was taken from 
previous experiments that showed IL-6'7' mice to be protected against peritonitis 
associated membrane thickening or fibrosis (Fielding et al 2009, submitted). In these 
studies, IL-6’7' mice displayed resistance to membrane fibrosis upon recurrent 
inflammation, and exhibited no increase in inflammatory leukocyte trafficking 
characteristic of a chronic inflammatory state (Fielding et al 2009, submitted). This was 
consistent with findings by other groups showing that IL-6 deficient mice are resistant to 
the induction of other chronic inflammatory diseases including experimental encephalitis, 
Crohn’s disease, colitis, lupus nephritis and rheumatoid arthritis (Galle et al 2007, 
Atreya, R. et al 2000, Nowell, M.A. et al 2003, Mihara, M. et al 1998). It has been 
documented that monocytic cell subsets such as macrophages and dendritic cells are 
involved in facilitating inflammation induced tissue injury through their release of 
cytokines and the generation of free radicals such as nitric oxide, and reactive oxygen 
species (Duffield et al 2000, Duffield et al 2001, Kipari et al 2002, Duffield et al 2001). 
Macrophages are also involved in tissue repair and are able to promote fibrosis and the 
deposition of extracellular matrix (Deodhar et al 1997, Gordon 2003), which could 
implicate them in contributing to the induction of uncontrolled fibrotic processes when 
present at large numbers. Therefore the aim of this Chapter was to determine a potential 
role for IL-6 in directing monocytic cell trafficking, and to correlate this to the onset of 
peritoneal fibrosis. These studies were performed using a recurrent model of SES 
induced inflammation, and the leukocyte infiltrates were examined both by differential 
cell counting and multiparameter flow cytometry.
Upon repeat inflammatory challenge, both WT and IL-67 mice exhibited a retention of 
the resident like macrophage and DC populations within the peritoneal cavity. This is 
potentially important, given that the retention of monocytic cells has previously been 
associated with a chronic disease state (Jones 2005). Wild type mice also exhibited an 
increased trafficking o f inflammatory leukocytes into the peritoneal cavity upon recurrent
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SES challenge, with the infiltrate being comprised of monocytes, lymphocytes and 
neutrophils. Most noticeable was the increased infiltration of the mononuclear cells seen 
in WT mice at the later time points, which consisted of infiltrating monocytes and 
lymphocytes. This increased and retained inflammatory infiltrate is highly characteristic 
of a chronic inflammatory state (Nowell et al 2003, 2009, Liote et al 1996). The IL-6'7' 
mice however, did not exhibit quite the same increased inflammatory leukocyte 
trafficking following SES induced peritonitis. This phenomenon is in part attributed to 
IL-6 signalling which is known to prevent T cell apoptosis (Atreya et al 2000, Teague et 
al 1997) and therefore may contribute to their retention within the peritoneal cavity. IL-6 
also directs mononuclear cell trafficking via the induction of CCL2 and CCL5, and this is 
likely to direct the increased leukocyte recruitment and retention during chronic 
inflammatory conditions (Hurst et al 2001, Nowell 2003, McLoughlin et al 2005). The 
absence of these IL-6 directed events may explain why the altered trafficking profile was 
not so significant in IL-6'7" mice following repeated SES activation. Interestingly, the 
studies described here showed that repeated rounds of peritoneal inflammation did not 
alter the magnitude of chemokine production in either WT or IL-6'7' mice. The 
mechanism by which increased leukocyte trafficking into the peritoneal cavity occurs in a 
repeat inflammatory model is therefore unknown.
The profile of resident-like macrophage trafficking during the fourth inflammatory 
episode was unchanged from the first, in that there was an initial clearance of the 
population, followed by a re-emergence later on in the time course. As previously 
discussed, this may be a result of trafficking of these cells to the lymphatic system 
following activation, and being replenished from the infiltrating monocyte pool, or due to 
increased adherence to the peritoneal membrane. Despite there being no change to the 
trafficking profile of these cells, there was a noticeable retention of the resident 
macrophage population, in both WT and IL-6'7' mice indicated by an increased presence 
of these cells at the beginning and end of the fourth inflammatory episode. This retention 
of macrophages in the peritoneal cavity could potentially contribute to the associated 
tissue damage observed in the recurrent inflammatory model, however this is unlikely 
given that IL-6'7' mice exhibited the same retention of these cells. Alternatively, the
186
absence of IL-6 may alter or attenuate the activity of these resident macrophages, 
resulting in reduced tissue injury inflicted by these cells.
The studies outlined in Section 6.3.6 showed that the recruitment of infiltrating 
monocytes was significantly increased in WT but not IL-6'7' mice, which exhibited 
normal monocyte trafficking into the peritoneal cavity. An enhanced monocytic cell 
recruitment is commonly associated with inflammatory disorders, an example being the 
accumulation of monocytes/macrophages in lungs during influenza infection, which has 
been associated with the development of lung injury (Lin et al 2007), and in other chronic 
inflammatory models such as rheumatoid arthritis where blood monocytes exhibit 
increased adhesion and trafficking into the synovium (Liote et al 1996). Infiltrating 
monocytes are considered to differentiate into inflammatory macrophages or DC 
(Randolph et al 1998, Gordon and Taylor 2005, Geissman et al 2003), and the increased 
presence of these cell types could potentially contribute to tissue injury and/or the 
promotion of tissue fibrosis in the peritoneal cavity. Given that approximately 50% of 
resident peritoneal cells are macrophages, and this population is rapidly cleared upon 
induction of the inflammatory response, it is reasonable to assume that infiltrating 
monocytes are recruited to provide a pool of cells from which the macrophage population 
can be replenished. This can however induce detrimental side effects in WT mice, with 
the increased monocyte infiltrate having the potential to contribute to tissue injury, 
especially since recruited macrophages are ascribed a greater destructive potential than 
resident macrophages (Gordon 1995). Monocyte/macrophages induce tissue damage via 
a number of mechanisms, which include their release of cytokines and generation of 
nitric oxide, and reactive oxygen species, which have been shown to induce apoptosis 
(Duffield et al 2000, Duffield et al 2001, Kipari et al 2002, Duffield et al 2001). 
Macrophages are also involved in tissue repair, being able to promote fibrosis and the 
deposition of extracellular matrix (Deodhar et al 1997, Gordon 2003), which could 
implicate them in contributing to the induction of uncontrolled fibrotic processes if large 
populations of these cells are retained for long periods. In this regard an increased 
presence of macrophages may result in an up-regulation of extracellular matrix 
deposition and fibrosis, resulting in the membrane thickening observed in WT mice. The
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absence of an enhanced recruitment of these inflammatory cells in IL-6'7' mice provides 
one potential mechanism for their protection against chronic disease.
Dendritic cells are also thought to contribute to tissue damage during chronic 
inflammation due to their ability to express high levels of inducible nitric oxide synthase 
(Serbina et al 2003), and induce cell death (Stary et al 2007). Analysis of the peritoneal 
DC subsets by flow cytometry confirmed the retention and heightened trafficking of these 
cells, demonstrated by the increased numbers of DC present in the peritoneal cavity of 
WT and IL-6'7’ mice during the fourth inflammatory episode compared to the first. It 
would be reasonable to speculate that these may contribute to tissue damage in these 
animals as a result of repeated inflammation. However, it was observed that IL-6'7' mice 
exhibited an enhanced increase in the number of DC in the peritoneal cavity following 
both a single and repeated rounds of inflammation, in particular the monocyte like DC. 
This indicates that the presence of DC does not significantly contribute to chronic 
inflammation associated tissue damage, since IL-6’7' mice have widely been reported to 
have a protected phenotype and do not incur the characteristic fibrosis that is seen in WT 
mice in this model. This leads onto further explanations that could be considered in the 
forms of IL-6 and its regulation of T helper cell differentiation and T regulatory (T-reg) 
cell activity. It has been documented that IL-6 is critical for CD4+ T cell memory 
responses to influenza virus, and the suppression of virus specific CD4+ CD25+ T-regs 
(Longhi et al 2008). It has also been shown that IL-6 production by DC in response to 
TLR ligation during infection is critical for T cell activation as it allows pathogen specific 
T cells to overcome suppression by CD4+ CD25+ T-regs (Pasare et al 2003). Finally,
IL-6 is required for the commitment of IL-17 secreting T helper cells (Bettelli et al 2006, 
Veldhoen et al 2006). This would provide a mechanism for the resistance of IL-6'7* mice 
to autoimmunity and their susceptibility to infection, in that the failure to overcome T-reg 
mediated suppression due to the absence of IL-6 may contribute to their protected 
phenotype, by dampening the immune response and inhibiting effector T cell responses 
and memory recall. This would directly apply to the studies described in this Chapter 
where IL-6'7' mice show protection from fibrosis. The inability of DC to overcome T-reg 
mediated suppression in these mice would result in the inflammatory response being
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much more tightly controlled, and potentially result in limiting the recruitment of tissue 
damage causing immune cells to the peritoneal cavity.
The significance of the monocyte like DC present in IL-6'7' mice during inflammation has 
yet to be determined, and do not appear to contribute to chronic disease pathology given 
that these mice are protected. One consideration is that they may be contributing to the 
protected phenotype of these animals, possibly through their regulation of T-reg activity, 
and the next chapter focused to investigate their phenotype and function, to further 
determine their significance.
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CHAPTER 7
An in vivo characterisation of the F4/80,oC D llbhlC D llc+ monocyte-like dendritic 
cell population unique to IL-6 deficient mice, and a study of the regulation of its
inflammatory trafficking
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7.1 Introduction
Dendritic cells (DC) within peripheral tissues are functionally involved in antigen 
capture, processing and presentation to T cells (Novak et al 2008). In this respect, 
activated DC are involved in the initiation and modulation of an inflammatory response 
and direct both the innate and adaptive immune response to infection. DC are also 
important for the maintenance of immune tolerance to self antigens (immune 
homeostasis) (Wu and Liu 2007).
DC are heterogeneous and although they are all capable of antigen uptake, processing and 
presentation to naive T cells, DC subtypes differ in location, migratory capacity, 
immunological function, and dependence on infectious/inflammatory stimuli for their 
generation (Shortman and Naik 2007, Wu and Liu 2007). There are thought to be three 
subclasses of DC, which include the Pre-DC, Conventional DC and Inflammatory DC 
(Shortman and Naik 2007). Pre-DC develop into functional DC, sometimes upon 
inflammatory stimuli and an example includes the interferon producing plasmacytoid 
DC. Conventional DC (cDC) can be divided into two categories: (1) Migratory DC act as 
sentinels in peripheral tissue and migrate to the lymph nodes through the lymphatics 
bearing antigens from the periphery where they present to T cells. Examples include 
Langerhans cells and dermal DC; (2) Lymphoid tissue resident DC life and function are 
restricted to one lymphoid organ where they collect and present foreign and self antigens. 
Examples include thymic cDC and splenic cDC (Shortman and Naik 2007). The final 
subclass of DC is the Inflammatory DC, which are not normally present in the steady 
state but appear as a consequence of inflammation or microbial stimuli. An example is 
the tumour necrosis factor and inducible nitric-oxide synthase producing DC (Tip DC) 
(Serbina et al 2003). Inflammatory monocytes also have the capacity to generate 
Inflammatory DC (Geissman et al 2003, Sunderkotter et al 2004, Gordon and Taylor 
2005, Shortman and Naik 2007).
Monocyte-derived inflammatory DC originate from the “inflammatory” 
CX3CRlloCCR2+G rl+ mouse monocyte subset, which are recruited as a consequence of 
inflammation. They make no contribution to the proportion of homeostatic/steady state
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“resident” DC in naive mice (Geissman et al 2003, Sunderkotter et al 2004, Gordon and 
Taylor 2005). When Grl+ “inflammatory” monocytes are transferred into mice subjected 
to a vigorous inflammatory response, they differentiate into DC in the peritoneum and 
enter the spleen to mature into a distinctive DC population (Geissman et al 2003). This 
process is dependent on GM-CSF, with GM-CSF receptor deficiency resulting in 
migration of this cell type to the spleen but failure to develop MHC class II+ DC 
(Shortman and Naik 2007). Monocyte-derived DC can be distinguished from steady state 
splenic DC by their intermediate rather than high expression of CD 11c, and by their 
expression of CD1 lb and MAC3 (a glycoprotein found on activated macrophages). These 
cells also characteristically lack expression of CD4 and CD8. Monocyte-derived DC 
generated in culture also express low MHCII levels (Agger et al 2000, Leon et al 2004). 
These inflammatory DC resemble Tip DC previously found in mice, which are 
functionally observed during infection (e.g. L. monocytogenes) and autoimmunity 
(Serbina et al 2003).
The generation of monocyte-derived DC was demonstrated in vitro using a reverse trans- 
endothelial migration model, designed to mimic the process of differentiation of 
monocytes into DC following extravasation into the target tissue. This showed that the 
differentiation of DC from monocytes is associated with the trans-migration of this 
inflammatory population (Randolph et al 1998). Following trans-migration, monocyte- 
derived DC are formed in the immature state, and their maturation is induced by 
immuno-modulators such as LPS, TNFa, IFN-y or CD40L (Ardavin et al 2001). These 
induce the up-regulation of MHCII, and co-stimulatory molecules as well as causing 
dramatic changes in antigen processing, presentation ability, migration behaviour and 
capacity to induce and modulate T cell, NK cell and B cell responses (Leon et al 2005). 
Interestingly, it has been shown that the immuno-modulators that induce the maturation 
of immature monocyte-derived DC, actually block their initial differentiation from 
monocytes into DC, and promote macrophage differentiation instead (Rotta et al 2003, 
Palucka et al 1999). Consequently, inflammatory processes may impact not only on the 
recruitment of monocytic cells, but also affect their subsequent activation, maturation and 
local differentiation.
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Having identified a novel population of monocyte-like dendritic cells that are unique to 
IL-6'7' mice during inflammation, more experiments were needed to characterise their 
phenotype and biological significance in an inflammatory setting. The aim of this 
Chapter was therefore to further characterise this novel population, and determine how 
IL-6 may contribute to its functional capacity.
193
7.2 Materials and methods
7.2.1 Generation of SES induced peritoneal inflammation
Lyophilised SES was prepared as described in Section 2.3.3 and reconstituted in 750pl 
sterile PBS. Peritoneal inflammation was induced by the injection of 500|xl of SES, and 
peritoneal leukocytes were collected by lavage at 12 hours following injection, as 
described in Section 2.3.2. To study the regulation of the CD llbhlCDllc+F4/80l0 
monocyte-like DC, recombinant mouse IL-6 (R&D systems, UK), human hyper-IL-6 
(From Stefan Rose-John, Christian-Albrechts, University of Kiel, Kiel, Germany) or anti 
IL-6R blocking antibodies 2B10 and 25F10 which block global IL-6 Signalling, or IL-6 
trans-signalling respectively (from Walter Ferlin, Novimmune, Switzerland) were 
administered in combination with the SES. After 12 hours, peritoneal leukocytes were 
recovered as described in Section 2.3.2, and flow cytometric analysis was used to 
examine the presence of the monocyte-like DC.
7.2.2 Phenotypic characterisation of F4/8010 C D llbhl C D llc+ monocyte-like 
dendritic cells
F4/8010 C D llbhl C D llc+ monocyte-like DC were phenotyped for various cell surface 
markers by flow cytometry. The population was identified by labelling with anti-F4/80 
FITC, anti-CD 1 lc PE and anti-CD 1 lb APC, and a range of markers were measured using 
biotinylated antibodies, conjugated to PE-Cy5. All flow cytometry staining and 
acquisition was performed as described in Section 2.4.3.
7.2.3 Labelling of resident peritoneal leukocytes
Resident peritoneal leukocytes were labelled by i.p injection of 500|il of PKH26 red 
fluorescent dye (Sigma, Poole, UK) at a lpM  concentration. 3 hours following the 
labelling of peritoneal cells, SES-induced inflammation was established and peritoneal 
cells recovered after 12 hours to analyse both resident (dye labelled) and elicited (dye 
free) cell populations.
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7.2.4 Isolation of bone marrow and blood total leukocytes
Bone marrow leukocytes were isolated by flushing out the marrow from mouse tibia and 
fibulas with sterile PBS as described in Section 2.2.2.5. Peripheral blood leukocytes 
were collected by cardiac puncture as described in Section 2.2.2.4. In both cases red 
blood cell contamination was removed by lysis (Section 2.2.2.4).
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7.3 Results
7.3.1 Characterisation of the F4/8010 C D llb hl C D llc+ monocyte-like dendritic cell 
population
Previous experiments detailed in Chapter 5, Section 5.3.4, showed that IL-6'/_ mice 
exhibited a temporal appearance of a novel DC-like population during SES induced 
inflammation, which was characterised as CD1 lbh,CDl lc+ and F4/8010 and subsequently 
referred to as a monocyte-like DC population. To fully characterise the phenotype of this 
subset, flow cytometry was used to examine defined pan DC markers and chemokine 
receptor expression (Figure 7.1). Analysis of the monocyte like DC showed that they 
expressed the DC markers CD40, CD80, CD86, and low levels of MHCII. They also 
expressed the chemokine receptors CCR3, CCR5, CCR6 and CXCR4, and displayed low 
IL-6R expression. These cells did not express CD83, the DC maturation marker, and 
were negative for CD3, CD4, B220, and CD 19. Expression was however high for both 
the monocyte marker CD14, and monocyte/neutrophil marker Grl (Figure 7.1).
7.3.2 F4/8010 C D llb hl C D llc+ monocyte-like dendritic cells are elicited from the 
circulation during inflammation
To determine whether the monocyte-like DC population arose from a localised 
differentiation or as a result of inflammatory recruitment, resident cells were globally 
labelled with a red fluorescent dye prior to the induction of SES-mediated inflammation 
in order to differentiate between resident and recruited leukocytes. Analysis of the 
F4/8010 CD1 lbhl CD1 lc+ monocyte-like DC showed that they did not possess the dye and 
were therefore elicited cells recruited from the circulation in response to SES activation 
(Figure 7.2).
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Figure 7.1: Phenotypic analysis o f  the C D llc+ monocyte like DC.
IL-6"7' mice were challenged with SES for 12 hours, and the peritoneal leukocytes 
were recovered by lavage. The CD1 lc+ monocyte like DC were analysed by flow 
cytometry for pan DC and monocytic markers. (A) The cell gate was set to 
identify the CD1 lc+ monocyte like DC population with high forward and side 
scatter as previously described (Figure 5.5). (B) This population was labelled with 
antibodies against a variety of DC markers. (C) This population was also labelled 
with antibodies against lymphocyte markers CD3, CD4, B220 and CD 19, and 
myeloid markers CD 14 and Grl. Data is representative of two independent 
experiments.
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Figure 7.2: The monocyte-like DC present in IL-6'' mice at 12 hours are elicited 
from the circulation. To determine if the monocyte like DC population was elicited 
from the circulation, resident peritoneal leukocytes were labelled by i.p injection 
of 500pl of PKH26, a dye that permanently labels cells and fluoresces in the FL2. 
This allows infiltrating leukocytes to be separated visually from resident cells. 
Inflammation was then induced in these mice by i.p injection of SES, and after 12 
hours the leukocyte infiltrate was recovered by lavage and labelled with anti F4/80, 
CD1 lb and CD1 lc for analysis by flow cytometry. (A) CD1 lc+ cells were gated 
and the monocyte like DC gated based on their forward and side scatter. (B) The 
high forward and side scatter gated monocyte like-DC were analysed for 
fluorescence in the FL2 indicating dye labelling. Each plot represents an 
independent experiment from one mouse. (C) Whole peritoneal cells labelled with 
PKH26 dye following i.p injection. 1QR
F7.3.3 C D llc+ bone marrow and blood monocytic cell numbers are equivalent in WT 
and IL-6"7" mice
To assess whether the monocyte-like DC arose as a result of the inflammatory response 
or were an inherent part of the peripheral circulation, the number of CD llc+ bone 
marrow and blood monocytes in WT and IL-6'7' mice were analysed (Figure 7.3).
Bone marrow monocytes were identified by their low forward and side scatter properties 
characteristic of monocytic cells. The number of these cells expressing CD 11c was 
quantified and no significant differences were observed between WT and IL-6’7' mice. 
Similarly blood monocytes were identified by their phenotype C D llb int F4/80mt, and the 
number of these monocytes that expressed CD1 lc were equivalent between WT and 
IL-6'7* mice.
7.3.4 The F4/8010 C D llb hl C D llc+ monocyte-like dendritic cell population is unique 
to IL-6'7" mice
To determine whether the appearance of the F4/8010 CD1 lbhl CD1 lc+ monocyte-like DC 
population was also regulated by alternative cytokines that signal via the STAT pathway, 
peritoneal inflammation was induced in WT, IL-6’7’, IFN-y'7’, IL-10*7’, OSMR'7' and 
gpl30Y757F7Y757F mice to analyse their infiltrating dendritic cell composition. The number 
of F4/8010 CD1 lbhl CD1 lc+ monocyte-like dendritic cells was quantified in each of these 
groups. These data indicated that this population was unique to IL-6’7' mice (Figure 7.4).
Subsequent experiments were designed to verify the role of IL-6 in coordinating the 
development of this inflammatory F4/8010 C D llbhl C D llc+ monocyte-like dendritic cell 
population. Specifically, IL-6'7' mice were administered with SES (i.p) in combination 
with either lOOng of hyper IL-6 or 500ng of recombinant IL-6, to reconstitute signalling 
by this cytokine in these mice, while WT mice received SES alone. After twelve hours, 
the peritoneal leukocytes were recovered by lavage and the presence of the monocyte like 
DC population was then determined by flow cytometry (Figure 7.5 A&B). IL-6'7' mice 
receiving SES alone exhibited the appearance of the F4/80,Q C D llbhl CD 11 c+monocyte­
like DC population, as was previously observed (Chapter 5, section 5.3.4), while WT 
mice lacked this population.
199
A C
Bone Marrow CDllc+ gated cells Blood F4/80intC D llb,nt gated cells
PMN
*
i I
FSC
WT IL-67
Mo=monocytes
PMN=neutrophils
B
10a 100
100 100
10010(
CDllc
WT IL-67
Isotype control 
C D llc +
Figure 7.3: IL-6' mice do not exhibit increased numbers o f  C D llc + bone marrow and 
blood monocytic cells. (A) Total bone marrow cells were recovered from WT and IL-6"7* 
mice by flushing the leg bones with PBS. These leukocytes were then labelled with anti 
CD1 lc and the CD1 lc  + monocytic cells were identified by their low forward and side 
scatter properties (Plots are representative o f three independent experiments). (B) Total 
percentage of CD1 lc+ bone marrow monocytes in WT and IL-6"7' mice (data represents 
three independent experiments). (C) Murine peripheral blood cells were labelled with anti 
F4/80, CD1 lb and CD1 lc. Monocytes were identified by their phenotype F4/80int 
CD1 lb int, and the number o f CD1 lc  expressing monocytes in this population was analysed 
(each plot represents an independent experiment from a single mouse).
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Figure 7.4: The appearance o f  CD I l c + monocyte-like DC is restricted to IL-6v' mice. 
WT, IL-6_/\  IFN-y/_, IL-10_/\  gpl30Y757F/Y757F and gpl30Y757F/+ mice were injected i.p 
with 500pl SES. After 12 hours, peritoneal leukocytes were recovered by lavage and 
labelled for FACS with anti-F4/80, CD1 lb  and CD1 lc. The CD 1 lb hiCDl lc+F4/80l0 
monocyte like DC were identified and quantified. (A) The number of CD1 lc+ 
monocyte-like DC present in the peritoneal cavity o f WT, IL-6_/\  IFN-yAand IL-10'7' 
mice at 12 hours was quantified by taking the flow cytometry gated percentage and 
multiplying by the total cell number. (B) The number o f CD1 lc + monocyte like DC 
present in the peritoneal cavity at 12 hours was measured by flow cytometry for 
gpl30Y757F/Y757F and gpl30Y757R+/‘ mice. Values represent the mean ±  SEM, n=5-10 
mice, * P <  0.05,
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Figure 7.5: The appearance o f the monocyte-like DC population can be regulated by 
IL-6 signalling. To induce peritoneal inflammation, WT mice were injected i.p with 
SES. IL-6 'A mice were injected i.p with SES alone, or SES in combination with 
lOOng hyper IL-6 (A) or 500ng of recombinant human IL-6 (B). These mice were 
then sacrificed at 12 hours, and the leukocyte infiltrate analyzed for the presence of 
C D llc+ monocyte like DC. The monocyte like DC were identified based on their 
phenotype F4/80,oCDl lbhiCDl lc+ and their high forward and side scatter properties, 
and the number of these cells present in the peritoneal cavity was quantified by taking 
the flow cytometry gated percentage and multiplying by the total cell number. (C) 
Neutrophil numbers were calculated in these mice by differential cell counting. (** P 
<0.01, ***P<  0.001).
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(IL-67 mice that received SES in combination with hyper-IL-6 displayed a decrease in the 
number of F4/80loCDl lbhl C D llc+ monocyte-like dendritic cells as compared to IL-6’7' 
mice challenged with SES alone. IL-6’7’ mice that received SES in combination with 
recombinant human IL-6 also exhibited a decrease in the number of these cells as 
compared to mice that received SES alone (Figure 7.5 A&B). As a control, the number 
of neutrophils in these animals was quantified, as IL-6 trans-signalling is well known to 
regulate neutrophil trafficking (Hurst et al 2001, McLoughlin et al 2003 and 2004). As 
expected, i.p administration of hyper-IL-6 in combination with SES reduced the number 
of infiltrating neutrophils in the IL-6’7' mice (Figure 7.5 C).
To support these findings, IL-6 signalling was also blocked in WT mice by administering 
two doses of an anti-IL-6R antibody (2B10) in combination with the SES required to 
induce peritoneal inflammation. These mice exhibited increased numbers of F4/8010 
C D llbhl C D llc+ monocyte-like DC in the peritoneal cavity at 6 hours following 
induction of inflammation. Mice that received SES challenge in combination with the 
25F10 antibody, which is designed to block only trans-signalling exhibited no change in 
their DC inflammatory infiltrate (Figure 7.6 B). Again, neutrophil numbers were 
quantified in these mice as a control, and the number of these cells increased with the 
blockade of IL-6 signalling (Figure 7.6 C).
7.3.5 MoFlo purification of C D llb hl C D llc+ F4/8010 dendritic like cells
Once the role of IL-6 in regulating the monocyte-like DC population had been verified, 
subsequent cell sorting approaches were adopted to more closely examine the 
morphology and functional characteristics exhibited by this F4/80,oCDl lbhlCDl lc+ 
population. Various cell sorting techniques were used in an attempt to achieve this. 
When using live cells for sorting, problems arose because the population was not easily 
visualised and located on the FACS calibur. In addition to this, the DC-like cells were 
also not detectable on the MoFlo cell sorter or the FACS Aria cell sorter (data not 
shown). It was only then discovered that fixation of these cells with BD cellfix made the 
population more defined and easily located by forward and side scatter as visualised by 
flow cytometry. It was therefore not possible to sort this population of cells for further 
analysis.
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Figure 7.6: Blocking IL-6 signalling in WT mice induced the appearance o f  the monocyte­
like DC population during inflammation. WT mice were injected with either SES alone 
or in combination with IL-6 cis and trans-signalling blocker 2B10 or IL-6 trans-signaling 
blocker 25F10. IL-6V* mice were injected with SES alone. Mice were sacrificed at (A) 3 
and (B) 6 hours following induction of inflammation and the peritoneal leukocytes were 
recovered by lavage and labelled with anti F4/80, CD lib  and CD 11c. The monocyte-like 
DC were identified based on their phenotype F4/80loC D llbhlCDl lc+ and their high 
forward and side scatter properties, and the number of these cells present in the peritoneal 
cavity was quantified by taking the flow cytometry gated percentage and multiplying by 
the total cell number. (C) As a control, neutrophils were quantified at 6 hours in each 
group by differential cell counting. (* P <0.05).
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7.3.7 Doublet exclusion from acquired FACS samples ruled out the F4/8010 CDllb*" 
C D llc+monocyte-like DC as a real population
Following the sorting difficulties outlined in Section 7.3.6, steps were taken to verify the 
true identity of the F4/80loCDl lbhlCDl lc+ monocyte-like DC population. It was 
speculated that the population observed in IL-6*7' mice may have arisen as a result of the 
formation of neutrophil aggregates which were acquired on the FACS calibur. These 
suspicions arose due to the fact that the migratory pattern observed in the monocyte-like 
DC population mirrored that seen by the neutrophils (Figures 5.1 A, 5.7, 7.5 and 7.6). In 
addition, IL-6'7' mice exhibited increased trafficking of neutrophils upon SES challenge, 
making the proportion of neutrophils recovered from these mice much greater (Figure
5.1 A). Adding to these concerns was the fact that the regulation of the monocyte-like DC 
population by IL-6 signalling, as outlined in Figures 7.5 and 7.6, was identical to the 
regulation of the neutrophil population seen concurrently in these mice. To determine if 
aggregation was occurring, peritoneal leukocytes from IL-6'7' mice challenged with SES 
for 12 hours, were recovered by lavage and labelled with the required antibodies to detect 
the F4/80loCDl lbh,CDl lc+monocyte-like DC population. These labelled cells were then 
acquired on both the BD FACS calibur, and the Becton Coulter CyAn ADP analyser for 
comparison (Figure 7.7). The population could be identified as usual using the FACS 
calibur, however the CyAn ADP analyser detected a much smaller number of these cells 
within the gate. The CyAn ADP analyser allows doublet exclusion from acquired 
samples, and upon application of this gate, the F4/80loCDl lbhlCDl lc+ monocyte-like DC 
population was completely excluded.
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Figure 7.7: Doublet exclusion from acquiredflow cytometry data eliminated the 
monocyte-like DC population. IL-6*7'm ice were injected i.p with SES to induce 
inflammation. After 12 hours, peritoneal leukocytes were collected and labelled with 
anti F4/80, CD1 lb  and CD1 lc  for flow cytometry, and samples were acquired on (A) 
the FACS calibur and (B) the CyAn CDP analyser respectively. CD1 lc+ cells were 
gated and analysed for forward and side scatter to isolate the monocyte like DC 
population. A doublet exclusion gate was applied to data acquired on the CyAn CDP 
analyser.
7.3.8 CCR5 staining of the anomalous population revealed a mixed population of 
neutrophil aggregates and infiltrating monocytes
Upon reviewing the characterisation data shown in Figure 7.1, it was noted that the CCR5 
staining of the anomalous/monocyte-like DC population revealed two populations of cells 
within this gate, one being CCR5 positive, the other CCR5 negative (Figure 7.8). This 
highlights the presence of two separate leukocyte populations within the anomalous gate. 
Back gating of these populations indicated the CCR5+ cells were likely to be part of the 
infiltrating monocyte population, while the CCR5' cells were probably aggregated 
neutrophils, making them appear in the higher forward and side scatter region of the plot.
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Figure 7.8: CCR5 staining o f the anomalous population reveals a mixed population o f 
neutrophil aggregates and infiltrating monocytes. IL-67' mice were injected i.p with 
SES to induce inflammation. After 12 hours peritoneal leukocytes were collected and 
labelled with anti F4/80, CD1 lb and CD1 lc for flow cytometry. (A) CD1 lbhi CD1 lc+ 
F4/80!o cells with high forward and side scatter (monocyte-like DC) were gated and (B) 
labelled for CCR5. PMN-neutrophils, Mo-infiltrating monocytes.
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7.4 Discussion
As these studies progressed, it became increasingly evident that the population of 
monocyte-like DC identified in the IL-6 7' mice were appearing as an anomaly. A number 
of observations confirmed this: First it was observed that fixation of the FACS labelled 
cells was necessary for the identification of the monocyte like DC population by flow 
cytometric forward and side scatter analysis. Fixation makes the cells smaller and more 
granular, and this “tightens” the population into a defined area, making it more 
distinguishable from other populations. Secondly, problems arose in attempts to purify 
this population for further phenotypic and functional analysis. It was not possible to 
detect this population on either the FACS Aria cell sorter or the MoFlo, both when the 
cells were live and fixed, making it impossible to purify this population. Upon revisiting 
the in vivo data in Chapter 5, it was noted that the trafficking pattern exhibited by the 
monocyte-like DC was identical to that observed for neutrophils. This arose suspicions 
that the monocyte-like DC population observed in IL-6'7' mice may have arisen as a result 
of neutrophil aggregates acquired by the FACS calibur flow cytometer, particularly since 
these mice have a significantly increased number and proportion of infiltrating 
neutrophils compared to WT mice at 6 and 12 hours following SES challenge. These 
suspicions were compounded by the identical regulation observed in the trafficking of the 
monocyte-like DC and neutrophil populations concurrently by IL-6 (Figure 7.5 and 7.6). 
This hypothesis was tested utilising data acquired on the Becton Coulter CyAn ADP 
analyser, which allows doublet exclusion. The application of a pulse width gate, which 
removes aggregates from the flow cytometry plot, lead to the complete exclusion of the 
monocyte-like DC confirming that this population arose as a result of an anomaly caused 
by aggregation of cells being detected by the flow cytometer. It is most likely that the 
aggregates seen during the flow cytometric acquisition were a result of neutrophil 
doublets. This can be concluded from a number of facts. First, the IL-6‘7' mice exhibit 
increased infiltration of neutrophils into the peritoneal cavity during inflammation, 
peaking at the 12 hour time point. This increased recruitment, which occurs as a result of 
enhanced CXCL1 expression in the peritoneal cavity (McLoughlin et al 2004), coincides 
with the appearance of the monocyte-like DC population. The higher concentration of 
neutrophils in theses animals would result in a higher concentration of neutrophils being 
passed through the flow cytometer, which would consequently increase the chances of
209
faggregate formation. Forward and side scatter analysis would therefore give rise to a 
larger and more granular cell population. This is likely since the anomalous monocyte­
like DC population displayed almost identical granularity to the known neutrophil 
population, differing only in their size, being indicative of aggregate formation. Finally 
the regulation of the monocyte like DC trafficking by IL-6 was identical to that seen in 
neutrophils, indicating that they were in fact the same population, one being represented 
by an aggregated form of neutrophils. The reduction in neutrophil infiltration observed in 
IL-6"7’ mice that were reconstituted with IL-6 most likely led to a reduction in doublet 
formation during the flow cytometric acquisition. Similarly, WT mice that received 
blocking antibodies for IL-6 signalling exhibited increased neutrophil infiltration, and as 
a result, the appearance of doublets was increased during the flow cytometric acquisition 
for these mice. This would have accounted for the appearance of the anomalous 
population observed, which were originally described as monocyte like DC. CCR5 
labelling of this population further indicated that this population was not uniquely made 
up of CCR5' neutrophil aggregates, but likely included a small number of CCR5+ 
infiltrating monocytes too.
Because the FACS calibur was used exclusively for the majority of work done for this 
thesis, and this machine does not have the capabilities for doublet exclusion, this anomaly 
did not come to light until the attempts to purify the so called monocyte-like DC 
population were made.
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ICHAPTER 8
The role of IL-10 in the peritoneal inflammatory response
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I8.1 Introduction
The principle role of IL-10 is to suppress the inflammatory response. In this respect,
IL-10 contributes to the destruction of the pathogen, whilst simultaneously dampening 
the immune response to limit collateral tissue damage. In addition to this, IL-10 regulates 
the growth and differentiation of various immune cells such as dendritic cells, 
macrophages, cytotoxic and helper T cells, and plays a key role in the differentiation and 
function of T regulatory cells (Moore et al 2001).
During inflammation, IL-10 plays a regulatory role and suppresses the pro-inflammatory 
functions of APC by suppressing their expression of co-stimulatory molecules, their 
release of inflammatory cytokines and chemokines, and their maturation, therefore 
rendering them unable to stimulate adaptive immune effector cells (Moore et al 2001). In 
this respect, IL-10 inhibits the release of the inflammatory chemokines monocyte 
inhibitory protein-la (M IP-la), MIP-ip, MCP-1 and IL-8 (Olszyna et al 2000, Berkman 
et al 1995), as well as cytokines including TNF-a, IL-ip and IL-6 (Fiorentino et al 1991, 
Chemoff et al 1995). As a result, IL-10 inhibits cytokine production and proliferation of 
CD4+ T cells via immunosuppression of APC function (Fiorentino et al 1991, de Waal 
Malefyt et al 1991, Chemoff et al 1995). Recently these observations have been 
elaborated to show that IL-10 treatment of DC can induce or contribute to a state of 
anergy in allo-antigen or peptide-antigen-activated T cells (Groux et al 1996, Takayama 
et al 1998).
IL-10 has been shown to inhibit the differentiation of monocytes into DC and instead 
promote their maturation to macrophages. Studies with human monocytes show that 
when cultured with GM-CSF and IL-4 for 6 days, monocytes differentiate into immature 
DC that can be activated by LPS, CD40 ligand or TNF to mature into efficient IL-12 
secreting APC, capable of inducing Thl polarisation. Addition of IL-10 inhibits the 
generation and maturation of monocyte-derived DC, and instead induces the 
differentiation of these immature DC into macrophage like cells. These macrophages are 
characterised by a lower expression of co-stimulatory molecules including MHC II, and 
display enhanced phagocytic capabilities (Allavena et al 1998, Fortsch et al 2000).
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Many animal studies have been performed to dissect the role of IL-10 in the 
inflammatory response to pathogens. These have determined that both the innate and 
acquired immune responses are enhanced or impaired by experimental depletion or 
elevation of IL-10 respectively. For example, increased IL-10 activity compromised 
resistance to Listeria monocytogenes in scid mice, through suppression of the innate 
immune response (Kelly and Bancroft 1996, Tripp et al 1995). Similarly, the enhanced 
innate response to Listeria in IL-10'7' mice or anti-IL-10 treated mice lead to a rapid 
control of Listeria within the first few days of infection. This was accompanied by 
enhanced acquired immunity during primary and secondary infection (Dai et al 1997). 
Therefore IL-10 facilitates the outgrowth and dissemination of bacteria, with IL-10'7' 
mice showing improved clearance of Escherichia coil and Staphylococcus aureus during 
infection (Sewnath et al 2001, Coles et al unpublished).
Studies have shown that pre-treatment of macrophages with IL-10 inhibits subsequent 
STAT3 activation by IL-6, however this does not work in reverse, and IL-10 induced 
STAT3 activation is not counteracted by pre-treatment with IL-6. This cross inhibition 
has been demonstrated to be dependent on active transcription and is likely explained by 
different sensitivities of IL-10 and IL-6 signalling towards the negative feedback 
inhibitor Suppressor of cytokine signalling 3 (SOCS3), which is induced by both 
cytokines (Niemand et al 2003). The activation of SOCS3 acts as a negative regulator of 
gpl30-mediated signalling (Nicholson et al 2000, Schmitz et al 2000). However the 
induction of SOCS3 by IL-10 does not suppress STAT3 signalling via the IL-10R 
(Niemand et al 2003). This difference in sensitivity of IL-10 and IL-6 to SOCS3 
regulation of the JAK/STAT pathway defines an important mechanistic distinction 
between these two STAT3-activating cytokines (Niemand et al 2003). Contributing to 
this interplay is the ability of IL-10 to inhibit IL-6 production by activated monocytes 
(Fiorentino et al 1991), and the ability of IL-6 to regulate IL-10 expression in vivo 
(Fielding et al unpublished).
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The aim of this Chapter was to investigate the role of IL-10 in cytokine and chemokine 
production and leukocyte trafficking in an in vivo model of acute peritonitis, drawing 
conclusions on its interplay with IL-6.
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8.2 Materials and methods
8.2.1 Determination of IL-10 production by murine peritoneal leukocytes in vitro
Peritoneal lavage fluids from 5 WT mice were pooled. Cells were cultured for three 
hours in 6 well microtitre plates in RPMI 1640 containing 10% FCS, 2mM L-glutamine, 
lOOU/ml Penicillin, lOOpg/ml Streptomycin, ImM sodium pyruvate and 55p,M 
p-mercaptoethanol in the presence or absence of SES (1/10) and 3 \xM monensin. Cells 
were scraped and surface labelled with antibodies against F4/80, CD lib , CDllc, B220, 
NK1.1 and CD4 as described in Section 2.3.4. Following permeabilisation, cells were 
labelled intracellularly for IL-10, and analysed by flow cytometry (Section 2.3.4).
8.2.2 Induction of SES induced peritoneal inflammation
SES induced inflammation was established in groups of WT, IL-10"7' and IL-6'7* mice 
(n=5 per group, mixture of males and females) by i.p administration of SES (Section
2.3.5). At defined intervals during the inflammatory response (0, 1, 3, 6, 12, 15, 18, 24, 
48 and 72 hours) mice were sacrificed and the leukocyte infiltrate collected by peritoneal 
lavage.
8.2.3 Cytospin analysis of leukocyte infiltrate
At each time point, animals were sacrificed by schedule 1 and peritoneal leukocytes 
collected by lavage as described in Section 2.3.2. Cytospins were prepared, stained with 
Wright Giemsa stain and differential cell counts performed as described in Section 2.3.2.
8.2.4 Flow cytometric analysis of leukocyte infiltrate
Peritoneal leukocytes were labelled for flow cytometric analysis with antibodies against 
macrophage and dendritic cell markers F4/80 FITC, C D llb  APC, and CD llc PE 
(Section 2.4.3). Details of the antibodies used are found in Table 2.1. Defined 
monocytic subsets were gated as described in Chapters 4 and 5. Cell numbers were 
quantified by taking the flow cytometry population gated percentages and multiplying by 
the total cell number.
215
8.2.5 In vitro stimulation of inflammatory peritoneal leukocytes and intracellular 
cytokine staining to identify CD4+ T helper cell subsets
Peritoneal leukocytes were cultured (lxlO6 cells/well) in 96 well plates for four hours in 
the presence of 50ng/ml PMA, 500ng/ml Ionomycin and 3pM monensin, as described in 
Section 2.3.8. Following this, cells were labelled with antibodies against the T helper cell 
marker CD4, and subsequently labelled with anti-IL-17A, IFN-y and IL-10 intracellularly 
to determine cytokine production by these cells (Section 2.4.3).
8.2.6 ELISA quantification of cytokine and chemokine levels in lavage supernatants
Peritoneal lavage supernatants were rendered cell free by centrifugation and stored at 
-70°C. Supernatants were analysed by ELISA for IL-6, sIL-6R, IL-10, CCL2 and 
CXCL1 as described in Section 2.5.
8.3 Results
8.3.1 Resident macrophages are the predominant IL-10 producing cells in the 
peritoneal cavity
To determine the peritoneal source of IL-10 following SES activation, resident peritoneal 
leukocytes were isolated and cultured in the presence or absence of SES and intracellular 
staining performed to identify IL-10 production by defined cell types (Figure 8.1). In this 
respect, the predominant cell type to produce IL-10 upon SES stimulation was the 
F4/80hlC D llbhl resident macrophages (Figure 8.1 B). Resident F4/80intC D llbhlCD llc+ 
dendritic cells exhibited a small shift indicating a low level of heterogeneous IL-10 
expression by these cells (Figure 8.1 A). CD1 lbmtB220int B1 cells also produced IL-10 
but not to the same magnitude as resident macrophages, whilst B220hlC D llb ' B2 cells 
produced low levels of IL-10 (Figure 8.1 C). NK1.1 Natural Killer cells produced no 
IL-10, while CD4+ T cells exhibited only a negligible shift for IL-10 staining (data not 
shown).
8.3.2 IL-10 limits leukocyte infiltration during acute peritoneal inflammation
To study the potential role of IL-10 in governing leukocyte recruitment, WT and IL-10'7' 
mice were challenged with SES and the leukocyte infiltrate quantified at defined time 
points (Figure 8.2). Since the inflammatory trafficking of leukocytes in IL-6'7' mice has 
been so extensively characterised in Chapter 5, and there is a known interplay between 
IL-6 and IL-10, it was decided to include this group for comparison. The data revealed 
that while each group had equivalent numbers of resident peritoneal leukocytes prior to 
SES challenge, IL-10'7' mice exhibited significantly enhanced leukocyte recruitment 
following induction of peritonitis, as compared to age matched WT and IL-67 mice.
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Figure 8.1: IL-10 expression by resident peritoneal cells. Peritoneal leukocytes were 
recovered by lavage from 5 WT mice and pooled. Cells were cultured for three hours 
in the presence or absence of SES (1/10) and 3pM monensin. Cells were then labelled 
with antibodies against markers for macrophages, DC, and B cells followed by 
intracellular staining for IL-10. (A) IL-10 expression by F4/80mtCDl lbhl resident DC, 
(B) F4/80hiCDl lbhi resident macrophages, (C) B220mtCDl lb,nt B1 cells and 
B220hiCDl lb' B2 cells . (D) IL-10 production by WT and IL-67- resident 
macrophages, as measured by luminex following 20 hours of culture in the presence or 
absence of SES (1/50). /
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Figure 8.2: Total leukocyte trafficking during SES-inducedperitoneal 
inflammation. Peritoneal inflammation was induced by i.p administration of SES 
and peritoneal leukocytes collected by lavage at defined intervals. Total cell counts 
were determined using a Coulter counter. Values represent the mean ±  SEM, n=5- 
15 mice per time point, * P<  0.05, ** P < 0.01, *** P < 0.001.
¥8.3.3 IL-10 regulates the inflammatory recruitment of neutrophils and mononuclear 
cells
To better understand the role of IL-10 in regulating the inflammatory recruitment of 
leukocytes, the inflammatory infiltrate was analysed by differential cell counting to 
determine the proportion of each individual cell type (Figure 8.3). The data revealed that 
IL-10'7’ mice exhibited an increased recruitment of neutrophils, monocytes and 
lymphocytes in comparison to both WT and IL-6'7' mice. Neutrophil recruitment in 
IL-10'7’ mice was 2-3 fold higher than in IL-6*7' mice and 3-4 fold higher than WT mice 
(Figure 8.3 A). Monocyte recruitment in IL-10'7' mice was approximately 2.5 fold higher 
than in both WT and IL-6'7’ mice (Figure 8.3 B). Lymphocyte recruitment in IL-10'7' mice 
was between 1 and 3 fold higher than in WT and IL-6'7' mice depending on the time point 
(Figure 8.3 C).
8.3.4 IL-10 regulation of monocytic cell trafficking during SES induced peritonitis
Lj
To define a role for IL-10 in the regulation of F4/80 /C D llb  resident macrophage, 
F4/80in,/CD 11 bh'/CD 11 c+ resident DC trafficking, and F4/80in7C D llbint infiltrating 
monocytes, these populations were monitored by flow cytometry following the induction 
of SES induced peritoneal inflammation in WT and IL-10*7" mice (Figure 8.4). IL-10 did 
not alter the trafficking profile of the F4/80hl/CDl lbhl resident-like macrophages, which 
remained equivalent in WT and IL-10'7' mice (Figure 8.4 B). In this respect, these cells 
exhibited an initial clearance, followed by a re-emergence of this population at later time 
points. The F4/80,nt/CDl lbhl/CDl lc+ resident DC population also exhibited an initial 
clearance followed by a recruitment at the later time points (Figure 8.4 D). However 
IL-10*7' mice exhibited an enhanced recruitment of this population as compared to the 
WT controls. Finally, IL-10'7* mice exhibited an enhanced recruitment of 
F4/80int/CDl lbmt infiltrating monocytes compared to the WT mice (Figure 8.4 F).
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Figure 83 : Neutrophil, monocyte and lymphocyte trafficking following the induction 
o f SES induced inflammation in WT, IL-6~~ and IL-10'/" mice. Peritoneal inflammation 
was induced in WT, IL-6‘''and IL-10'7' mice by i.p administration of SES and 
peritoneal leukocytes were collected by lavage at defined intervals. (A) Differential 
cell counts were performed and the number of neutrophils calculated at each time 
point. (B) The number of lymphocytes calculated at each time point. (C) The number 
of monocytes at each time point, (values represent the mean ±  SEM, n=5-15 mice per 
time point, * P < 0.05, ** P < 0.01, *** P < 0.001).
221
B 2 .0-to”'O
*.15“
<A Q
S’ 1.0-.C Q.
g 0.5^
s
CD llb
C D llb C D llc
0.0-1
D 10.0-
«nO 7.5-
5,
O
Q
5.0-
15
£ 2.5-
0.0-
CD llb
o 7-
(A
O
6-
o
5-
oc
4-
o
E 3-
O)
c 2-
*■>
2 1-
* *
C
0-
■WT
IL-10
I----1---- I----1----1----1----1 I I
0 10 20 30 40 50 60 70 80
Time (hours)
WT
IL-10-/-
r- t 1 i--i i  i i i----1
0 10 20 30 40 50 60 70 80
Time (hours)
*** *** WT
IL-10-/-
I- I'"' I ' I I I I I I
0 10 20 30 40 50 60 70 80
Time (hours)
Figure 8.4: IL-10 regulation o f monocytic subset trafficking following SES 
induced peritonitis. Peritoneal inflammation was induced by i.p administration of SES 
and peritoneal leukocytes were collected by lavage at defined intervals. (A) Peritoneal 
leukocytes were labelled with anti F4/80 and CD1 lb and the macrophages identified 
by their F4/80hlCDl lbhl phenotype. (B) The number of resident-like macrophages, defined 
by the indicated gates (Panel A) were calculated at each time point by taking the flow 
cytometry gated percentage and multiplying by the total cell number. (C) Peritoneal leukocytes 
were labelled with anti F4/80 and CD1 lb and cells that were positive for F4/80 and CD1 lb 
were labelled for CD1 lc. Cells that resided in this F4/80mtCDl lbhlCDl lc+ gate were defined 
as DC. (D) The number of F4/80intCDl lbhiCDl lc+ DC within the defined gate (Panel C) was 
calculated at each time point. (E) Peritoneal leukocytes were labelled with anti F4/80 and 
CD1 lb and infiltrating monocytes identified by their FT/SO^VCDl lbint phenotype. (F) The 
number of infiltrating monocytes, defined by the indicated gates (Panel E) were calculated at 
each time point. Values represent the mean ±  SEM, n=5 mice per time point, * P < 0.05,
** P < 0.01, *** P < 0.001. 222
8.3.5 IL-10 regulates the production of soluble mediators upon SES activation
To determine the mechanism of the increased leukocyte recruitment observed in Section 
8.3.3, inflammatory chemokines were measured in lavage supernatants by ELISA (Figure
8.5). IL-10'7* mice exhibited an enhanced production of CCL2 as compared to the WT 
mice, while IL-6"7" mice exhibited impaired levels of CCL2 production as seen previously 
in Chapter 5 (Figure 8.5 A). CCL2 production in IL-10"7" mice was 1.5-2.5 fold higher 
than in WT mice, while IL-6"7" mice exhibited 2-3 fold lower levels of CCL2 than WT.
WT and IL-6"7" mice exhibited a transient expression of the neutrophil activating 
chemokine CXCL1 (KC), that occurred one hour after SES activation, and disappeared 
by three hours (Figure 8.5 B). This expression was elevated in IL-6"7* mice as was seen 
previously (Chapter 5). The absence of IL-10 led to a prolonged production of CXCL1 
as compared to WT and IL-6*7" mice. In this respect, while IL-10'7' mice expressed 
similar levels of CXCL1 to the WT at one hour, this chemokine was still detectable in the 
peritoneal cavity of the IL-10"7" mice three hours post SES activation.
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Figure 8.5: Regulation o f  inflammatory chemokine expression by IL-6 and IL-10. 
Peritoneal inflammation was induced in WT, IL-6'7'and IL-10'7" mice by i.p 
administration of SES. Peritoneal fluids were recovered by lavage. Chemokines 
were then measured by ELISA . (A) CCL2 and (B) CXCL1 (KC) expression. 
Values represent the mean ±  SEM, n=5-15 mice per time point, * P < 0.05, *** P 
<  0 .001.
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8.3.6 IL-10 impairs IL-6 production, and regulates sIL-6R levels
It has previously been published that IL-10 impairs the release of IL-6 by APC. To 
confirm this, IL-6 levels were measured in lavage fluids by ELISA (Figure 8.6 A). These 
results confirmed previous findings, with IL-10'7' mice exhibiting a large and prolonged 
increase in IL-6 production upon SES activation. In this respect, IL-6 levels were 10 fold 
higher than those observed in WT mice three hours after SES activation. Soluble IL-6R 
levels were also measured since the control of chemokine directed leukocyte trafficking 
and apoptosis by IL-6 trans-signalling is reliant on the formation o f the IL-6/sIL-6R 
complex (Figure 8.6 B). Results revealed that sIL-6R levels were equivalent in WT and 
IL-6'7" mice, whilst IL-10'7' mice exhibited an enhanced production, suggesting that IL-10 
influences the inflammatory shedding of IL-6R (Jones et al 1998). Finally IL-10 levels 
were measured to determine if IL-6 regulates the production o f IL-10, as has previously 
been indicated by Fielding et al who showed an IL-6 dependent regulation of IL-10 
production in vivo (Fielding et al unpublished). IL-10 levels peaked at one hour, with no 
significant differences existing between WT and IL-6'7' mice.
8.3.7 IL-10 regulates T cell recruitment
To investigate how IL-10 directed the recruitment of CD4+ T cells and potentially their 
commitment, leukocytes were recovered from WT, IL-10'7' and IL-6'7' mice 24, 48 and 72 
hours after the induction of peritoneal inflammation, and cultured in vitro (Section 2.3.8). 
Cells were then labelled with anti-CD4, IFN-y and IL-17A to determine the phenotype of 
the activated T helper cell infiltrate. Cell numbers were calculated by multiplying the 
FACS gated population percentages by the total cell number (Figure 8.7). The data 
revealed that the absence of IL-10 led to an enhanced recruitment of CD4+ T cells (Figure
8.7 A). In this respect, IL-10'7' mice exhibited a significantly increased recruitment of 
Thl7 cells (Figure 8.7 B), while the recruitment of Thl cells remained equivalent to WT 
mice (Figure 8.7 C). In comparison, IL-6'7' mice exhibited an impaired recruitment of 
total CD4+ T helper cells (Figure 8.7 A), specifically Thl (Figure 8.7 B) and T h l7 cells 
(Figure 8.7 C). Whilst this was not observed from differential cell count data in Chapter 
5, flow cytometry allows a specific analysis of CD4+ T helper cells without interference 
from other lymphocyte subsets.
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Figure 8.6: Regulation o f inflammatory cytokine expression by IL-6 and IL-10. 
Peritoneal inflammation was induced in WT, IL-6"7'and IL-10'7" mice by i.p 
administration of SES. Peritoneal fluids were recovered by lavage and cytokines 
quantified by ELISA . (A) IL-6, (B) sIL-6R and (C) IL-10 expression . Values 
represent the mean ±  SEM, n=5-15 mice per time point, * P < 0.05, ** P < 0.01, 
***p<  0.001.
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Figure 8.7: T helper cell commitment and recruitment is regulated by IL-6 and 
IL-10. Peritoneal inflammation was induced by i.p administration of SES and 
peritoneal leukocytes collected by lavage at defined intervals, lx l0 6 Cells were 
cultured for 4 hours in 200pl of RIO medium supplemented with 50ng/ml PMA, 
500ng/ml ionomycin and 3pM monensin. Cells were surface labelled with anti CD4, 
and intracellularly stained for IL-17A and IFN-y. (A)The total number of CD4+ T 
cells was calculated by multiplying the flow cytometry gated population percentage 
by the total cell number. (B) The number of IL-17A secreting Thl7 cells at each 
time point. (C) The number of IFN-y secreting Thl cells at each time point. Values 
represent the mean ±  SEM, n=5 mice per time point, * P < 0.05, ** P < 0.01, 
***/>< 0.001).
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( 8.3.8 IL-6 regulates the recruitment but not the commitment of IL-10 secreting T
i
■ cells
I To investigate how IL-6 directed the recruitment of IL-10 secreting T cells, leukocytes
were recovered from WT, IL-1 O'7' and IL-6'7' mice 24, 48 and 72 hours after the induction 
of peritoneal inflammation, and cultured in vitro as described in Section 2.3.8. Cells were 
then labelled with anti-CD4 and IL-10 to determine the phenotype of the activated T
helper cell infiltrate (Figure 8.8). The data revealed that IL-6'7' mice exhibited impaired
recruitment of IL-10-secreting T cells. This was due to a global impairment of CD4+
T helper cell recruitment as opposed to an impaired commitment. This was indicated by 
the equivalent proportion of IL-10 secreting T cells in both WT and IL-6'7' mice, 
suggesting that the differences in number of these cells arise as a result of an impaired 
recruitment of T cells in IL-6'7' mice.
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Figure 8.8: IL-6 regulates the recruitment o f  IL-10 secreting T cells. Peritoneal 
inflammation was induced by i.p administration of SES and peritoneal leukocytes 
collected by lavage at defined intervals, lx l0 6 Cells were cultured for 4 hours in 
200pl of R10 medium supplemented with 50ng/ml PMA, 500ng/ml ionomycin and 
3pM monensin. Cells were surface labelled with anti-CD4, and intracellularly 
stained for IL-10 (A) The total number of CD4+ T cells was calculated by 
multiplying the flow cytometry gated population percentage by the total cell number. 
(B) The number of IL-10 secreting ThlO cells at each time point. (C) The 
percentage of ThlO cells at each time point. Values represent the mean ±  SEM, n=5 
mice per time point, * P < 0.05, ** P ^^01.
8.4 Discussion
Previous literature has reported an interplay between IL-6 and IL-10 (Niemand et al
2003). The data presented in this Chapter support a role for IL-10 in regulating both the 
innate and adaptive arms of the inflammatory response. These studies show that IL-10 
appears to limit neutrophil recruitment by its control of CXCL1 (KC) production in 
response to SES activation. IL-10 is known to inhibit IL-1, TNFa and IL-17 expression 
in macrophages, all of which are important for driving the expression of CXCL1 (KC) by 
mesothelial cells and the subsequent recruitment of neutrophils (Gu et al 2008, Witowski 
et al 2000, Fiorentino et al 1991, Chemoff et al 1995, Hurst et al 2001). This therefore 
provides a potential mechanism by which IL-10 limits neutrophil recruitment. 
Neutrophils are important for microbial killing, an integral part of the innate immune 
response, but the anti-microbial agents and reactive oxygen species released by these 
leukocytes are well known to have the potential to cause collateral tissue damage 
(Mahmudi-Azer and Eeden 2003). In this respect, IL-10 potentially regulates neutrophil 
recruitment to ensure that there is an appropriate level of infiltrate to clear the pathogen, 
whilst avoiding tissue damage that may be caused by the presence of excessive numbers 
of these cells. Interestingly, current studies in the group, using a model of live bacterial 
infection, have shown that bacterial clearance is significantly improved in IL-10'7' (Coles 
et al unpublished). This supports other studies that have shown improved clearance in 
IL-10 deficient mice, indicating that IL-10 facilitates the outgrowth and dissemination of 
bacteria during infections (Sewnath et al 2001). IL-10 therefore can be shown to control 
the rate of bacterial clearance by regulating the recruitment of neutrophils to the 
peritoneal cavity upon induction of inflammation. IL-10 may also control the rate of 
bacterial clearance via the regulation of neutrophil activation, activity or their apoptotic 
clearance following the phagocytic uptake of bacteria. The increased recruitment of 
neutrophils and prolonged production of CXCL1 (KC) observed in IL-10'7' mice (Figures 
8.3A and 8.5B respectively), correlated with a prolonged production of sIL-6R in these 
mice (Figure 8.6C). Since neutrophils are the main source of sIL-6R during peritoneal 
inflammation, and shedding is usually triggered by activation or apoptosis, these results 
imply that IL-10 may also negatively regulate the chemokine (KC)-directed activation or 
apoptotic clearance of these cells, accounting for the increased sIL-6R levels in the
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fperitoneal cavity and the improved microbial clearance capacity in the IL-10"7" mice. In 
this respect, IL-10 is known to inhibit bacterial phagocytosis and attenuate neutrophil 
microbicidal activity towards internalised bacteria (Laichalk et al 1996). Further studies 
would need to be performed to properly demonstrate this, which could investigate the 
activation, killing capacity and apoptotic clearance of neutrophils from a STAT3 
conditional knock out mouse.
Data presented in Figure 8.1 showed that the predominant IL-10 secreting cell types in 
the peritoneal cavity upon SES activation were the resident macrophages, and this 
appears to be IL-6 regulated since IL-6"7' macrophages produced lower levels of IL-10. 
This supports previous data showing that IL-10 levels were elevated in the gpl30 knock 
in mice, that exhibit constitutive STAT1/3 signalling, and this was attenuated when these 
mice were crossed to an IL-6'7" background, implying an IL-6 dependent release of IL-10 
in these mice in vivo (Fielding et al unpublished). However in this regard a detectable 
difference in the overall IL-10 levels in the peritoneal cavity was not observed (Figure 
8.5).
IL-10 production by the resident macrophages implicates these resident cells in a role for 
the regulation of the recruitment of neutrophils and other cell types during acute 
peritonitis through their production of IL-10. Previous work has shown that depletion of 
resident peritoneal macrophages resulted in increased neutrophil recruitment upon 
zymosan-induced peritonitis, which was attributed to an inhibitory action of macrophage 
derived IL-10 on chemokine production and neutrophil recruitment (Ajuebor et al 1999). 
This supports the general belief that resident macrophages are primarily involved in 
immune modulation and resolution, and infers a role for these cells in immunoregulation 
via the release of IL-10. However this contrasts with data presented by Callhier et al who 
showed that macrophage depletion resulted in impaired neutrophil recruitment following 
thioglycollate-induced peritonitis (Callhier et al 2005). This could be explained by the 
use of different inflammatory models.
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The results discussed in this Chapter have also highlighted a role for IL-10 in the 
regulation of monocyte recruitment during peritoneal inflammation. In this respect,
IL-10 limits the recruitment of monocytic cells during the peritoneal inflammatory 
response, which would appear to be due to its negative regulation of the monocyte 
chemoattractant CCL2. Evidence has shown that upon migration across the endothelium, 
inflammatory monocytes are able to differentiate into both macrophages and DC 
(Randolph et al 1998, Gordon and Taylor 2005). As discussed in Chapter 6, 
macrophages and DC are both known to augment inflammation-induced tissue damage 
(Duffield et al 2000, DufField et al 2001, Kipari et al 2002, Duffield et al 2001, Stary et 
al 2007, Serbina et al 2003) whilst macrophages are also involved in tissue repair, 
promoting fibrosis and the deposition of extracellular matrix (Deodhar et al 1997, 
Gordon 2003). These activities therefore potentially implicate monocytic cells in 
contributing to the induction of uncontrolled fibrotic processes when present in large 
numbers. Consequently, it is proposed, that IL-10 functions to limit monocytic cell 
recruitment in order to contain tissue injury or fibrosis afflicted by these cells. Previous 
studies by the group have shown that IL-6 differentially effects mesothelial expression of 
neutrophil activating chemokines and chemokines associated with mononuclear cell 
recruitment. In this respect, IL-6 is important in inducing a switch from neutrophil 
activating chemokine production, to mononuclear chemokine production thereby 
promoting the transition from innate to acquired immunity (Jones 2005, Hurst et al 2001, 
McLoughlin et al 2005). In the current study, data has shown that IL-10'7' mice have 
significantly elevated levels of peritoneal IL-6, which is potentially a result of increased 
IL-6 production by monocytic cells, which would confirm previous reports that IL-10 
inhibits IL-6 release from activated monocytes (Fiorentino et al 1991). Since IL-6 drives 
the molecular switch to turn on CCL2 expression by mesothelial cells, it is proposed that 
the mechanism by which IL-10 limits monocyte recruitment is via both its negative 
control of IL-6 mediated signalling and its ability to inhibit IL-6 production. Further 
experiments would need to be performed to confirm this, and could potentially be 
demonstrated by reconstituting IL-10 in IL-10'7' mice by administering a defined dose of 
recombinant IL-10 or by introducing blocking antibodies for IL-10 in WT mice, and 
monitoring the levels of IL-6 and CCL2 upon induction of inflammation.
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Multi-parameter flow cytometry revealed an increased recruitment of both infiltrating 
monocytes and DC in IL-1O'7' mice. Based on previous literature stating that IL-10 
inhibits IL-6 production by APC (Fiorentino et al 1991, Chemoff et al 1995), it is 
proposed that the recruited DC observed in IL-10’7" mice (Figure 8.4) may produce 
elevated levels of IL-6. This would implicate them in facilitating an enhanced adaptive 
immune response via an increased ability to suppress T-reg activity, promote T cell 
commitment and activation and promote the T cell memory response (Pasare and 
Medzhitov 2003, Longhi et al 2008, Park et al 2004, Veldhoen et al 2006, Betelli et al 
2006). Evidence for this was shown following investigations into the trafficking of T 
cells in IL-10"7" mice, which is discussed below. Overall, this provides a potential role for 
IL-10 in limiting the recruitment of inflammatory DC during inflammation, and their 
secretion of IL-6, thereby limiting the potential for these APC to suppress T-regs and 
activate T helper cells. This would support evidence that has shown that IL-10 attenuates 
the adaptive immune response (Dai et al 1997).
The studies described in this Chapter finally showed that IL-10 also limits lymphocyte 
recruitment during peritoneal inflammation. Flow cytometric analysis of the lymphocyte 
population showed that IL-10 regulates the recruitment of CD4+ T cells, and may also 
regulate their commitment. In this respect, IL-10 appears to suppress a Th-17 phenotype, 
but does not appear to regulate Th-1 cell commitment. This could be explained by the 
increased expression of IL-6 in IL-10"7" mice, which is known to drive Th-17 cell 
commitment (Bettelli et al 2007, Veldhoen et al 2006) and the fact that IL-10 has been 
shown to block Thl7 commitment ex vivo (Gu et al 2008). Th-17 cells have been widely 
associated with autoimmune disease pathology (Langrish et al 2005), revealing another 
mechanism by which IL-10 is likely to dampen the immune response. Alternatively, the 
increased numbers of Thl7 cells in IL-10'7" mice could simply be a result of increased 
expansion and recruitment of these cells, potentially facilitated by the IL-6 mediated 
inhibition of T-regs, and further work would be required to determine this. The opposite 
effect is true for IL-6'7" mice, which exhibit impaired recruitment of CD4+ T cells (Figure
8.7), which is expected since IL-6 trans-signalling drives the recruitment of chemokine
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mediated T cell recruitment (McLoughlin et al 2005). In this respect IL-6‘/_ mice show 
an impaired commitment and recruitment of Th-17, Thl and IL-10 secreting T cells.
IL-6 has previously been shown to drive the commitment of IL-17 secreting T cells 
(Bettelli et al 2006, Veldhoen et al 2006) and also induce IL-10 secretion by Thl, Th2 
and Thl7 cells (Stumhofer et al 2007), thereby presenting an alternative mechanism by 
which IL-6"7' mice suppress the T cell content within the peritoneal cavity.
When the profile of lymphocyte recruitment is overlaid with the profile of bacterial 
clearance obtained from studies using a model of live bacterial peritonitis, it can be seen 
that the majority of bacteria is cleared between 18 and 24 hours of infection whilst the 
recruitment of T helper cells occurs between 36-72 hours post infection (Coles et al 
unpublished, data not shown). This implies that the recruited T cell population does not 
contribute to the bacterial clearance, which brings into question their role in the 
inflammatory response. One possible explanation could be that they direct the 
re-establishment of the resident monocytic populations by the production of soluble 
mediators which have the potential to drive macrophage or DC differentiation from 
recruited monocytes. Alternatively they may control memory responses by the formation 
of a memory T cell pool within the cavity, providing a faster immunological response 
during recurrent infection. Finally, they may contribute quite substantially to tissue 
injury or the induction of membrane fibrosis, which has previously been associated with 
increased recruitment of IFN-y secreting T cells and the activation of a STAT1 driven 
response (Fielding et al 2009, submitted).
In summary the findings outlined in this Chapter have effectively demonstrated that 
IL-10 plays an immunoregulatory role by limiting leukocyte recruitment during the 
peritoneal inflammatory response. This supports its known role as an anti-inflammatory 
cytokine that serves to limit the damage triggered by the pathogen by contributing to its 
destruction, while simultaneously limiting collateral damage by dampening the immune 
response (Moore et al 2001). These anti-inflammatory activities appear to be mediated 
through the interplay between IL-10 and IL-6, with the regulation of IL-6 by IL-10 being 
implicated as a mechanism for the control of IL-6 directed production of specific
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chemokines and the subsequent chemokine directed recruitment of inflammatory 
leukocytes.
It would be interesting to see how the integrity of the peritoneal membrane of IL-10"7' 
mice is affected during a repeat model of inflammation. Since the data presented in this 
Chapter support a role for IL-10 in limiting the inflammatory response by suppressing the 
excessive recruitment of activated leukocytes, one would expect that in the absence of 
this cytokine, tissue damage to the peritoneal membrane would be significantly enhanced. 
This may arise due to an increased presence of neutrophils and mononuclear cells, which 
are known to contribute to tissue injury and fibrosis by their production of pro-fibrotic 
agents including reactive oxygen species, nitric oxide and TGF-p, but may also be driven 
by increased numbers of Th-17 cells (Duffield et al 2000, Duffield et al 2001, Kipari et al 
2002, Duffield et al 2001, Stary et al 2007, Serbina et al 2003, Deodhar et al 1997, 
Gordon 2003). Importantly, IL-17 has recently been shown to induce MMP and TIMP 
activity, which, if unbalanced, could contribute to aberrant tissue metabolism or collagen 
deposition (Koshy et al 2002, Jovanovic et al 2001). This could be confirmed using the 
model of repeat inflammation described in Chapter 6, and may implicate IL-10 as a 
potential therapeutic molecule, which could be administered to prevent the onset of 
chronic inflammatory or autoimmune diseases, which are strongly associated with high 
levels of detrimental tissue damage.
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CHAPTER 9
General Discussion
9. Discussion
Prior experiments have illustrated that IL-6 plays an important role in controlling both the 
chemokine directed recruitment and apoptotic removal of neutrophils and lymphocytes 
(Hurst et al 2001, McLoughlin et al 2003, McLoughlin et al 2005). However little is 
currently known about the role of IL-6 in governing the phenotype, activation and 
inflammatory trafficking of monocytic cells. The studies described in this thesis have 
provided a vast array of answers to these questions, by focusing on the IL-6 regulation of 
both resident and infiltrating monocytic cells within the peritoneal cavity. These studies 
also introduce the role of IL-10 in regulating the peritoneal inflammatory response, with a 
focus on leukocyte recruitment and chemokine production. These are discussed herein.
9.1 IL-6 exerts an immunosuppressive role in resident peritoneal DC
The findings presented in Chapter 3 demonstrated that IL-6 promotes resident DC 
numbers in the peritoneal cavity. This supports previous findings stating that IL-6 
promotes the differentiation of DC from their precursors (Brasel et al 2000, Santiago- 
Schwartz et al 1995, Bernhard et al 2000). Findings outlined in Chapters 3 and 4 showed 
that these resident cells demonstrated an activation-induced loss of the IL-6R, coinciding 
with an up-regulation of maturation markers MHC II and CD83, thereby rendering them 
unresponsive to IL-6 stimulation. This data would appear to provide a potential 
mechanism by which DC liberate themselves from the immunosuppressive constraint 
exerted by IL-6, which is known to maintain resident DC in an immature state (Park et al
2004). In this respect, IL-6 mediated STAT3 activation was shown to be required for the 
suppression of LPS-induced bone marrow derived DC maturation, thereby implicating 
IL-6 as a potent regulator of DC maturation thought to continually stimulate and maintain 
immature DC in the steady state (Park et al 2004). Ex vivo activation of resident DC, 
contributed to an induction of a wide range of inflammatory mediators, including IL-6 
(Chapter 3). IL-6 is important for the function of mature DC, the activation of naive T 
helper cells (Bleier et al 2004), and is known to attenuate the activity of antigen specific 
T-regulatory cells (Longhi et al 2009, Pasare and Medzhitov 2003). In this respect, 
initial in vitro studies using isolated peritoneal DC and T cells, showed that these cells 
can promote generation of both the IFN-y and IL-17A-secreting T cells (data not shown).
237
Therefore, these studies have provided support to previous work, thereby shaping a 
potential two-sided immunoregulatory model for IL-6 in the control of DC activity 
(Figure 9.1): 1) IL-6 can initially exert an immunosuppressive constraint on resident DC 
by maintaining them in the immature state (Park et al 2004). Upon activation, DC down- 
modulate their surface IL-6 as part of the maturation process thereby becoming 
unresponsive to IL-6 stimulation and liberating themselves from the suppressive effects 
of IL-6 (Chapters 3&4). This coincides with an up-regulation of MHCII (Chapter 4), 
potentially ameliorating their antigen presenting capacity, but not CCR7. The expression 
of both MHC II and CCR7 have previously been shown to be negatively regulated by 
IL-6 (Kitamura et al 2005, Hedge et al 2004). 2) Following this, inflammatory release of 
IL-6 by resident DC following SES-mediated TLR2 activation (Chapter 3) would be 
predicted to take on a pro-inflammatory role, and is important for DC mediated T cell 
activation and the suppression of Foxp3+ T-reg activity (Longhi et al 2009, Pasare and 
Medzhitov 2003, Bleier et al 2004).
Further work would be required to rule out an IL-6 trans-signalling responsiveness by the 
resident DC following activation, and to determine their ability to drive effector T helper 
cell expansion and suppression of T regulatory cell activity.
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Figure 9.1 Immunosuppressive and pro-inflammatory IL-6 (A) IL-6 positively regulates resident 
DC numbers in the murine peritoneal cavity (Chapter 3). This supports previous findings stating 
that IL-6 promotes the differentiation o f  DC from their precursors (Brasel et al 2000, Santiago- 
Schwartz et al 1995, Bernhard et al 2000) (B) Removal o f  IL-6 responsiveness is predicted to 
direct the transition from an immature resident DC to mature DC capable o f  T cell activation. It 
is hypothesised that resident DC may down-regulate their surface IL-6R upon activation (Chapter 
4) in order to allow maturation, since previous work has defined a role for IL-6 in maintaining 
DC in an immature state (Kitamura et al 2004, Hedge et al 2005). SES mediated TLR2 
stimulation induces an up-regulation in IL-6 production (Chapter 3), thereby potentially 
promoting DC activity.
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9.2 Regulation of leukocyte trafficking by IL-6
Over the past 5-10 years, our group has defined a role for IL-6 in regulating the 
inflammatory response during bacterial peritonitis. Findings have characterised the IL-6 
control of chemokine directed recruitment and apoptotic clearance of neutrophils and 
lymphocytes (Hurst et al 2001, McLoughlin et al 2003, 2004, 2005) and the important 
role for IL-6 in driving microbial clearance (Coles et al unpublished). These protective 
qualities of IL-6 biology are however tempered by the detrimental outcomes associated 
with IL-6 activity in driving the induction of chronic inflammatory damage and the 
associated fibrosis (Nowell et al 2003, 2009, Fielding et al 2009, submitted). In this 
respect, many members of the group have contributed to work that has shown that IL-6*7' 
mice are protected from inflammatory induced peritoneal fibrosis as a consequence of 
recurrent inflammatory challenge. Work in this thesis has contributed to the group effort 
by identifying the role of IL-6 in directing the trafficking of defined subsets of monocytic 
cells. Monocytic cell subsets, including monocytes, macrophages and DC, are important 
in the immune response both for the removal of the pathogen, clearance of apoptotic cells 
and activation of T helper cells. Studies outlined in this thesis have shown that while 
IL-6 does not regulate the trafficking of these cells during a single episode of acute 
inflammation (Chapter 5), it does contribute to their dysregulation during a repeat 
inflammatory model (Chapter 6), resulting in retention of resident populations, and 
increased recruitment of infiltrating monocytes (Figure 9.2). This phenomenon appears 
to be chemokine independent since no changes in KC, CCL2 or CCL5 levels were 
observed following multiple rounds of inflammation, although other chemokines would 
need to explored to be conclusive (Chapter 6). Consequently this increased retention and 
recruitment could be explained by an increased number of circulating monocytes, a local 
expansion of monocytic cells, or reduced adhesion of monocytic subsets to the peritoneal 
membrane. Future experiments are required to define this.
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Figure 9.2 The distortion o f  monocytic cell trafficking follow ing repeated rounds o f  
inflammation. Red lines represent WT leukocyte trafficking, blue lines represent IL-6'7' mice. 
Repeated inflammatory episodes in WT mice result in an enhanced recruitment o f  infiltrating 
monocytes and increased retention o f  resident macrophages (Chapter 6). The increased and 
retained inflammatory monocytic infiltrate may contribute to the tissue damage associated with 
recurrent inflammation. IL-6 appears to drive the increased recruitment o f  infiltrating monocytes, 
but not the retention o f  resident populations, implicating the recruited monocytes as the 
predominant monocytic cell subset contributing to fibrosis. This correlates with the widely 
accepted opinion that recruited monocytes macrophages are ascribed a much greater destructive 
potential than their resident family members (Gordon 1995).
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Monocytic cells are known contributors to tissue damage and degradation, due to their 
production of reactive oxygen species, nitric oxide and degradative enzymes such as 
metalloproteinases (MMPs) (Duffield et al 2000, Duffield et al 2001, Kipari et al 2002, 
Duffield et al 2001, Serbina et al 2003, Stary et al 2007, Gueders et al 2006). 
Additionally some macrophages have the ability to facilitate tissue repair and promote 
fibrosis and the deposition of extracellular matrix (Deodhar et al 1997, Gordon 2003). 
Impaired regulation of either of these processes could lead to uncontrolled injury and 
overcompensated repair mechanisms. Consequently monocytic cells have the potential to 
contribute substantially to tissue injury and the induction of peritoneal membrane 
scarring and fibrosis.
Given the significance of monocytic cells in mediating fibrotic processes, the trafficking 
of these cells was analysed in a recurrent inflammatory model, utilising flow cytometry to 
enable an independent analysis of resident macrophage and DC populations and recruited 
monocytes. Analysis of the resident monocytic populations (macrophage and DC) 
highlighted a retention of these cells following repeated SES activation (Chapter 6). 
However it was concluded that this retention of resident populations was unlikely to 
contribute substantially to tissue injury or fibrosis since the IL-6'7' mice, which have a 
protective phenotype, exhibited an equivalent retention of these resident populations. 
Adding to this, infiltrating inflammatory monocytes are considered to differentiate into 
inflammatory macrophages or DC upon recruitment to the inflammatory site (Geissman 
et al 2003), and elicited inflammatory macrophages have been ascribed a greater 
destructive potential than resident macrophages (Gordon 1995). Consequently, the 
enhanced infiltration of monocytes, observed in the WT mice following repeated 
inflammatory episodes, are likely to be the predominant monocytic cell contributors to 
fibrosis in this model. The differentiation of these recruited cells into macrophages and 
DC would lead to their potential contribution to peritoneal membrane thickening either 
via the damage of surrounding tissues by the release of nitric oxide and reactive oxygen 
species, or by the induction of fibrosis. Macrophages are known to promote fibrosis 
either by the regulation of fibroblast recruitment, or by contributing to the production of 
extracellular matrix (Deodhar et al 1997, Gordon 2003). Furthermore, macrophages have
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been shown previously to release TGF-p (Khalil et al 1996, Bissell et al 1995, Letterio 
and Roberts 1998), and this growth factor is known to drive epithelial to mesenchymal 
transition (EMT), the dysregulation of which is key for the induction of membrane 
thickening or fibrosis (Selgas et al 2006). This would not normally occur in an acute 
resolving inflammatory episode, however following recurrent inflammatory events, tissue 
injury may become more severe, and potential increases in local TGF-p levels may 
increase monocytic cell recruitment or activation status to promote EMT and subsequent 
fibrotic changes.
In addition to its control of monocytic cell recruitment during repeated inflammatory 
episodes, IL-6 similarly induced an increased recruitment of other inflammatory cell 
types, including neutrophils (Chapter 6), and effector Thl and Thl7 cells (Jones et al- 
under revision, J.Immunol. 2009). Neutrophils can contribute to tissue injury by their 
production of anti-microbial peptides and reactive oxygen species (Mahmudi-Azer and 
Eeden 2003), whilst the IL-6 control of effector T cell migration, activation-induced T 
cell clearance, and suppression of DC and regulatory T cell activity may lead to the 
retention of activated T cell subsets within the affected or damaged tissue (Mahmudi- 
Azer and Eeden 2003, Teague et al 2000, Longhi et al 2008). In this respect, Fielding et 
al have shown that the development of peritoneal membrane fibrosis as a consequence of 
repeated inflammatory episodes, correlates with enhanced STAT3 activity and the 
emergence of STAT1 signalling within the peritoneal membrane of WT but not IL-6"7' 
mice. This shift in the STAT1/STAT3 balance was attributable to the IL-6 dependent 
regulation of IFN-y secreting T cells. In this respect IL-6 is proposed to drive the 
development of an IFN-y secreting T cell population, potentially via the attenuation of 
CD4+CD25+ T regulatory cell activity, thereby resulting in an increased recruitment of 
IFN-y secreting T cells and a subsequent initiation of STAT1-mediated fibrotic events 
(e.g. MMP regulation) within the peritoneal membrane (Fielding et al 2009, submitted). 
Whilst the IL-6 dependent induction of IFN-y responsiveness further underlines the role 
of IL-6 in T cell memory expansion, IL-6 suppression of T-reg activity has been linked to 
the positive control of type I IFN responses and the development of adaptive immunity 
by DC (Detoumay et al 2005, Longhi et al 2008).
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A combined regulation of cellular events by IL-6, as detailed above, including the 
potential for uncontrolled activity of regulatory T cells, resulting in an attenuated 
expansion of pro-inflammatory effector and memory T cells, may help to explain why 
IL-6'7' animals display a highly protected phenotype in experimental models of chronic 
peritonitis. Contributing to this is their protection against dysregulated leukocyte 
recruitment, including infiltrating monocytes, neutrophils and lymphocytes.
It is therefore conceivable that the enhanced recruitment of monocytes, T helper cells and 
neutrophils following repeated SES activation (Chapter 6) are collectively responsible for 
driving fibrosis. This may also be coupled with the ability of IL-6 to suppress T 
regulatory cell activity, thereby promoting pro-inflammatory T helper cell differentiation 
and activation. Therefore during a persistent inflammatory condition, IL-6 evolves from 
providing a tight control of the inflammatory response, driving the transition from innate 
to acquired immunity, and promoting the successful resolution of the inflammatory 
response, to facilitating the increased recruitment of pro-inflammatory leukocytes, which 
contribute to membrane fibrosis. The cause of this switch is still unclear, and future 
experiments are required to unravel this phenomenon. However a specific balance in the 
control of STAT1 and STAT3 activity may contribute to these inflammatory changes 
(Figure 9.3) (Fielding et al 2009, submitted).
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Figure 9.3: The appropriate balance ofST A T  activity is required fo r  the successful orchestration 
o f  th e  inflammatory response leading to the competent cell mediated immunity against infection 
w hilst limiting collateral tissue injury. IL-6 mediated STATS activation is vital for the resolution 
o f  acute neutrophil infiltration and the promotion o f  chemokine directed T cell trafficking (Hurst 
et a l 2001, McLoughlin et a l 2005, Fielding et a l 2008, Nowell et al 2009). IL-6 is also required 
for th e generation o f  IFN-y secreting T cells (Fielding et al 2009, submitted), potentially through 
a suppression o f  T regulatory cell activity (Longhi et al 2008, Pasare and Medhitzov 2003), and 
their subsequent recruitment (Fielding et a l 2009, submitted). Increased recruitment o f  these cells 
during recurrent inflammation results in an IFN-y induced STAT1 activation in the peritoneal 
membrane, which is associated with, and thought to facilitate tissue injury and fibrosis during a 
persistent inflammatory condition (Fielding et al 2009, submitted). This detrimental biology 
exhibited by IL-6 must be balanced by the importance o f  IL-6 in regulating anti-microbial 
immunity. Mice deficient in IL-6 exhibit impaired clearance and increased dissemination (Coles 
et a l unpublished). Since IL-6/STAT3 activity is important for neutrophil resolution and T cell 
recruitment, it is proposed that the ability o f  IL-6 to control STAT3 mediated processes is 
required for successful anti-microbial immunity.
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9.3 IL-10: Anti-inflammatory roles in peritonitis and the interplay with IL-6.
The protective qualities afforded by IL-6 during infection are balanced by the deleterious 
outcomes associated with IL-6 activity in chronic disease. This is mirrored by the 
activity of IL-10, which hinders anti-microbial immunity (Coles et al unpublished, 
Sewnath et al 2001) but provides protection in chronic inflammation (Chmiel et al 1999, 
Mu et al 2005) (Figure 9.4). An interplay between IL-6 and IL-10 has been known to 
exist for some time, with studies showing that IL-10 inhibits IL-6 production by 
monocytes (Fiorentino et al 1991), and also inhibits IL-6 mediated STAT3 activation by 
the induction of the negative regulator SOCS3 (Niemand et al 2003). Studies detailed in 
Chapter 8 o f this thesis have added further evidence for the known interplay between 
IL-6 and IL-10. The predominant cell type to secrete IL-10 upon SES/TLR2 mediated 
activation was the resident macrophage population (Chapter 8). Mice deficient in IL-10 
produced very enhanced levels of IL-6 during acute peritoneal inflammation, which is 
potentially attributable to the IL-10 inhibition of IL-6 production by monocytic cells 
(Fiorentino et al 1991). In addition, other work by the group has shown that IL-6 
mediated ST AT activity induces an up-regulation of IL-10 in the peritoneal cavity 
following SES activation, indicating a control of IL-10 expression by IL-6 (Fielding et al 
unpublished). This is suggestive of a negative feedback regulation of IL-6 production by 
resident macrophages, mediated by their production of IL-10. In combination these 
studies show an important interplay between the pro-inflammatory IL-6 and anti­
inflammatory IL-10, demonstrated by the IL-6 induction of IL-10 expression, and the 
IL-10 inhibition of IL-6 expression and activation of STAT3 (Fielding et al 2009 
submitted, Fiorentino et al 1991, Niemand et al 2003). The balance of this interplay is 
important for the tight regulation of the inflammatory response.
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F igu re 9.4: IL-10 and IL-6 must be finely  balanced to prom ote microbial killing and clearance, 
whilst preventing tissue injury. WT mice exhibit tissue fibrosis o f  the peritoneal membrane upon 
repeated inflammatory insult, whilst IL-6'7' mice remain protected (Chapter 6). WT mice exhibit 
increased recruitment o f  inflammatory leukocytes, including infiltrating monocytes that are likely 
to contribute to the tissue damage seen in these mice (Chapter 6). Since IL-10'' mice exhibit 
enhanced recruitment o f  inflammatory leukocytes during acute peritonitis (Chapter 8), it is 
hypothesised that this would be heightened upon repeated inflammatory insult, which would 
exacerbate chronic disease and tissue damage, resulting in a more severe fibrotic score. 
Microbial clearance on the other hand is enhanced in IL-107' mice (Coles et al unpublished) but 
impaired in IL-6"7' mice (K opf et al 1994). This would define opposing roles for IL-6 and IL-10, 
with the former being pro-inflammatory and vital for microbial killing, but also pro-fibrotic and 
the latter being anti-fibrotic, and anti-inflammatory, thereby attenuating microbial clearance but 
protecting against fibrosis. As a result, these two cytokines, being interrelated and regulated by 
one another must be tightly regulated on order to maintain a competent cell mediated immunity to 
infection whilst preventing collateral damage. How this balance is altered during repeated 
inflammatory challenge remains to be determined. Dotted lines refer to hypothesised results that 
are yet to be determined experimentally.
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9.3.1 Potential mechanism of IL-6 regulation by IL-10
Upon induction of inflammation, IL-6 is produced predominantly by the mesothelial cells 
lining the peritoneal cavity (Topley et al 1993), but is also secreted by the resident 
macrophage population (Chapter 3). Since stromal cells do not respond to IL-10, it is 
likely that this cytokine inhibits IL-6 production by the resident macrophages, as has 
previously been shown (Fiorentino et al 1991). Of course, IL-10 may also regulate IL-6 
expression in the mesothelial cells by the regulation of other pro-inflammatory cytokines 
including IL-1 and TNF-a, which are known inducers of IL-6 production by mesothelial 
cells (Topley et al 1993). Previous work has in fact shown that IL-10 inhibits IL-1 and 
TNF-a production by activated macrophages (Fiorentino et al 1991), which would 
support this notion. This provides an alternative mechanism for the regulation of IL-6 
production by IL-10.
9.3.2 Anti-inflammatory activities of IL-10
Studies outlined in Chapter 8 demonstrate that IL-10 exhibits potent anti-inflammatory 
activities during peritoneal inflammation, by limiting the recruitment of leukocytes, 
specifically neutrophils, lymphocytes (Thl7 cells) and monocytes, to the peritoneal 
cavity (Chapter 8). This was facilitated by control of inflammatory chemokines, with 
IL-10'7' mice showing a prolonged production of the neutrophil activating chemokine KC, 
and enhanced levels of the mononuclear chemokine CCL2. The production of CCL2 by 
mesothelial cells is regulated by IL-6 trans-signalling (Hurst et al 2001), compounded by 
data from IL-6'7' mice, which exhibit an impaired production of this chemokine (Chapter 
5). Therefore the enhanced production of CCL2 in IL-10'7' mice is likely to be a result of 
the increased levels of IL-6 in these mice, which is known to drive CCL2 expression and 
consequently the recruitment of mononuclear cells (Hurst et al 2001). The IL-10 
mediated limitation of chemokine expression and leukocyte recruitment is important to 
ensure that the magnitude of the inflammatory response is sufficient to successfully clear 
the pathogen, whilst preventing collateral tissue damage that may arise from the presence 
of large numbers of infiltrating leukocytes (Moore et al 2001). In this respect, IL-10 
plays an important role in maintaining and controlling both the innate and acquired arms 
of the immune response (Kelly and Bancroft 1996, Tripp et al 1995, Dai et al 1997).
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When comparing the roles of IL-6 and IL-10 in directing the inflammatory response, it 
becomes clear that IL-6 exhibits a strong pro-inflammatory role and directs the transition 
from innate to acquired immunity (Jones 2005, Hurst et al 2001, McLoughlin et al 2003, 
2004, 2005), while IL-10 functions to limit the inflammatory response to prevent large- 
scale leukocyte infiltration and potential tissue damage (Chapter 8). Further work could 
be done to determine how IL-10 co-ordinates its anti-inflammatory roles in a repeat 
model of peritonitis, and how this impacts on the potential fibrosis in these animals. One 
might expect that IL-10'7' mice would exhibit more severe tissue damage following repeat 
episodes of inflammation, given that the infiltration of leukocytes is so enhanced in these 
mice during acute inflammation, and their levels of pro-inflammatory cytokines such as 
IL-6 are elevated. This would contrast with what is known in the IL-6'7' mice, which 
exhibit protection from tissue fibrosis and have normal leukocyte trafficking (Chapter 6, 
Fielding et al 2009, submitted). If IL-10'7’ mice proved to exhibit more severe tissue 
damage, this potentially would provide a central concept for the role of STAT3 activating 
cytokines in the regulation of the immune response, with opposing roles defined for IL-6 
and IL-10 in the regulation of the inflammatory response and their exacerbation or 
protection from the onset of chronic disease associated fibrosis respectively.
While the role of IL-10 in fibrosis is likely to be protective, the suppressive properties of 
IL-10 may hinder anti-microbial immunity. Due to its role in containing the 
inflammatory response in order to prevent tissue damage and fibrosis, IL-10 also 
selectively impairs microbial clearance upon infection, and facilitates bacterial outgrowth 
and dissemination (Sewnath et al 2001). This is highlighted in IL-10'7' mice, which 
exhibit significantly improved clearance of Staphylococcus epidermidis and Escherichia 
coli when compared to WT littermate controls (Coles et al unpublished, Sewnath et al 
2001). In WT mice, inflammatory challenge induces a rapid and transient STAT3 
activation in the peritoneal membrane. This STAT3 activation in the mesothelial cells is 
driven uniquely by IL-6, and coincides with the initial infiltration of neutrophils (Fielding 
et al 2008). The removal of inflammatory neutrophils is also reliant on IL-6 activity 
(McLoughlin et al 2003, Fielding et al 2008), and the profile of bacterial killing 
correlates with the clearance of this neutrophil population (Coles et al unpublished). In
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this respect, IL-6/STAT3 signalling is vital for the resolution of acute neutrophil 
infiltration by the regulation of their apoptotic clearance, and the promotion of 
chemokine directed T cell trafficking (Hurst et al 2001, McLoughlin et al 2005, Fielding 
et al 2008). However T cell recruitment is only observed once the bacterial infection has 
been resolved. Therefore it is proposed that successful anti-microbial immunity relies 
upon the ability of IL-6 to control STAT3-mediated processes, and the communication 
between peritoneal stromal cells and innate effector cells. This regulation may 
potentially occur at two levels, either by regulating innate anti-microbial effector 
functions, or by the clearance of activated neutrophils that are laden with phagocytosed 
bacteria. This brings a potential indirect role for IL-10 in the regulation of microbial 
clearance via its regulation of IL-6 and subsequent IL-6 driven STAT activity. The 
regulation of IL-6 by IL-10 is important to allow competent host defence against 
infection, whilst preventing dysregulation of cellular immunity (by limiting neutrophil 
recruitment and their apoptotic clearance), which could result in tissue injury. Indeed, 
IL-10 has previously been shown to impair the recruitment and subsequent microbicidal 
activity of neutrophils (Laichalk et al 1996, Ajuebor et al 1999).
This concept is however complicated by the fact that IL-6'7' mice also exhibit enhanced 
neutrophil recruitment (Chapter 5) and yet their capacity to kill and clear away bacteria is 
inhibited (Coles et al unpublished). The question therefore remains, how do two STAT3 
activating cytokines differ so dramatically in their ability to regulate microbial immunity? 
Neutrophil recruitment is significantly greater in IL-10'7' mice than in IL-6'7' mice 
(Chapter 8), therefore this may play a significant role in their improved ability to clear 
bacterial infections. In addition, IL-6'7' mice may potentially exhibit an impaired 
activation of recruited neutrophils, thereby inhibiting their ability to mediate microbial 
killing. In this respect, STAT3 conditional mutants have been shown to exhibit impaired 
mature neutrophil function and microbicidal activity (Panopoulos et al 2006, Matsukawa 
et al 2003). This provides a potential explanation as to why these mice exhibit impaired 
microbial immunity, even in the presence of increased neutrophils. In addition to this, 
IL-6 trans-signalling is regulated by the availability of the soluble IL-6R in vivo. This 
presents a level of regulation for IL-6 that is absent for IL-10, which could potentially
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contribute to the differences seen between these two STAT3 activating cytokines. An 
alternative explanation could also come in the form of the regulation of antimicrobial 
peptide production by the mesothelial cell layer. There have been reports that human 
peritoneal mesothelial cells produce P-defensin-2, which is regulated by TNF-a 
(Zarrinkalam et al 2001). IL-10 could potentially inhibit or limit the production of these 
defensins by mesothelial cells via its known negative regulation of TNF-a production by 
monocytes (Fiorentino et al 1991, de Waal Malefyt et al 1991), thereby impairing the 
antimicrobial properties exhibited by these cells. Finally, the results presented in Chapter 
8 implied that IL-10 negatively regulates the chemokine (KC)-directed neutrophil 
activation or apoptotic clearance, indicated by an increased level of sIL-6R in the 
peritoneal cavity of IL-10'7' mice. This would provide yet another alternative mechanism 
by which these mice exhibit an improved microbial clearance capacity. To support this, 
IL-10 is known to inhibit bacterial phagocytosis and attenuate neutrophil microbicidal 
activity towards internalised bacteria (Laichalk et al 1996). Further experiments are 
therefore required to determine the actual mechanisms by which IL-10 inhibits microbial 
clearance, whilst the potential inflammatory interplay between IL-6 and IL-10 requires 
further mechanistic clarification.
In summary, the IL-10 regulation of IL-6-STAT3 activation therefore provides a potential 
mediation of microbial clearance, regulated and balanced by an interplay between IL-6 
and IL-10. This interplay is in place to allow competent host defence against infection 
whilst limiting tissue injury that arises due to the dysregulation of inflammatory infiltrate 
recruitment. The mechanisms by which this is facilitated must be investigated further, 
with potential investigations into how the balance between these two cytokines is 
maintained or altered during the onset of chronic disease.
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9.4 Lessons learned in Flow Cytometry
The ability to use flow cytometry to characterise the trafficking patterns of dendritic cells 
was complicated by the emergence of aggregate formation following neutrophil 
recruitment (Chapter 6&7). The phenomenon of aggregate formation appears to be a 
common occurrence in the practise of flow cytometry. This can arise when the flow rate 
is set too high during data acquisition, or when the concentration of cells is too high. The 
formation of neutrophil aggregates was observed exclusively in IL-6'7' mice, and were 
absent in gpl30Y757F/Y757F or IL-10'7' mice, despite these animals exhibiting a significantly 
greater recruitment of neutrophils compared to WT (Chapter 7). This can be attributed to 
the fact that these mice had higher total cell counts in general, meaning that the 
proportion or concentration of neutrophils in these mice remained equivalent to WT. In 
contrast, IL-6'7' mice possessed equivalent overall peritoneal cell numbers to the WT, but 
with a higher abundance of neutrophils, resulting in the increased incidence of aggregate 
formation upon their acquisition on the FACS calibur.
Aggregates or doublets can be visualised and excluded from flow cytometry data files 
using a pulse width size exclusion gate. This option is only available on more modem 
models of flow cytometers and was unfortunately not compatible with the BD FACS 
Calibur used for the studies presented in this thesis. The FACS Calibur does have an area 
width setting which is used for cell cycle analysis and could potentially be used for 
doublet exclusion however a linear scale is required and was not possible in this case. 
This teaches a valuable lesson and emphasises the importance of exercising vigilance 
when it comes to data analysis and exploring the alternative explanations for a result. It 
also highlights the importance of routinely using size exclusion to remove aggregates 
from flow cytometry plots, in order to exclude any erroneous events that may distort the 
result.
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9.5 Future directions
The work presented in this thesis has defined a role for IL-6 in the homeostatic regulation 
of monocytic cell numbers and their dysregulated recruitment following repeated 
inflammatory challenge. Subsequent studies began to introduce IL-10 and define its role 
in the regulation of the inflammatory response during peritonitis, highlighting important 
anti-inflammatory functions by this cytokine and a potential interplay with IL-6. Further 
experiments are required to develop these studies and are listed below:
■ Resident DC are important for homeostatic antigen sampling, and the induction 
of the adaptive immune response during infection. As a result, it is important to 
maintain a considerable pool of DC resident in the peripheral tissues. Studies in 
Chapter 3 showed that the number of resident DC was regulated by IL-6 and 
IFN-y in a positive and negative manner respectively. Future work is required to 
determine whether these cytokines differentially regulate haematopoiesis, their 
inward migration of DC, their differentiation from monocyte precursors, or their 
turnover/egress.
■ Studies in Chapter 3 showed that resident macrophage and DC do not respond to 
signalling by IL-6 through the classical route of engagement with the surface 
bound IL-6R. IL-6 is also known to signal via a soluble form of the receptor and 
therefore studies should be done to determine if activated resident DC are able to 
respond to IL-6 trans-signalling following loss of the IL-6R. This would be 
achieved by measuring their release of inflammatory mediators following 
stimulation of these cells by Hyper IL-6. To reduce the number of mice required 
to sort sufficient numbers of cells for culture, work could be done to derive an 
immortalised cell line from these cells, which would better enable one to 
perform such studies. This could be performed using the Hox oncoprotein, 
which enforces self renewal of factor-dependent myeloid progenitors (Wang et 
al 2006).
■ It has long been characterised that resident macrophages and DC exhibit a 
clearance upon inflammatory activation, followed by a subsequent re-emergence
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later in the inflammatory response. However it is currently unknown what is 
responsible for this pattern of trafficking. Therefore it would be important to 
investigate the migratory fate of these resident populations following SES 
activation. Is the initial clearance of these cells a result of migration to the 
lymph nodes or increased adherence to the peritoneal membrane? Further 
investigation of chemokine receptor expression, adhesion molecules and 
integrins could provide potential explanations. Also, recovery of the draining 
lymph nodes for analysis of cell content following induction of peritoneal 
inflammation would allow us to determine if resident DC are in fact trafficking 
away from the peritoneal cavity.
■ Studies so far have defined a role for IFN-y secreting T cells in mediating 
ST ATI activation in the peritoneal membrane following repeated inflammatory 
challenge, which is associated with fibrosis (Fielding et al 2009, submitted). 
Studies outlined in Chapter 6 have shown that increased recruitment of 
neutrophils and monocytes are also evident following repeat inflammatory 
episodes. The contribution of this process by monocytic cells and neutrophils 
has not been determined, therefore further studies are required to dissect the role 
played by individual cell types in the onset of membrane fibrosis.
■ Studies performed to characterise the inflammatory trafficking of leukocytes in 
IL-10 deficient mice showed that these mice have dramatically enhanced 
leukocyte recruitment (Chapter 8). The next step in these studies would be to 
perform the repeat inflammatory model in IL-10"7' mice to study changes in 
leukocyte trafficking, inflammatory mediator production and peritoneal tissue 
injury. IL-6 is extremely detrimental in chronic disease, and drives tissue injury 
and fibrosis through the regulation of T cell effector function, trafficking and 
through the prevention of activation-induced cell death. Given the known 
interplay between IL-6 and IL-10, and the ability of IL-10 to inhibit IL-6 
production by monocytic cells, it is important to determine how this balance is 
regulated to provide immunity against infection whilst preventing collateral 
tissue damage. It is also important to understand how this balance is altered 
upon repeat inflammatory challenge, resulting in peritoneal fibrosis. It is
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predicted that IL-10'7' mice, which have elevated IL-6 production during 
peritoneal inflammation, would exhibit a more severe fibrotic score compared to 
WT, given that the absence of IL-6 protects mice from peritoneal fibrosis 
(Chapter 6). Experiments would determine the fibrotic score in these mice and 
correlate this to potential changes in T cell (IFN-y secreting), monocytic cell and 
neutrophil recruitment and retention.
■ Finally, the group has seen from recent studies that the complete clearance of 
bacteria in mice subjected to the live peritoneal inflammation model (Section
2.3.7) precedes the recruitment or recall of inflammatory T helper cell subsets 
(Thl, Thl7) (Coles et al unpublished, Jones et al 2009-under revision). This 
brings into question the role of the recruited T lymphocytes, since they are 
unlikely to be contributing to the antimicrobial response. Experimental work 
would therefore try to determine the contribution of T helper cells to the 
inflammatory response, addressing questions as to whether they are important 
for directing the re-establishment of resident leukocyte populations following 
inflammatory challenge, the formation of memory cells, and how they 
potentially contribute to tissue fibrosis.
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